struct_id,strength,patent_no,description,trade_name,applicant,appl_type,appl_no,type,dose_form,route,approval_date,patent_expire_date
5241,80MG,8557852,PROPHYLAXIS OF VENOUS THROMBOSIS,BEVYXXA,PORTOLA PHARMS INC,N,208383,DISCN,CAPSULE,ORAL,2017-06-23,2028-09-08
4913,EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**,8680106,"TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.",VIEKIRA XR,ABBVIE,N,208624,DISCN,"TABLET, EXTENDED RELEASE",ORAL,2016-07-22,2032-09-04
5227,EQ 60MG BASE,11026931,TREATMENT OF TARDIVE DYSKINESIA,INGREZZA,NEUROCRINE,N,209241,RX,CAPSULE,ORAL,2021-04-23,2039-08-14
435,105MG;45MG,11273133,DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER,AUVELITY,AXSOME,N,215430,RX,"TABLET, EXTENDED RELEASE",ORAL,2022-08-18,2034-11-05
1123,2MG/0.85ML (2MG/0.85ML),8461105,IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE,BYDUREON BCISE,ASTRAZENECA AB,N,209210,RX,"SUSPENSION, EXTENDED RELEASE",SUBCUTANEOUS,2017-10-20,2025-04-13
2389,150MG/0.42ML (150MG/0.42ML),8741327,TREATMENT OF SCHIZOPHRENIA,UZEDY,TEVA,N,213586,RX,"SUSPENSION, EXTENDED RELEASE",SUBCUTANEOUS,2023-04-28,2027-11-12
1709,1GM/VIAL;1GM/VIAL,9694025,TREATMENT OF PATIENTS 18 YEARS OF AGE AND OLDER WITH COMPLICATED URINARY TRACT INFECTIONS CAUSED BY SUSCEPTIBLE MICROORGANISMS,VABOMERE,REMPEX,N,209776,RX,POWDER,INTRAVENOUS,2017-08-29,2031-08-08
403,EQ 0.8MG BASE,10688094,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 28 AND 29,CYCLOSET,VEROSCIENCE,N,020866,RX,TABLET,ORAL,2009-05-05,2032-04-30
5384,EQ 1MG BASE,10709691,CUSHINGS DISEASE,ISTURISA,RECORDATI RARE,N,212801,RX,TABLET,ORAL,2020-03-06,2035-10-12
4190,EQ 20MG BASE,8822481,FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA,JAKAFI,INCYTE CORP,N,202192,RX,TABLET,ORAL,2011-11-16,2028-06-12
1123,2MG/0.85ML (2MG/0.85ML),8461105,AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AS ADD-ON TO METFORMIN,BYDUREON BCISE,ASTRAZENECA AB,N,209210,RX,"SUSPENSION, EXTENDED RELEASE",SUBCUTANEOUS,2017-10-20,2025-04-13
4913,EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**,9044480,TREATMENT OF HCV INFECTION USING PARITAPREVIR,VIEKIRA XR,ABBVIE,N,208624,DISCN,"TABLET, EXTENDED RELEASE",ORAL,2016-07-22,2031-04-10
403,EQ 0.8MG BASE,11000522,"ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1, 11, AND 12",CYCLOSET,VEROSCIENCE,N,020866,RX,TABLET,ORAL,2009-05-05,2032-04-30
4299,150MG;150MG;200MG;EQ 10MG BASE,7176220,TREATMENT OF HIV INFECTION,GENVOYA,GILEAD SCIENCES INC,N,207561,RX,TABLET,ORAL,2015-11-05,2026-08-27
3317,10MG,8404717,USE OF REVLIMID (LENALIDOMIDE) FOR TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA DUE TO LOW-OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A DELETION 5Q ABNORMALITY WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES,REVLIMID,CELGENE,N,021880,RX,CAPSULE,ORAL,2005-12-27,2023-04-11
5001,75MG,8772325,TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).,VIBERZI,ABBVIE,N,206940,RX,TABLET,ORAL,2015-05-27,2025-03-14
1413,1GM,11213504,"USE OF VASCEPA TO REDUCE TRIGLYCERIDE LEVELS IN AN ADULT PATIENT ON STATIN THERAPY AND HAVING ATRIAL FIBRILLATION OR ATRIAL FLUTTER AND TRIGLYCERIDE LEVELS OF ABOUT 500 MG/DL TO ABOUT 2,000 MG/DL",VASCEPA,AMARIN PHARMS,N,202057,RX,CAPSULE,ORAL,2012-07-26,2030-04-29
2459,EQ 200MG BASE,8877933,"TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA, ADVANCED RENAL CELL CARCINOMA, OR DIFFERENTIATED THYROID CARCINOMA.",NEXAVAR,BAYER HLTHCARE,N,021923,RX,TABLET,ORAL,2005-12-20,2027-12-24
5154,200MG;50MG/PACKET,8334270,FOR THE TREATMENT OF HEPATITIS C,EPCLUSA,GILEAD SCIENCES INC,N,214187,RX,PELLETS,ORAL,2021-06-10,2028-03-21
4810,420MG,9801883,TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION,IMBRUVICA,PHARMACYCLICS LLC,N,210563,RX,TABLET,ORAL,2018-02-16,2031-06-03
2448,1GM;EQ 50MG BASE,7326708,METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE,JANUMET XR,MERCK SHARP DOHME,N,202270,RX,"TABLET, EXTENDED RELEASE",ORAL,2012-02-02,2026-11-24
5276,"75MG;75MG, 50MG",10081621,"TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 12 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,081,621",SYMDEKO (COPACKAGED),VERTEX PHARMS INC,N,210491,RX,TABLET,ORAL,2019-06-21,2031-03-25
939,20MG/ML (20MG/ML),9763880,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY,DOCETAXEL,SHILPA,N,205934,RX,INJECTABLE,INJECTION,2015-12-22,2033-09-30
434,EQ 11.4MG BASE;EQ 2.9MG BASE,11020387,USE OF ZUBSOLV FOR TREATMENT OF OPIOID DEPENDENCE,ZUBSOLV,OREXO US INC,N,204242,RX,TABLET,SUBLINGUAL,2014-12-11,2032-09-18
434,96MG/0.27ML (356MG/ML),8236292,A METHOD OF DELIVERY OF A BIOACTIVE AGENT BY SUBCUTANEOUS INJECTION. A METHOD OF TREATMENT OF A HUMAN FOR ADDICTION,BRIXADI,BRAEBURN,N,210136,RX,"SOLUTION, EXTENDED RELEASE",SUBCUTANEOUS,2023-05-23,2027-01-10
5128,1GM IRON/20ML (50MG IRON/ML),11478502,METHOD TO TREAT IDA IN ADULTS WITH INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON & HEAVY UTERINE BLEEDING OR GI DISORDER WEIGHING AT LEAST 40 KG BY ADMINISTERING IV FERRIC CARBOXYMALTOSE TO GIVE AT LEAST 0.6 G OF IRON IN 15 MINUTES OR LESS,INJECTAFER,AM REGENT,N,203565,RX,SOLUTION,INTRAVENOUS,2021-04-28,2027-01-08
1164,1.2MG,9642797,TREATMENT OF PAIN,SUBSYS,BTCP PHARMA,N,202788,DISCN,SPRAY,SUBLINGUAL,2012-08-30,2027-01-25
5372,"50MG,37.5MG,25MG; 75MG",10758534,"TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR",TRIKAFTA (COPACKAGED),VERTEX PHARMS INC,N,212273,RX,TABLET,ORAL,2021-06-08,2035-10-06
842,105MG;45MG,11096937,DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER,AUVELITY,AXSOME,N,215430,RX,"TABLET, EXTENDED RELEASE",ORAL,2022-08-18,2034-11-05
2407,2MG/24HR,8246979,TREATMENT OF SIGNS AND SYMPTOMS OF PARKINSONS DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM,NEUPRO,UCB INC,N,021829,RX,"FILM, EXTENDED RELEASE",TRANSDERMAL,2007-05-09,2027-09-01
4944,EQ 25MG BASE,8754065,TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS,VEMLIDY,GILEAD SCIENCES INC,N,208464,RX,TABLET,ORAL,2016-11-10,2032-08-15
4757,240MG,11129806,METHOD OF TREATING MULTIPLE SCLEROSIS,TECFIDERA,BIOGEN INC,N,204063,RX,"CAPSULE, DELAYED RELEASE",ORAL,2013-03-27,2035-11-16
2608,112.5MG,8778922,TESTOSTERONE REPLACEMENT THERAPY IN ADULT MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE; PRIMARY HYPOGONADISM (CONGENITAL OR ACQUIRED); HYPOGONADOTROPIC HYPOGONADISM (CONGENITAL OR ACQUIRED).,TLANDO,ANTARES PHARMA INC,N,208088,RX,CAPSULE,ORAL,2022-03-28,2029-01-08
5304,EQ 25MG BASE,11168066,"USE, IN COMBINATION WITH LOW-DOSE CYTARABINE, FOR THE TREATMENT OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULT PATIENTS WHO ARE >= 75 YEARS OLD OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY",DAURISMO,PFIZER,N,210656,RX,TABLET,ORAL,2018-11-21,2036-04-13
228,25MG,9283219,TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSONS DISEASE,KYNMOBI,SUMITOMO PHARMA AM,N,210875,DISCN,FILM,SUBLINGUAL,2020-05-21,2030-06-11
435,105MG;45MG,10874663,DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER,AUVELITY,AXSOME,N,215430,RX,"TABLET, EXTENDED RELEASE",ORAL,2022-08-18,2034-11-05
2720,EQ 5MG BASE,9278901,USE OF ORENITRAM FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1).,ORENITRAM,UNITED THERAP,N,203496,RX,"TABLET, EXTENDED RELEASE",ORAL,2016-10-07,2024-05-24
302,100MG/4ML (25MG/ML),9597398,FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA,BENDEKA,EAGLE PHARMS,N,208194,RX,SOLUTION,IV (INFUSION),2015-12-07,2033-03-15
5077,0.6MG,9284280,METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A CRYSTALLINE FORM OF SELEXIPAG,UPTRAVI,ACTELION,N,207947,RX,TABLET,ORAL,2015-12-21,2030-06-25
1725,12.5MG;2.5MG;1GM,10406172,"METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN",TRIJARDY XR,BOEHRINGER INGELHEIM,N,212614,RX,"TABLET, EXTENDED RELEASE",ORAL,2020-01-27,2030-06-15
4811,200MG;50MG/PACKET,8735372,FOR THE TREATMENT OF HEPATITIS C,EPCLUSA,GILEAD SCIENCES INC,N,214187,RX,PELLETS,ORAL,2021-06-10,2028-03-21
5421,2MG,8557834,TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE,JESDUVROQ,GLAXOSMITHKLINE,N,216951,RX,TABLET,ORAL,2023-02-01,2027-06-22
4810,70MG/ML,8497277,TREATMENT OF PEDIATRIC PATIENTS AGE 1 YEAR AND OLDER WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY,IMBRUVICA,PHARMACYCLICS LLC,N,217003,RX,SUSPENSION,ORAL,2022-08-24,2026-12-28
353,0.064%;0.005%,10660908,TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 12 YEARS AND OLDER,ENSTILAR,LEO PHARMA AS,N,207589,RX,"AEROSOL, FOAM",TOPICAL,2015-10-16,2031-06-10
5128,500MG IRON/10ML (50MG IRON/ML),7754702,A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 GRAMS OF ELEMENTAL IRON,INJECTAFER,AM REGENT,N,203565,RX,SOLUTION,INTRAVENOUS,2020-10-08,2028-02-15
1123,2MG/0.85ML (2MG/0.85ML),8329648,AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN,BYDUREON BCISE,ASTRAZENECA AB,N,209210,RX,"SUSPENSION, EXTENDED RELEASE",SUBCUTANEOUS,2017-10-20,2026-08-18
3064,8%,8889113,METHOD OF USING CAPSAICIN IN COMBINATION WITH A GEL COMPOSITION FOR REMOVAL OF CAPSAICIN FROM A TREATMENT AREA OR UNINTENDED AREA,QUTENZA,AVERITAS,N,022395,RX,PATCH,TOPICAL,2009-11-16,2023-09-05
5259,50MG,7855211,"IN COMBINATION WITH ENDOCRINE THERAPY (TAMOXIFEN OR AN AROMATASE INHIBITOR) FOR THE ADJUVANT TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE, NODE POSITIVE, EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE",VERZENIO,ELI LILLY AND CO,N,208716,RX,TABLET,ORAL,2017-09-28,2029-12-15
2448,15MG;EQ 100MG BASE,9439901,AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES,STEGLUJAN,MSD SUB MERCK,N,209805,RX,TABLET,ORAL,2017-12-19,2030-10-21
3317,15MG,7468363,"USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB",REVLIMID,CELGENE,N,021880,RX,CAPSULE,ORAL,2006-06-29,2023-10-07
5037,EQ 4.5MG BASE,RE49110,TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) WITH CARIPRAZINE,VRAYLAR,ABBVIE,N,204370,RX,CAPSULE,ORAL,2015-09-17,2029-07-16
4811,400MG;100MG,9085573,FOR THE TREATMENT OF HEPATITIS C,EPCLUSA,GILEAD SCIENCES INC,N,208341,RX,TABLET,ORAL,2016-06-28,2028-03-21
4799,0.1MG/INH;EQ 0.025MG BASE/INH,11116721,"INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS",BREO ELLIPTA,GLAXO GRP LTD,N,204275,RX,POWDER,INHALATION,2013-05-10,2029-02-26
3317,25MG,7468363,"USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB",REVLIMID,CELGENE,N,021880,RX,CAPSULE,ORAL,2006-06-29,2023-10-07
5154,400MG;100MG,11116783,FOR THE TREATMENT OF HEPATITIS C,EPCLUSA,GILEAD SCIENCES INC,N,208341,RX,TABLET,ORAL,2016-06-28,2034-01-30
242,300MG/VIAL,8030313,"TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA",ABILIFY MAINTENA KIT,OTSUKA PHARM CO LTD,N,202971,RX,"FOR SUSPENSION, EXTENDED RELEASE",INTRAMUSCULAR,2013-02-28,2024-10-19
1003,150MG;150MG;200MG;300MG,7635704,TREATMENT OF HIV INFECTION,STRIBILD,GILEAD SCIENCES INC,N,203100,RX,TABLET,ORAL,2012-08-27,2026-10-26
1567,36.25MG;145MG,9901640,TREATMENT OF PARKINSONS DISEASE,RYTARY,IMPAX LABS INC,N,203312,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2015-01-07,2028-12-26
1413,500MG,9198892,USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF ONSET AND/OR RECURRENCE OF CARDIOVASCULAR EVENTS IN A PATIENT WHO HAS ESCAPED THE UNSTABLE PERIOD AFTER CARDIOVASCULAR ANGIOPLASTY,VASCEPA,AMARIN PHARMS,N,202057,RX,CAPSULE,ORAL,2017-02-16,2027-09-25
1057,0.01MG,11497709,TREATMENT OF DYSPAREUNIA,IMVEXXY,MAYNE PHARMA,N,208564,RX,INSERT,VAGINAL,2018-05-29,2032-11-21
4721,EQ 5MG BASE,10016404,A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES,JUXTAPID,AMRYT,N,203858,RX,CAPSULE,ORAL,2012-12-21,2025-03-07
4188,80MG/ML,8703156,METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD,FERRIPROX,CHIESI,N,208030,DISCN,SOLUTION,ORAL,2018-04-20,2029-10-26
5142,EQ 17MG BASE,9566271,TREATMENT OF HALLUCINATIONS AND DELUSIONS ASSOCIATED WITH PARKINSONS DISEASE PSYCHOSIS,NUPLAZID,ACADIA PHARMS INC,N,207318,DISCN,TABLET,ORAL,2016-04-29,2024-01-15
5226,24MG,11311488,A METHOD OF TREATING HUNTINGTONS CHOREA,AUSTEDO XR,TEVA,N,216354,RX,"TABLET, EXTENDED RELEASE",ORAL,2023-02-17,2041-06-10
5067,EQ 2.3MG BASE,8003819,USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY,NINLARO,TAKEDA PHARMS USA,N,208462,RX,CAPSULE,ORAL,2015-11-20,2027-08-06
5446,4MG,9062014,"TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS",PONVORY,JANSSEN PHARMS,N,213498,RX,TABLET,ORAL,2021-03-18,2032-05-06
5372,"100MG,75MG,50MG; 150MG",11179367,TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A MUTATION THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH A COMPOSITION ACCORDING TO AT LEAST ONE OF CLAIMS 1-9 OF US11179367,TRIKAFTA (COPACKAGED),VERTEX PHARMS INC,N,212273,RX,TABLET,ORAL,2019-10-21,2037-12-08
4399,EQ 25MG ACID,8052993,PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY,PROMACTA,NOVARTIS,N,022291,RX,TABLET,ORAL,2008-11-20,2027-08-01
4715,EQ 80MG BASE,11098015,METHOD OF TREATING MEDULLARY THYROID CANCER,COMETRIQ,EXELIXIS,N,203756,RX,CAPSULE,ORAL,2012-11-29,2030-01-15
1932,EQ 50MG BASE,7169791,A METHOD FOR THE TREATMENT OF LEUKEMIAS,TASIGNA,NOVARTIS,N,022068,RX,CAPSULE,ORAL,2018-03-22,2023-07-04
5202,2MG,9089574,"TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN HOSPITALIZED ADULTS REQUIRING SUPPLEMENTAL OXYGEN, NON-INVASIVE OR INVASIVE MECHANICAL VENTILATION, OR EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)",OLUMIANT,ELI LILLY AND CO,N,207924,RX,TABLET,ORAL,2018-05-31,2032-11-30
144,EQ 137MG BASE,10646456,"TREATMENT OF DYSKINESIA, DECREASING OFF TIME, AND INCREASING ON TIME WITHOUT TROUBLESOME DYSKINESIA IN PATIENTS WITH PARKINSONS DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS",GOCOVRI,ADAMAS OPERATIONS,N,208944,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2017-08-24,2034-06-17
4921,EQ 50MG BASE,8076515,ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSONS DISEASE EXPERIENCING OFF EPISODES,XADAGO,MDD US,N,207145,RX,TABLET,ORAL,2017-03-21,2028-12-10
4190,EQ 20MG BASE,8829013,FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA,JAKAFI,INCYTE CORP,N,202192,RX,TABLET,ORAL,2011-11-16,2028-06-12
4881,15MG,7951797,TREATMENT OF INSOMNIA,BELSOMRA,MERCK SHARP DOHME,N,204569,RX,TABLET,ORAL,2014-08-13,2029-11-20
1725,5MG;1GM;EQ 2.5MG BASE,8501698,TREATMENT OF TYPE 2 DIABETES MELLITUS,QTERNMET XR,ASTRAZENECA AB,N,210874,DISCN,"TABLET, EXTENDED RELEASE",ORAL,2019-05-02,2027-06-20
4907,150MG,8143241,"TREATMENT OF HR-POSITIVE, HER-2 NEGATIVE, GBRCA-MUTATED METASTATIC BREAST CANCER, WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT, OR METASTATIC SETTING, AND WITH ENDOCRINE THERAPY OR ARE INAPPROPRIATE FOR ENDOCRINE THERAPY",LYNPARZA,ASTRAZENECA,N,208558,RX,TABLET,ORAL,2017-08-17,2027-08-12
4228,188MG/PACKET;150MG/PACKET,8324242,TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND IVACAFTOR,ORKAMBI,VERTEX PHARMS INC,N,211358,RX,GRANULE,ORAL,2018-08-07,2027-08-05
4758,50MG;500MG,7943582,TREATMENT OF TYPE 2 DIABETES MELLITUS,INVOKAMET,JANSSEN PHARMS,N,204353,RX,TABLET,ORAL,2014-08-08,2029-02-26
4175,5MG;2.5MG;1GM,8551957,"METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN",TRIJARDY XR,BOEHRINGER INGELHEIM,N,212614,RX,"TABLET, EXTENDED RELEASE",ORAL,2020-01-27,2029-10-14
2046,EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL,10828297,USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMOTHERAPY,AKYNZEO,HELSINN HLTHCARE,N,210493,RX,POWDER,INTRAVENOUS,2018-04-19,2030-12-17
4758,50MG;500MG,8513202,TREATMENT OF TYPE 2 DIABETES MELLITUS,INVOKAMET,JANSSEN PHARMS,N,204353,RX,TABLET,ORAL,2014-08-08,2027-12-03
4715,EQ 60MG BASE,11098015,TREATMENT OF DIFFERENTIATED THYROID CANCER THAT HAS PROGRESSED FOLLOWING PRIOR VEGFR-TARGETED THERAPY,CABOMETYX,EXELIXIS INC,N,208692,RX,TABLET,ORAL,2016-04-25,2030-01-15
1883,EQ 200MG BASE,10028925,TEMPORARY RELIEF OF MINOR ACHES AND PAINS,NAPROXEN SODIUM,BIONPHARMA,N,021920,OTC,CAPSULE,ORAL,2006-02-17,2026-03-03
1225,0.055MG/INH;EQ 0.014MG BASE/INH,9415008,TREATMENT OF ASTHMA,AIRDUO RESPICLICK,TEVA PHARM,N,208799,RX,POWDER,INHALATION,2017-01-27,2034-10-06
4810,420MG,10004746,TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION,IMBRUVICA,PHARMACYCLICS LLC,N,210563,RX,TABLET,ORAL,2018-02-16,2031-06-03
5222,EQ 100MG BASE,8859562,"A METHOD OF TREATMENT OF ADVANCED OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER ASSOCIATED WITH HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) POSITIVE STATUS",ZEJULA,GLAXOSMITHKLINE,N,214876,RX,TABLET,ORAL,2023-04-26,2031-08-04
2029,18MG,9968598,"MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE",XTAMPZA ER,COLLEGIUM PHARM INC,N,208090,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2016-04-26,2036-09-02
1572,52MG,10028858,A METHOD FOR PREVENTION OF PREGNANCY,LILETTA,MEDICINES360,N,206229,RX,INTRAUTERINE DEVICE,INTRAUTERINE,2015-02-26,2034-03-22
1676,300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML),11083730,"TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION",ZYNRELEF KIT,HERON THERAPS INC,N,211988,DISCN,"SOLUTION, EXTENDED RELEASE",PERIARTICULAR,2021-05-12,2035-04-20
5128,100MG IRON/2ML (50MG IRON/ML),11590097,METHOD OF TREATING IDA IN ADULT PATIENTS WITH NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE & WEIGHING AT LEAST 40 KG BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 GRAMS OF ELEMENTAL IRON,INJECTAFER,AM REGENT,N,203565,RX,SOLUTION,INTRAVENOUS,2022-02-04,2023-10-20
4188,1GM,10940115,METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD,FERRIPROX,CHIESI,N,212269,RX,TABLET,ORAL,2020-05-19,2038-10-25
4921,EQ 100MG BASE,8283380,ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSONS DISEASE EXPERIENCING OFF EPISODES,XADAGO,MDD US,N,207145,RX,TABLET,ORAL,2017-03-21,2031-03-21
5462,EQ 150MG BASE,8188085,TREATMENT OF ADULT AND POST-MENARCHAL PEDIATRIC FEMALES WITH VULVOVAGINAL CANDIDIASIS (VVC),BREXAFEMME,SCYNEXIS,N,214900,RX,TABLET,ORAL,2021-06-01,2030-08-28
4801,EQ 75MG BASE,7994185,"TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION",TAFINLAR,NOVARTIS,N,202806,RX,CAPSULE,ORAL,2013-05-29,2030-01-20
4483,60MG/VIAL,8129346,TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY,KYPROLIS,ONYX PHARMS AMGEN,N,202714,RX,POWDER,INTRAVENOUS,2012-07-20,2025-04-14
144,EQ 137MG BASE,11197835,"TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSONS DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS",GOCOVRI,ADAMAS OPERATIONS,N,208944,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2017-08-24,2030-12-02
4483,10MG/VIAL,8129346,KYPROLIS IS INDICATED AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE OR MORE LINES OF THERAPY,KYPROLIS,ONYX PHARMS AMGEN,N,202714,RX,POWDER,INTRAVENOUS,2018-06-07,2025-04-14
4811,400MG,8633309,FOR THE TREATMENT OF HEPATITIS C,SOVALDI,GILEAD SCIENCES INC,N,204671,RX,TABLET,ORAL,2013-12-06,2029-03-26
2029,80MG,11304909,"MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE",OXYCONTIN,PURDUE PHARMA LP,N,022272,RX,"TABLET, EXTENDED RELEASE",ORAL,2010-04-05,2027-08-24
4224,801MG,7635707,DOSING 1602 MG/DAY PIRFENIDONE FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF,ESBRIET,GENENTECH INC,N,208780,RX,TABLET,ORAL,2017-01-11,2029-04-22
1725,10MG;1GM,9949997,METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN,SYNJARDY XR,BOEHRINGER INGELHEIM,N,208658,RX,"TABLET, EXTENDED RELEASE",ORAL,2016-12-09,2034-05-17
5278,240MG,8445507,"TREATMENT OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)",ERLEADA,JANSSEN BIOTECH,N,210951,RX,TABLET,ORAL,2023-02-17,2030-09-15
5014,0.25MG,9839637,TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER,REXULTI,OTSUKA,N,205422,RX,TABLET,ORAL,2015-07-10,2026-04-12
302,100MG/4ML (25MG/ML),11103483,FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA,BENDEKA,EAGLE PHARMS,N,208194,RX,SOLUTION,IV (INFUSION),2015-12-07,2031-01-28
5382,180MG;10MG,10912751,A METHOD OF TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE BY DECREASING THE LEVEL OF LDL-C USING A FIXED DOSE COMBINATION OF 180 MG BEMPEDOIC ACID AND 10 MG EZETIMIBE,NEXLIZET,ESPERION THERAPS INC,N,211617,RX,TABLET,ORAL,2020-02-26,2036-03-14
2684,28MG,10207066,TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA,TOBI PODHALER,MYLAN SPECIALITY LP,N,201688,RX,POWDER,INHALATION,2013-03-22,2030-11-04
2713,650MG,8487005,TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING,LYSTEDA,AMRING PHARMS,N,022430,RX,TABLET,ORAL,2009-11-13,2025-03-04
1725,10MG;1GM,10596120,TREATMENT OF A TREATMENT-NAÃVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN,SYNJARDY XR,BOEHRINGER INGELHEIM,N,208658,RX,"TABLET, EXTENDED RELEASE",ORAL,2016-12-09,2032-03-07
5468,0.6MG,10981952,METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC),BYLVAY,ALBIREO,N,215498,RX,"CAPSULE, PELLETS",ORAL,2021-07-20,2031-11-08
2029,325MG;7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**,8372432,MANAGEMENT OF ACUTE PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA,XARTEMIS XR,MALLINCKRODT INC,N,204031,DISCN,"TABLET, EXTENDED RELEASE",ORAL,2014-03-11,2029-03-11
5010,125MG;100MG,11564916,TREATMENT OF CF IN A PATIENT AGE 6 YEARS AND OLDER WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE COMPOSITION RECITED IN CLAIM 1 OF US 11564916,ORKAMBI,VERTEX PHARMS INC,N,206038,RX,TABLET,ORAL,2016-09-28,2029-08-13
2593,600MG;200MG;300MG,9545414,TREATMENT OF HIV-1 INFECTION IN ADULTS,ATRIPLA,GILEAD SCIENCES,N,021937,RX,TABLET,ORAL,2006-07-12,2026-06-13
228,10MG,10420763,TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSONS DISEASE,KYNMOBI,SUMITOMO PHARMA AM,N,210875,DISCN,FILM,SUBLINGUAL,2020-05-21,2030-06-11
5218,EQ 200MG BASE,8962630,"IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER",KISQALI,NOVARTIS,N,209092,RX,TABLET,ORAL,2017-03-13,2029-12-09
4382,50MG,8772315,"USE IN COMBINATION WITH THE MUSCARINIC ANTAGONIST SOLIFENACIN SUCCINATE FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY",MYRBETRIQ,APGDI,N,202611,RX,"TABLET, EXTENDED RELEASE",ORAL,2012-06-28,2028-10-30
5226,24MG,11446291,TREATMENT OF TARDIVE DYSKINESIA,AUSTEDO XR,TEVA,N,216354,RX,"TABLET, EXTENDED RELEASE",ORAL,2023-02-17,2036-03-07
5258,EQ 0.89MG BASE,11504365,TREATMENT OF ADULTS WITH MODERATE HEPATIC IMPAIRMENT AND RELAPSED OR REFRACTORY ADVANCED RENAL CELL CARCINOMA FOLLOWING TWO OR MORE PRIOR SYSTEMIC ANTI-CANCER THERAPIES WITH 1MG TIVOZANIB HCL ORALLY FOR 21 DAYS FOLLOWED BY NO DRUG FOR 7 DAYS,FOTIVDA,AVEO PHARMS,N,212904,RX,CAPSULE,ORAL,2021-03-10,2039-11-05
5110,EQ 123MG BASE,10525045,THE TREATMENT OF FABRY PATIENTS,GALAFOLD,AMICUS THERAP US,N,208623,RX,CAPSULE,ORAL,2018-08-10,2028-04-28
2029,10MG,8808741,"MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE",OXYCONTIN,PURDUE PHARMA LP,N,022272,RX,"TABLET, EXTENDED RELEASE",ORAL,2010-04-05,2027-08-24
1003,150MG;150MG;200MG;300MG,8148374,TREATMENT OF HIV INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE,STRIBILD,GILEAD SCIENCES INC,N,203100,RX,TABLET,ORAL,2012-08-27,2029-09-03
179,5MG/2ML (2.5MG/ML),9889118,TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING,BARHEMSYS,ACACIA,N,209510,RX,SOLUTION,INTRAVENOUS,2020-02-26,2031-03-10
1813,EQ 90MG BASE,7919483,TREATMENT OF ACNE,XIMINO,JOURNEY,N,201922,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2012-07-11,2027-03-07
2571,0.01%;0.045%,11679115,TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS,DUOBRII,BAUSCH,N,209354,RX,LOTION,TOPICAL,2019-04-25,2036-06-06
5372,"50MG,37.5MG,25MG; 75MG",9974781,"TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR",TRIKAFTA (COPACKAGED),VERTEX PHARMS INC,N,212273,RX,TABLET,ORAL,2021-06-08,2027-04-09
5227,EQ 40MG BASE,10912771,TREATMENT OF TARDIVE DYSKINESIA,INGREZZA,NEUROCRINE,N,209241,RX,CAPSULE,ORAL,2017-04-11,2037-10-10
403,EQ 0.8MG BASE,9700555,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 13,CYCLOSET,VEROSCIENCE,N,020866,RX,TABLET,ORAL,2009-05-05,2032-04-30
1386,80MG,10130591,"MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE",HYSINGLA ER,PURDUE PHARMA LP,N,206627,RX,"TABLET, EXTENDED RELEASE",ORAL,2014-11-20,2023-11-20
4875,EQ 60MG BASE,8642025,METHOD OF INHIBITING HEPATITIS C VIRUS,DAKLINZA,BRISTOL-MYERS SQUIBB,N,206843,DISCN,TABLET,ORAL,2015-07-24,2027-08-11
968,3.5MG,10179140,PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE,DROSPIRENONE,EXELTIS USA INC,N,216285,DISCN,"TABLET, CHEWABLE",ORAL,2022-06-29,2031-06-28
1055,EQ 20MG BASE;375MG,8945621,RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS ALSO TAKING LOW DOSE ASPIRIN,VIMOVO,HORIZON,N,022511,RX,"TABLET, DELAYED RELEASE",ORAL,2010-04-30,2031-10-17
4830,25MG;5MG;1GM,10596120,TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN,TRIJARDY XR,BOEHRINGER INGELHEIM,N,212614,RX,"TABLET, EXTENDED RELEASE",ORAL,2020-01-27,2032-03-07
4797,"300MG/10ML(30MG/ML),N/A;N/A,12.5GM/50ML(250MG/ML)",9687506,SODIUM NITRITE INJECTION IS ADMINISTERED BY INTRAVENOUS INJECTION,NITHIODOTE,HOPE PHARMS,N,201444,RX,"SOLUTION, SOLUTION","INTRAVENOUS, INTRAVENOUS",2011-01-14,2030-02-10
3317,10MG,7468363,"USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB",REVLIMID,CELGENE,N,021880,RX,CAPSULE,ORAL,2005-12-27,2023-10-07
5276,"150MG;150MG, 100MG",10206877,"TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 12 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,206,877",SYMDEKO (COPACKAGED),VERTEX PHARMS INC,N,210491,RX,TABLET,ORAL,2018-02-12,2035-04-14
4820,20MG,10149829,TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH CYP1A2 STRONG INHIBITORS,HETLIOZ,VANDA PHARMS INC,N,205677,RX,CAPSULE,ORAL,2014-01-31,2033-01-25
5355,12.5MG,11654133,CO-ADMINISTRATION OF CENOBAMATE WITH PHENOBARBITAL AND/OR PHENYTOIN FOR THE TREATMENT OF PARTIAL ONSET SEIZURES,XCOPRI,SK LIFE,N,212839,RX,TABLET,ORAL,2020-03-10,2039-06-16
1386,40MG,9333201,TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT,ZOHYDRO ER,RECRO GAINESVILLE,N,202880,DISCN,"CAPSULE, EXTENDED RELEASE",ORAL,2013-10-25,2033-07-25
4810,140MG,8952015,TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION,IMBRUVICA,PHARMACYCLICS LLC,N,210563,RX,TABLET,ORAL,2018-02-16,2026-12-28
4830,12.5MG;2.5MG;1GM,10596120,TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN,TRIJARDY XR,BOEHRINGER INGELHEIM,N,212614,RX,"TABLET, EXTENDED RELEASE",ORAL,2020-01-27,2032-03-07
2029,13.5MG,9682075,"MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE",XTAMPZA ER,COLLEGIUM PHARM INC,N,208090,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2016-04-26,2030-12-10
403,EQ 0.8MG BASE,9700555,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 15 AND 27,CYCLOSET,VEROSCIENCE,N,020866,RX,TABLET,ORAL,2009-05-05,2032-04-30
1832,1.35MG,8109918,TREATMENT OF NASAL POLYPS IN PATIENTS >=18 YEARS OF AGE WHO HAVE HAD ETHMOID SINUS SURGERY USING A CORTICOSTEROID-ELUTING (MOMETASONE FUROATE) IMPLANT,SINUVA,INTERSECT ENT INC,N,209310,RX,IMPLANT,IMPLANTATION,2017-12-08,2024-03-12
835,EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML),8455527,USE FOR SEDATION,PRECEDEX,HOSPIRA,N,021038,RX,INJECTABLE,INJECTION,2013-03-13,2032-01-04
666,12GM/BOT;3.5GM/BOT;10MG/BOT,11191753,FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY,CLENPIQ,FERRING PHARMS INC,N,209589,RX,SOLUTION,ORAL,2017-11-28,2034-06-23
2233,0.75MG,8679533,TREATMENT OF PARKINSONS DISEASE,MIRAPEX ER,BOEHRINGER INGELHEIM,N,022421,RX,"TABLET, EXTENDED RELEASE",ORAL,2010-02-19,2029-09-08
726,0.6MG,8440721,METHOD OF TREATING GOUT FLARES,COLCRYS,TAKEDA PHARMS USA,N,022352,RX,TABLET,ORAL,2009-07-29,2029-02-17
2352,EQ 100MG BASE/PACKET,7754731,TREATMENT OF HIV INFECTION,ISENTRESS,MSD SUB MERCK,N,205786,RX,POWDER,ORAL,2013-12-20,2029-03-11
2706,200MG,8298580,TREATMENT OF EPILEPSY,TROKENDI XR,SUPERNUS PHARMS,N,201635,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2013-08-16,2027-11-16
4135,60MG,7674774,INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD),VYVANSE,TAKEDA PHARMS USA,N,021977,RX,CAPSULE,ORAL,2007-12-10,2023-02-24
1082,"0.01MG,0.01MG,N/A;1MG,N/A,N/A",7704984,PREVENTION OF PREGNANCY,LO MINASTRIN FE,APIL,N,204654,DISCN,"TABLET, CHEWABLE, TABLET",ORAL,2013-07-24,2029-02-02
5406,1MG/ML (1MG/ML),11077098,MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION,OLINVYK,TREVENA,N,210730,RX,SOLUTION,INTRAVENOUS,2020-10-30,2032-03-23
4830,5MG;1GM,9949997,METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN,SYNJARDY XR,BOEHRINGER INGELHEIM,N,208658,RX,"TABLET, EXTENDED RELEASE",ORAL,2016-12-09,2034-05-17
1413,1GM,8563608,METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA,VASCEPA,AMARIN PHARMS,N,202057,RX,CAPSULE,ORAL,2012-07-26,2030-04-29
842,105MG;45MG,10881624,DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER,AUVELITY,AXSOME,N,215430,RX,"TABLET, EXTENDED RELEASE",ORAL,2022-08-18,2034-11-05
2389,90MG,10376590,METHOD OF TREATING SCHIZOPHRENIA,PERSERIS KIT,INDIVIOR,N,210655,RX,"FOR SUSPENSION, EXTENDED RELEASE",SUBCUTANEOUS,2018-07-27,2028-02-13
946,10MG;14MG,8058291,MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE,NAMZARIC,ABBVIE,N,206439,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2014-12-23,2029-12-05
1413,500MG,8445003,METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA,VASCEPA,AMARIN PHARMS,N,202057,RX,CAPSULE,ORAL,2017-02-16,2030-04-29
432,133MG/10ML (13.3MG/ML),11278494,"METHOD OF TREATING PAIN, FOR EXAMPLE, TREATING POSTSURGICAL PAIN VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA",EXPAREL,PACIRA PHARMS INC,N,022496,RX,"INJECTABLE, LIPOSOMAL",INJECTION,2011-10-28,2041-01-22
5062,EQ 40MG BASE,8946235,ADJUVANT THERAPY AFTER TUMOR RESECTION IN PATIENTS WITH NON-SMALL CELL LUNG CANCER(NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19DELETIONS OR EXON 21 L858R MUTATIONS,TAGRISSO,ASTRAZENECA,N,208065,RX,TABLET,ORAL,2015-11-13,2032-08-08
4483,30MG/VIAL,8207127,KYPROLIS IS INDICATED IN COMBINATION WITH DARATUMUMAB PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY,KYPROLIS,ONYX PHARMS AMGEN,N,202714,RX,POWDER,INTRAVENOUS,2016-06-03,2025-04-14
432,200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML),11413350,"TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER FOOT AND ANKLE, SMALL-TO-MEDIUM OPEN ABDOMINAL, AND LOWER EXTREMITY TOTAL JOINT ARTHROPLASTY SURGICAL PROCEDURES VIA INSTILLATION",ZYNRELEF KIT,HERON THERAPS INC,N,211988,RX,"SOLUTION, EXTENDED RELEASE",PERIARTICULAR,2021-05-12,2035-04-20
434,96MG/0.27ML (356MG/ML),11110084,A METHOD OF ADMINISTERING AN OPIOID MAINTENANCE TREATMENT COMPRISING BUPRENORPHINE,BRIXADI,BRAEBURN,N,210136,RX,"SOLUTION, EXTENDED RELEASE",SUBCUTANEOUS,2023-05-23,2032-07-26
1725,5MG;2.5MG;1GM,10022379,"METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID",TRIJARDY XR,BOEHRINGER INGELHEIM,N,212614,RX,"TABLET, EXTENDED RELEASE",ORAL,2020-01-27,2029-04-02
1028,2MG/250ML (8MCG/ML),11083698,TO INCREASE MEAN ARTERIAL BLOOD PRESSURE IN ADULT PATIENTS WITH HYPOTENSION ASSOCIATED WITH SEPTIC SHOCK,EPINEPHRINE IN 0.9% SODIUM CHLORIDE,PAR STERILE PRODUCTS,N,215875,RX,SOLUTION,INTRAVENOUS,2023-04-21,2039-03-21
4716,EQ 45MG BASE,11192897,A METHOD FOR TREATING CHRONIC MYELOID LEUKEMIA,ICLUSIG,TAKEDA PHARMS USA,N,203469,RX,TABLET,ORAL,2012-12-14,2033-12-12
5014,0.25MG,8618109,TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER,REXULTI,OTSUKA,N,205422,RX,TABLET,ORAL,2015-07-10,2026-04-12
4498,78MG/0.5ML (78MG/0.5ML),9439906,DOSING REGIMEN FOR THE TREATMENT OF SCHIZOAFFECTIVE DISORDER IN ADULTS AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS BY ADMINISTERING TWO LOADING DOSES OF PALIPERIDONE PALMITATE FOLLOWED BY MAINTENANCE DOSE(S),INVEGA SUSTENNA,JANSSEN PHARMS,N,022264,RX,"SUSPENSION, EXTENDED RELEASE",INTRAMUSCULAR,2009-07-31,2031-01-26
4810,280MG,10004746,TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION,IMBRUVICA,PHARMACYCLICS LLC,N,210563,RX,TABLET,ORAL,2018-02-16,2031-06-03
4907,150MG,8912187,"MAINTENANCE TREATMENT OF RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY",LYNPARZA,ASTRAZENECA,N,208558,RX,TABLET,ORAL,2017-08-17,2024-03-12
4801,EQ 50MG BASE,8835443,"TAFINLAR(R) IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST.",TAFINLAR,NOVARTIS,N,202806,RX,CAPSULE,ORAL,2013-05-29,2025-06-10
1725,5MG;1GM,10022379,"USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS",JENTADUETO XR,BOEHRINGER INGELHEIM,N,208026,RX,"TABLET, EXTENDED RELEASE",ORAL,2016-05-27,2029-04-02
4135,20MG,7662788,FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),VYVANSE,TAKEDA PHARMS USA,N,021977,RX,CAPSULE,ORAL,2007-12-10,2023-02-24
956,EQ 3MG BASE,10653660,TREATMENT OF INSOMNIA,SILENOR,CURRAX,N,022036,RX,TABLET,ORAL,2010-03-17,2027-07-20
4135,30MG,7678771,FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),VYVANSE,TAKEDA PHARMS USA,N,208510,RX,"TABLET, CHEWABLE",ORAL,2017-01-28,2023-02-24
4359,EQ 500MG BASE,11103497,"A METHOD FOR TREATING A BCRABL POSITIVE LEUKEMIA IN A SUBJECT THAT IS RESISTANT TO IMATINIB COMPRISING ADMINISTERING TO THE SUBJECT A THERAPEUTICALLY EFFECTIVE AMOUNT OF BOSUTINIB, WHEREIN THE SUBJECT HAS A MUTATION IN THE BCRABL PROTEIN AT 949T>C",BOSULIF,PF PRISM CV,N,203341,RX,TABLET,ORAL,2012-09-04,2034-02-28
4810,420MG,8754090,TREATMENT OF MANTLE CELL LYMPHOMA,IMBRUVICA,PHARMACYCLICS LLC,N,210563,RX,TABLET,ORAL,2018-02-16,2031-06-03
228,25MG,8846074,TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSONS DISEASE,KYNMOBI,SUMITOMO PHARMA AM,N,210875,DISCN,FILM,SUBLINGUAL,2020-05-21,2031-12-16
1725,5MG;1GM,9949997,METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN,SYNJARDY XR,BOEHRINGER INGELHEIM,N,208658,RX,"TABLET, EXTENDED RELEASE",ORAL,2016-12-09,2034-05-17
328,3.75%;EQ 1.2% BASE,10220049,TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER,ONEXTON,BAUSCH,N,050819,RX,GEL,TOPICAL,2014-11-24,2029-06-03
4811,400MG,8334270,FOR THE TREATMENT OF HEPATITIS C,SOVALDI,GILEAD SCIENCES INC,N,204671,RX,TABLET,ORAL,2013-12-06,2028-03-21
2448,15MG;EQ 100MG BASE,7326708,AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES,STEGLUJAN,MSD SUB MERCK,N,209805,RX,TABLET,ORAL,2017-12-19,2026-11-24
1413,1GM,8617594,METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA,VASCEPA,AMARIN PHARMS,N,202057,RX,CAPSULE,ORAL,2012-07-26,2030-04-29
435,105MG;45MG,11541048,DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER,AUVELITY,AXSOME,N,215430,RX,"TABLET, EXTENDED RELEASE",ORAL,2022-08-18,2034-11-05
4832,EQ 12.5MG BASE,7056500,TREATMENT OF OPIOID-INDUCED CONSTIPATION,MOVANTIK,VALINOR,N,204760,RX,TABLET,ORAL,2014-09-16,2024-06-29
5126,1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS,10117844,TREATMENT OF SEVERE HYPERTRIGLYCERIDEMIA (500 MG/DL) IN ADULT PATIENTS AS AN ADJUNCT TO DIET,EPANOVA,ASTRAZENECA,N,205060,DISCN,CAPSULE,ORAL,2014-05-05,2033-01-04
242,5MG,8759350,ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD),ABILIFY,OTSUKA,N,021436,RX,TABLET,ORAL,2002-11-15,2027-03-02
5400,EQ 20MG BASE/VIAL,10195210,USE OF REMIMAZOLAM FOR INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION IN ADULTS UNDERGOING PROCEDURES LASTING 30 MINUTES OR LESS,BYFAVO,ACACIA,N,212295,RX,POWDER,INTRAVENOUS,2020-10-06,2031-11-07
4224,534MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**,7635707,"DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY 801 MG/DAY, DOSE, THEN 1602 MG/DAY IN TREATMENT OF IPF",ESBRIET,GENENTECH INC,N,208780,DISCN,TABLET,ORAL,2017-01-11,2029-04-22
2140,EQ 11.25MG BASE;69MG,8895057,"FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG/M2 OR BMI >=27 KG/M2 WITH A WEIGHT-RELATED COMORBIDITY, AND PATIENTS AGE 12-17 WITH BMI >=25 KG/M2 IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX)",QSYMIA,VIVUS,N,022580,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2012-07-17,2028-06-09
4228,25MG/PACKET,8324242,TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA,KALYDECO,VERTEX PHARMS INC,N,207925,RX,GRANULE,ORAL,2019-04-29,2027-08-05
5154,200MG;50MG,10086011,FOR THE TREATMENT OF HEPATITIS C,EPCLUSA,GILEAD SCIENCES INC,N,208341,RX,TABLET,ORAL,2020-03-19,2034-01-30
4498,1.560GM/5ML (312MG/ML),11324751,TREATMENT OF SCHIZOPHRENIA BY ADMINISTERING A DOSE UP TO TWO WEEKS BEFORE OR THREE WEEKS AFTER THE SCHEDULED SIX-MONTH DOSE,INVEGA HAFYERA,JANSSEN PHARMS,N,207946,RX,"SUSPENSION, EXTENDED RELEASE",INTRAMUSCULAR,2021-08-30,2041-05-07
242,15MG,9444503,METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT,ABILIFY MYCITE KIT,OTSUKA,N,207202,RX,TABLET,ORAL,2017-11-13,2027-11-19
4810,280MG,8476284,TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA,IMBRUVICA,PHARMACYCLICS LLC,N,210563,RX,TABLET,ORAL,2018-02-16,2026-12-28
4802,EQ 2MG,8703781,"MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST",MEKINIST,NOVARTIS,N,204114,RX,TABLET,ORAL,2013-05-29,2030-10-15
328,5%,11426378,TOPICAL TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA IN ADULTS 18 YEARS OF AGE AND OLDER,EPSOLAY,GALDERMA LABS LP,N,214510,RX,CREAM,TOPICAL,2022-04-22,2040-08-18
434,300MG/1.5ML (200MG/ML),9498432,IN SITU FORMATION OF SOLID BUPRENORPHINE COMPOSITION,SUBLOCADE,INDIVIOR,N,209819,RX,"SOLUTION, EXTENDED RELEASE",SUBCUTANEOUS,2017-11-30,2031-06-06
144,EQ 68.5MG BASE,11077073,"DECREASING OFF TIME IN PATIENTS WITH PARKINSONS DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS",GOCOVRI,ADAMAS OPERATIONS,N,208944,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2017-08-24,2038-08-23
2427,2GM/PACKET,11000508,TREATMENT OF TRICHOMONIASIS IN PATIENTS 12 YEARS OF AGE AND OLDER,SOLOSEC,LUPIN,N,209363,RX,GRANULE,ORAL,2017-09-15,2035-09-04
4224,801MG,8648098,DISCONTINUING SMOKING TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE,ESBRIET,GENENTECH INC,N,208780,RX,TABLET,ORAL,2017-01-11,2030-01-08
1123,2MG/VIAL,7456254,"AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES",BYDUREON,ASTRAZENECA AB,N,022200,DISCN,"FOR SUSPENSION, EXTENDED RELEASE",SUBCUTANEOUS,2012-01-27,2025-06-30
5128,1GM IRON/20ML (50MG IRON/ML),7754702,METHOD TO TREAT IDA IN ADULTS WEIGHING AT LEAST 40 KG WITH HEART FAILURE & NY HEART ASSOCIATION CLASS II/III TO IMPROVE EXERCISE CAPACITY BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 G OF ELEMENTAL IRON,INJECTAFER,AM REGENT,N,203565,RX,SOLUTION,INTRAVENOUS,2021-04-28,2028-02-15
2552,EQ 1MG BASE,10864199,PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS CONVERTED FROM TACROLIMUS IMMEDIATE-RELEASE FORMULATIONS,ENVARSUS XR,VELOXIS PHARMS INC,N,206406,RX,"TABLET, EXTENDED RELEASE",ORAL,2015-07-10,2028-05-30
228,25MG,8414922,TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSONS DISEASE,KYNMOBI,SUMITOMO PHARMA AM,N,210875,DISCN,FILM,SUBLINGUAL,2020-05-21,2031-12-16
1725,10MG;1GM,8685934,"TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE",XIGDUO XR,ASTRAZENECA AB,N,205649,RX,"TABLET, EXTENDED RELEASE",ORAL,2014-10-29,2030-05-26
1832,0.025MG/SPRAY;0.665MG/SPRAY,10758550,TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE TO A PEDIATRIC PATIENT,RYALTRIS,GLENMARK SPECIALTY,N,211746,RX,"SPRAY, METERED",NASAL,2022-01-13,2034-09-04
2464,150MG/10ML (15MG/ML),11583216,INTRAVENOUS SOTALOL DOSING REGIMEN FOR USE IN A FACILITY THAT CAN PROVIDE ELECTROCARDIOGRAPHIC MONITORING,SOTALOL HYDROCHLORIDE,ALTATHERA PHARMS LLC,N,022306,RX,SOLUTION,INTRAVENOUS,2009-07-02,2039-08-21
4745,1.1GM/ML,9254278,TREATMENT OF A UREA CYCLE DISORDER,RAVICTI,HORIZON THERAP US,N,203284,RX,LIQUID,ORAL,2013-02-01,2032-03-09
2391,150MG;100MG,11351149,"TREATMENT OF MILD-TO-MODERATE CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS WHO ARE AT HIGH RISK FOR PROGRESSION TO SEVERE COVID-19, INCLUDING HOSPITALIZATION OR DEATH",PAXLOVID (COPACKAGED),PFIZER,N,217188,RX,TABLET,ORAL,2023-05-25,2041-08-05
841,9.375MG;9.375MG;9.375MG;9.375MG,6913768,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER,MYDAYIS,TAKEDA PHARMS USA,N,022063,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2017-06-20,2023-05-24
946,10MG;28MG,8039009,MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE,NAMZARIC,ABBVIE,N,206439,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2014-12-23,2029-03-24
5393,40MG,10172851,TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH A RET GENE FUSION THAT HAVE PROGRESSED ON OR FOLLOWING PRIOR SYSTEMIC TREATMENT OR WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS,RETEVMO,LOXO ONCOL ELI LILLY,N,213246,RX,CAPSULE,ORAL,2020-05-08,2037-10-10
4135,50MG,7678770,FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),VYVANSE,TAKEDA PHARMS USA,N,208510,RX,"TABLET, CHEWABLE",ORAL,2017-01-28,2023-02-24
1413,1GM,8709475,USE OF VASCEPA TO TREAT MIXED DYSLIPIDEMIA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (>=150 MG/DL) AND ON STATIN THERAPY,VASCEPA,AMARIN PHARMS,N,202057,RX,CAPSULE,ORAL,2012-07-26,2030-04-29
1551,0.005%;EQ 0.02% BASE,10588901,REDUCTION OF ELEVATED INTRAOCULAR PRESSURE,ROCKLATAN,ALCON LABS INC,N,208259,RX,SOLUTION/DROPS,OPHTHALMIC,2019-03-12,2034-03-14
4806,EQ 5MG BASE,9125908,"USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION",TRINTELLIX,TAKEDA PHARMS USA,N,204447,RX,TABLET,ORAL,2013-09-30,2027-06-15
1832,0.025MG/SPRAY;0.665MG/SPRAY,9750754,TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE,RYALTRIS,GLENMARK SPECIALTY,N,211746,RX,"SPRAY, METERED",NASAL,2022-01-13,2034-09-04
4628,40MG,8183274,THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC).,XTANDI,ASTELLAS,N,203415,RX,CAPSULE,ORAL,2012-08-31,2026-08-24
1386,20MG,9333201,TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT,ZOHYDRO ER,RECRO GAINESVILLE,N,202880,DISCN,"CAPSULE, EXTENDED RELEASE",ORAL,2013-10-25,2033-07-25
5291,200MG,8802714,TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG,TPOXX,SIGA TECHNOLOGIES,N,208627,RX,CAPSULE,ORAL,2018-07-13,2024-06-18
5126,1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS,9132112,TREATMENT OF HYPERTRIGLYCERIDEMIA,EPANOVA,ASTRAZENECA,N,205060,DISCN,CAPSULE,ORAL,2014-05-05,2025-02-07
4175,10MG;5MG;1GM,8119648,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN,TRIJARDY XR,BOEHRINGER INGELHEIM,N,212614,RX,"TABLET, EXTENDED RELEASE",ORAL,2020-01-27,2023-08-12
5289,50MG,9763941,TREATMENT OF MELANOMA,BRAFTOVI,ARRAY BIOPHARMA INC,N,210496,DISCN,CAPSULE,ORAL,2018-06-27,2032-11-21
5380,EQ 200MG BASE,9872862,METHOD OF TREATING A LUNG METASTASIS OF EPITHELIOID SARCOMA,TAZVERIK,EPIZYME INC,N,211723,RX,TABLET,ORAL,2020-01-23,2033-04-11
5345,200MG,9649306,TREATMENT OF SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION,ROZLYTREK,GENENTECH INC,N,212725,RX,CAPSULE,ORAL,2019-08-15,2033-05-22
1123,2MG/0.85ML (2MG/0.85ML),8431685,AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA,BYDUREON BCISE,ASTRAZENECA AB,N,209210,RX,"SUSPENSION, EXTENDED RELEASE",SUBCUTANEOUS,2017-10-20,2025-04-13
1725,12.5MG;2.5MG;1GM,10258637,METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN,TRIJARDY XR,BOEHRINGER INGELHEIM,N,212614,RX,"TABLET, EXTENDED RELEASE",ORAL,2020-01-27,2034-04-03
1386,50MG,9433619,TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT,ZOHYDRO ER,RECRO GAINESVILLE,N,202880,DISCN,"CAPSULE, EXTENDED RELEASE",ORAL,2013-10-25,2033-07-25
961,EQ 60MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**,9295652,TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET,DORYX MPC,MAYNE PHARMA,N,050795,RX,"TABLET, DELAYED RELEASE",ORAL,2016-05-20,2034-10-23
5716,EQ 200MG BASE/VIAL,11654196,TREATMENT OF CANDIDEMIA AND INVASIVE CANDIDIASIS WITH REZAFUNGIN BY INTRAVENOUS ADMINISTRATION,REZZAYO,CIDARA THERAPS,N,217417,RX,POWDER,INTRAVENOUS,2023-03-22,2032-03-02
5390,13.5MG,11628162,"TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FGFR2 FUSION OR OTHER REARRANGEMENT BY ADMINISTERING PEMIGATINIB WHILE AVOIDING THE CONCOMITANT USE OF STRONG AND MODERATE CYP3A INHIBITORS",PEMAZYRE,INCYTE CORP,N,213736,RX,TABLET,ORAL,2020-04-17,2040-08-30
403,EQ 0.8MG BASE,10688155,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 49 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44,CYCLOSET,VEROSCIENCE,N,020866,RX,TABLET,ORAL,2009-05-05,2030-06-07
242,400MG,11154553,"TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA",ABILIFY MAINTENA KIT,OTSUKA PHARM CO LTD,N,202971,RX,"FOR SUSPENSION, EXTENDED RELEASE",INTRAMUSCULAR,2014-09-29,2033-09-24
4175,10MG;5MG,11090323,METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN,GLYXAMBI,BOEHRINGER INGELHEIM,N,206073,RX,TABLET,ORAL,2015-01-30,2034-04-03
5058,1%,9399014,TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES,XEPI,FERRER INTERNACIONAL,N,208945,RX,CREAM,TOPICAL,2017-12-11,2029-12-15
1567,61.25MG;245MG,9089607,"TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION",RYTARY,IMPAX LABS INC,N,203312,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2015-01-07,2028-12-26
1413,1GM,10278936,"USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CARDIOVASCULAR EVENT (CARDIOVASCULAR DEATH, CORONARY REVASCULARIZATION AND/OR UNSTABLE ANGINA) IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS",VASCEPA,AMARIN PHARMS,N,202057,RX,CAPSULE,ORAL,2012-07-26,2033-06-28
4616,12MG/0.6ML (12MG/0.6ML),10376584,TREATMENT OF OPIOID-INDUCED CONSTIPATION,RELISTOR,SALIX PHARMS,N,021964,RX,SOLUTION,SUBCUTANEOUS,2008-04-24,2024-04-08
5305,EQ 25MG BASE,10813936,"METHOD OF TREATING LUNG CANCER, UNDIFFERENTIATED SARCOMA, OR COLORECTAL CANCER THAT EXHIBITS AN NTRK GENE FUSION",VITRAKVI,BAYER HLTHCARE,N,210861,RX,CAPSULE,ORAL,2018-11-26,2035-11-16
5393,80MG,10786489,TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE REFRACTORY DIFFERENTIATED THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND ARE RADIOACTIVE IODINE-REFRACTORY,RETEVMO,LOXO ONCOL ELI LILLY,N,213246,RX,CAPSULE,ORAL,2020-05-08,2038-10-10
4228,"75MG;75MG, 50MG",8354427,TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE A R117H MUTATION IN THE CFTR GENE,SYMDEKO (COPACKAGED),VERTEX PHARMS INC,N,210491,RX,TABLET,ORAL,2019-06-21,2026-07-06
4820,20MG,10980770,TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF TASIMELTEON TO SMOKERS OR TO PATIENTS BEING TREATED WITH A CYP1A2 INHIBITOR,HETLIOZ,VANDA PHARMS INC,N,205677,RX,CAPSULE,ORAL,2014-01-31,2033-01-25
5203,EQ 250MG BASE,9861638,"A METHOD FOR TREATING OVARIAN CANCER BY ADMINISTERING RUCAPARIB, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION",RUBRACA,ZR PHARMA,N,209115,RX,TABLET,ORAL,2017-05-01,2031-02-10
2607,50MG/5GM PACKET,7608605,METHOD FOR ADMINISTRATION OF TESTOSTERONE,TESTIM,AUXILIUM PHARMS LLC,N,021454,RX,GEL,TRANSDERMAL,2002-10-31,2023-04-21
946,10MG;7MG,8058291,MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE,NAMZARIC,ABBVIE,N,206439,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2016-07-18,2029-12-05
4228,"100MG, 75MG, 50MG;75MG",11179367,TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A MUTATION THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH A COMPOSITION ACCORDING TO ANY ONE OF CLAIMS 1-3 AND 7-9 OF US11179367,TRIKAFTA (COPACKAGED),VERTEX PHARMS INC,N,217660,RX,GRANULES,ORAL,2023-04-26,2037-12-08
5232,3.12MG/1.56ML (2MG/ML),8748382,TREATMENT TO INCREASE BONE DENSITY IN MEN WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE,TYMLOS,RADIUS HEALTH INC,N,208743,RX,SOLUTION,SUBCUTANEOUS,2017-04-28,2027-10-03
1676,30MG/ML (30MG/ML),10709713,MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION,ANJESO,BAUDAX,N,210583,DISCN,SOLUTION,INTRAVENOUS,2020-02-20,2030-05-26
817,0.0553MG,7560429,TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS,NOCDURNA,FERRING PHARMS INC,N,022517,RX,TABLET,SUBLINGUAL,2018-06-21,2024-02-02
1980,EQ 20MG BASE,10238709,USE OF ORAL OCTREOTIDE FOR LONG-TERM MAINTENANCE TREATMENT IN ACROMEGALY PATIENTS WHO HAVE RESPONDED TO AND TOLERATED TREATMENT WITH OCTREOTIDE OR LANREOTIDE,MYCAPSSA,AMRYT,N,208232,RX,"CAPSULE, DELAYED RELEASE",ORAL,2020-06-26,2036-02-03
432,660MG/5ML (132MG/ML),8846072,METHOD FOR PROVIDING SUSTAINED LOCAL ANESTHESIA FOR AT LEAST 24 HOURS,POSIMIR,INNOCOLL,N,204803,RX,"SOLUTION, EXTENDED RELEASE",INFILTRATION,2021-02-01,2025-09-15
1057,0.004MG,10835487,TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY,IMVEXXY,MAYNE PHARMA,N,208564,RX,INSERT,VAGINAL,2018-05-29,2032-11-21
4715,EQ 20MG BASE,11098015,TREATMENT OF RENAL CELL CARCINOMA,CABOMETYX,EXELIXIS INC,N,208692,RX,TABLET,ORAL,2016-04-25,2030-01-15
5128,750MG IRON/15ML (50MG IRON/ML),8895612,"METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX, WITH A SUBSTANTIALLY NON-IMMUNOGENIC CARBOHYDRATE COMPONENT, IN ABOUT 15 MINUTES OR LESS.",INJECTAFER,AM REGENT,N,203565,RX,SOLUTION,INTRAVENOUS,2013-07-25,2027-01-08
52,325MG;7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**,9468636,MANAGEMENT OF ACUTE PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA,XARTEMIS XR,MALLINCKRODT INC,N,204031,DISCN,"TABLET, EXTENDED RELEASE",ORAL,2014-03-11,2032-05-16
5233,180MG,10385078,TREATMENT OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC),ALUNBRIG,TAKEDA PHARMS USA,N,208772,RX,TABLET,ORAL,2017-10-02,2035-11-10
1123,2MG/VIAL,8906851,IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML,BYDUREON,ASTRAZENECA AB,N,022200,DISCN,"FOR SUSPENSION, EXTENDED RELEASE",SUBCUTANEOUS,2012-01-27,2026-08-18
4830,10MG;5MG,8119648,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN,GLYXAMBI,BOEHRINGER INGELHEIM,N,206073,RX,TABLET,ORAL,2015-01-30,2023-08-12
4135,20MG,7723305,INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD),VYVANSE,TAKEDA PHARMS USA,N,021977,RX,CAPSULE,ORAL,2007-12-10,2023-02-24
179,5MG/2ML (2.5MG/ML),9084765,TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING,BARHEMSYS,ACACIA,N,209510,RX,SOLUTION,INTRAVENOUS,2020-02-26,2034-02-26
228,30MG,9669021,TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSONS DISEASE,KYNMOBI,SUMITOMO PHARMA AM,N,210875,DISCN,FILM,SUBLINGUAL,2020-05-21,2030-06-11
1751,10MG/0.4ML (10MG/0.4ML),8480631,SUBCUTANEOUS INJECTION OF METHOTREXATE,OTREXUP,OTTER PHARMS,N,204824,RX,SOLUTION,SUBCUTANEOUS,2013-10-11,2030-03-19
4810,560MG,10751342,TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA,IMBRUVICA,PHARMACYCLICS LLC,N,210563,DISCN,TABLET,ORAL,2018-02-16,2031-06-03
5001,100MG,8772325,TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).,VIBERZI,ABBVIE,N,206940,RX,TABLET,ORAL,2015-05-27,2025-03-14
4810,140MG,10478439,TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA,IMBRUVICA,PHARMACYCLICS LLC,N,205552,RX,CAPSULE,ORAL,2013-11-13,2031-06-03
1725,5MG;1GM,10258637,METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN,SYNJARDY,BOEHRINGER INGELHEIM,N,206111,RX,TABLET,ORAL,2015-08-26,2034-04-03
435,105MG;45MG,11285146,DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER,AUVELITY,AXSOME,N,215430,RX,"TABLET, EXTENDED RELEASE",ORAL,2022-08-18,2034-11-05
4820,4MG/ML,10376487,TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD,HETLIOZ LQ,VANDA PHARMS INC,N,214517,RX,SUSPENSION,ORAL,2020-12-01,2035-07-27
2806,49MG;51MG,11135192,TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION,ENTRESTO,NOVARTIS PHARMS CORP,N,207620,RX,TABLET,ORAL,2015-07-07,2033-08-22
1751,25MG/0.4ML (25MG/0.4ML),8579865,SUBCUTANEOUS INJECTION OF METHOTREXATE,OTREXUP,OTTER PHARMS,N,204824,RX,SOLUTION,SUBCUTANEOUS,2013-10-11,2030-03-19
5110,EQ 123MG BASE,11357761,THE TREATMENT OF FABRY PATIENTS,GALAFOLD,AMICUS THERAP US,N,208623,RX,CAPSULE,ORAL,2018-08-10,2038-05-30
489,300MG,6977253,"THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.",EQUETRO,VALIDUS PHARMS,N,021710,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2004-12-10,2024-05-19
2809,EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**,8273876,TREATMENT OF ERECTILE DYSFUNCTION BY ADMINISTERING A FILM-COATED TABLET,LEVITRA,BAYER HLTHCARE,N,021400,DISCN,TABLET,ORAL,2003-08-19,2027-07-23
2104,6.52MG/ML,10588988,METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING,DEFINITY RT,LANTHEUS MEDCL,N,021064,RX,INJECTABLE,INTRAVENOUS,2020-11-17,2037-05-04
1725,2.5MG;1GM,8685934,"TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE",XIGDUO XR,ASTRAZENECA AB,N,205649,RX,"TABLET, EXTENDED RELEASE",ORAL,2017-07-28,2030-05-26
5406,30MG/30ML (1MG/ML),9309234,MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION,OLINVYK,TREVENA,N,210730,RX,SOLUTION,INTRAVENOUS,2020-10-30,2032-03-23
2279,1MG;100MG,10806740,"TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS",BIJUVA,MAYNE PHARMA,N,210132,RX,CAPSULE,ORAL,2018-10-28,2032-11-21
824,0.7MG,8034366,TREATMENT OF MACULAR EDEMA,OZURDEX,ABBVIE,N,022315,RX,IMPLANT,INTRAVITREAL,2009-06-17,2023-01-09
1118,2.5MG,9006224,"TREATMENT OF PATIENTS WITH PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC",AFINITOR,NOVARTIS,N,022334,RX,TABLET,ORAL,2010-07-09,2028-07-01
4875,EQ 60MG BASE,8900566,METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY,DAKLINZA,BRISTOL-MYERS SQUIBB,N,206843,DISCN,TABLET,ORAL,2015-07-24,2027-08-08
4115,EQ 5MG BASE,7741358,TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA,SAPHRIS,ALLERGAN,N,022117,RX,TABLET,SUBLINGUAL,2009-08-13,2026-04-06
5460,20MG;EQ 10MG BASE,10716785,"METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN",LYBALVI,ALKERMES INC,N,213378,RX,TABLET,ORAL,2021-05-28,2031-08-23
242,300MG/VIAL,11344547,TREATMENT OF SCHIZOPHRENIA,ABILIFY MAINTENA KIT,OTSUKA PHARM CO LTD,N,202971,RX,"FOR SUSPENSION, EXTENDED RELEASE",INTRAMUSCULAR,2013-02-28,2033-09-24
939,80MG/4ML (20MG/ML),9763880,TREATMENT OF PATIENTS WITH LOCALLY ADVANCED METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY,DOCETAXEL,SHILPA,N,205934,RX,INJECTABLE,INJECTION,2015-12-22,2033-09-30
4505,105MG,7915247,ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA,FIBRICOR,ATHENA,N,022418,DISCN,TABLET,ORAL,2009-08-14,2027-08-20
4830,10MG;5MG,8178541,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT METFORMIN),GLYXAMBI,BOEHRINGER INGELHEIM,N,206073,RX,TABLET,ORAL,2015-01-30,2023-08-12
4922,EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL,9724353,TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA,ZERBAXA,CUBIST PHARMS LLC,N,206829,RX,POWDER,INTRAVENOUS,2014-12-19,2032-09-07
5400,EQ 20MG BASE/VIAL,10472365,USE OF REMIMAZOLAM FOR INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION IN ADULTS UNDERGOING PROCEDURES LASTING 30 MINUTES OR LESS,BYFAVO,ACACIA,N,212295,RX,POWDER,INTRAVENOUS,2020-10-06,2027-07-10
403,EQ 0.8MG BASE,9895422,ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 2 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 2,CYCLOSET,VEROSCIENCE,N,020866,RX,TABLET,ORAL,2009-05-05,2030-06-07
1679,10MG;28MG,8362085,MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE,NAMZARIC,ABBVIE,N,206439,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2014-12-23,2025-11-22
2379,550MG,8741904,TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS.,XIFAXAN,SALIX PHARMS,N,021361,RX,TABLET,ORAL,2010-03-24,2026-02-27
4340,EQ 12.5MG BASE;EQ 30MG BASE,7807689,METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN,OSENI,TAKEDA PHARMS USA,N,022426,RX,TABLET,ORAL,2013-01-25,2028-06-27
2608,198MG,11331325,METHOD OF TREATING TESTOSTERONE DEFICIENCY,JATENZO,TOLMAR,N,206089,RX,CAPSULE,ORAL,2019-03-27,2027-01-06
4684,6MG,6949571,TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY,FYCOMPA,CATALYST PHARMS,N,202834,RX,TABLET,ORAL,2012-10-22,2024-06-08
4757,120MG,11129806,METHOD OF TREATING MULTIPLE SCLEROSIS,TECFIDERA,BIOGEN INC,N,204063,RX,"CAPSULE, DELAYED RELEASE",ORAL,2013-03-27,2035-11-16
4757,240MG,10994003,METHOD OF TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS BEFORE AND AFTER ADMINISTERING AN INACTIVE VACCINE,TECFIDERA,BIOGEN INC,N,204063,RX,"CAPSULE, DELAYED RELEASE",ORAL,2013-03-27,2035-03-13
3294,6MG,9157121,DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE,FANAPT,VANDA PHARMS INC,N,022192,RX,TABLET,ORAL,2009-05-06,2030-04-05
842,105MG;45MG,10806710,DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER,AUVELITY,AXSOME,N,215430,RX,"TABLET, EXTENDED RELEASE",ORAL,2022-08-18,2034-11-05
4228,125MG;200MG,8846718,METHOD OF TREATING CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE,ORKAMBI,VERTEX PHARMS INC,N,206038,RX,TABLET,ORAL,2015-07-02,2029-07-02
1003,200MG;EQ 25MG BASE,8754065,TREATMENT OF HIV INFECTION,DESCOVY,GILEAD SCIENCES INC,N,208215,RX,TABLET,ORAL,2016-04-04,2032-08-15
1003,150MG;150MG;200MG;300MG,8633219,TREATMENT OF HIV INFECTION,STRIBILD,GILEAD SCIENCES INC,N,203100,RX,TABLET,ORAL,2012-08-27,2030-04-30
2593,200MG;300MG,8592397,METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1,TRUVADA,GILEAD,N,021752,RX,TABLET,ORAL,2004-08-02,2024-01-13
5289,75MG,9850230,"BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH A BRAF V600E OR V600K MUTATION, AS DETECTED BY AN FDA- APPROVED TEST",BRAFTOVI,ARRAY BIOPHARMA INC,N,210496,RX,CAPSULE,ORAL,2018-06-27,2030-08-27
4810,140MG,9540382,TREATMENT OF MANTLE CELL LYMPHOMA,IMBRUVICA,PHARMACYCLICS LLC,N,205552,RX,CAPSULE,ORAL,2013-11-13,2033-08-18
5372,"50MG,37.5MG,25MG; 75MG",9931334,"TREATMENT OF CF IN PATIENTS 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA USING A SOLID COMPOSITION COMPRISING ELX, TEZ, AMORPHOUS IVA, AND < ~30% CRYSTALLINE IVA",TRIKAFTA (COPACKAGED),VERTEX PHARMS INC,N,212273,RX,TABLET,ORAL,2021-06-08,2026-12-28
4135,50MG,7674774,INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD),VYVANSE,TAKEDA PHARMS USA,N,021977,RX,CAPSULE,ORAL,2007-02-23,2023-02-24
4816,0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH,RE44874,"INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA; AND ASTHMA",TRELEGY ELLIPTA,GLAXOSMITHKLINE,N,209482,RX,POWDER,INHALATION,2017-09-18,2023-03-23
2046,EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL,8895586,USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMOTHERAPY,AKYNZEO,HELSINN HLTHCARE,N,210493,RX,POWDER,INTRAVENOUS,2018-04-19,2032-05-23
228,25MG,9669019,TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSONS DISEASE,KYNMOBI,SUMITOMO PHARMA AM,N,210875,DISCN,FILM,SUBLINGUAL,2020-05-21,2030-06-11
5380,EQ 200MG BASE,10420775,METHOD OF TREATING EPITHELIOID SARCOMA,TAZVERIK,EPIZYME INC,N,211723,RX,TABLET,ORAL,2020-01-23,2032-04-13
4758,150MG;1GM,8222219,REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS,INVOKAMET XR,JANSSEN PHARMS,N,205879,RX,"TABLET, EXTENDED RELEASE",ORAL,2016-09-20,2025-04-11
5355,150MG,11654133,CO-ADMINISTRATION OF CENOBAMATE WITH PHENOBARBITAL AND/OR PHENYTOIN FOR THE TREATMENT OF PARTIAL ONSET SEIZURES,XCOPRI,SK LIFE,N,212839,RX,TABLET,ORAL,2020-03-10,2039-06-16
2543,EQ 6.5MG BASE/4HR,9427578,"METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA,  COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF",ZECUITY,TEVA BRANDED PHARM,N,202278,DISCN,SYSTEM,IONTOPHORESIS,2013-01-17,2027-04-12
5154,150MG;37.5MG/PACKET,9085573,FOR THE TREATMENT OF HEPATITIS C,EPCLUSA,GILEAD SCIENCES INC,N,214187,RX,PELLETS,ORAL,2021-06-10,2028-03-21
1024,50MG/10ML (5MG/ML),11090278,USE OF EPHEDRINE SULFATE FOR TREATING HYPOTENSION,EMERPHED,NEXUS,N,213407,RX,SOLUTION,INTRAVENOUS,2020-04-17,2040-05-16
568,25MG/ML,10799517,ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS,ELYXYB,SCILEX HLDG,N,212157,DISCN,SOLUTION,ORAL,2020-05-05,2036-05-27
5154,200MG;50MG/PACKET,8633309,FOR THE TREATMENT OF HEPATITIS C,EPCLUSA,GILEAD SCIENCES INC,N,214187,RX,PELLETS,ORAL,2021-06-10,2029-03-26
2607,50MG/5GM PACKET,7608608,METHOD FOR ADMINISTRATION OF TESTOSTERONE,TESTIM,AUXILIUM PHARMS LLC,N,021454,RX,GEL,TRANSDERMAL,2002-10-31,2023-04-21
4135,20MG,7659254,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS,VYVANSE,TAKEDA PHARMS USA,N,021977,RX,CAPSULE,ORAL,2007-12-10,2023-02-24
403,EQ 0.8MG BASE,10688155,"ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1, 17 AND 18 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1",CYCLOSET,VEROSCIENCE,N,020866,RX,TABLET,ORAL,2009-05-05,2030-06-07
4304,10MG,8906851,TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE,FARXIGA,ASTRAZENECA AB,N,202293,RX,TABLET,ORAL,2014-01-08,2026-08-18
5225,5GM/PACKET,10398730,TREATMENT OF HYPERKALEMIA IN ADULTS,LOKELMA,ASTRAZENECA,N,207078,RX,FOR SUSPENSION,ORAL,2018-05-18,2032-02-10
4329,EQ 40MG BASE/VIAL,8822637,METHOD OF TREATING ACROMEGALY,SIGNIFOR LAR KIT,RECORDATI RARE,N,203255,RX,FOR SUSPENSION,INTRAMUSCULAR,2014-12-15,2023-08-06
1767,5MG/ML,8956649,METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING THE COMPOSITION OF CLAIM 1,QUILLIVANT XR,NEXTWAVE,N,202100,RX,"FOR SUSPENSION, EXTENDED RELEASE",ORAL,2012-09-27,2031-02-15
2810,20UNITS/ML (20UNITS/ML),9687526,"TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES",VASOSTRICT,PAR STERILE PRODUCTS,N,204485,RX,SOLUTION,INTRAVENOUS,2014-04-17,2035-01-30
2032,0.1%,10940138,METHOD OF TREATING BLEPHAROPTOSIS,UPNEEQ,RVL PHARMS,N,212520,RX,SOLUTION/DROPS,OPHTHALMIC,2020-07-08,2039-12-16
842,105MG;45MG,10092561,DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER,AUVELITY,AXSOME,N,215430,RX,"TABLET, EXTENDED RELEASE",ORAL,2022-08-18,2034-11-05
4224,534MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**,8609701,"DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING A SUB-1600 MG/DAY DOSE, FOLLOWED BY ADMINISTERING AT LEAST 1602 MG/DAY",ESBRIET,GENENTECH INC,N,208780,DISCN,TABLET,ORAL,2017-01-11,2029-04-22
956,EQ 3MG BASE,9861607,TREATMENT OF INSOMNIA,SILENOR,CURRAX,N,022036,RX,TABLET,ORAL,2010-03-17,2027-05-18
4816,0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH,8511304,"METHOD OF DISPENSING A COMBINATION MEDICAMENT PRODUCT FROM CLAIMED DELIVERY DEVICE, FOR EXAMPLE FOR THE TREATMENT OF ASTHMA OR COPD",TRELEGY ELLIPTA,GLAXOSMITHKLINE,N,209482,RX,POWDER,INHALATION,2017-09-18,2027-06-14
5289,50MG,8541575,TREATMENT OF MELANOMA,BRAFTOVI,ARRAY BIOPHARMA INC,N,210496,DISCN,CAPSULE,ORAL,2018-06-27,2030-02-26
4554,0.1MG/INH;EQ 0.025MG BASE/INH,11116721,"INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS",BREO ELLIPTA,GLAXO GRP LTD,N,204275,RX,POWDER,INHALATION,2013-05-10,2029-02-26
956,EQ 3MG BASE,11234954,TREATMENT OF INSOMNIA,SILENOR,CURRAX,N,022036,RX,TABLET,ORAL,2010-03-17,2028-01-18
1559,30MG,8470359,METHOD OF TREATING CANCER,ELIGARD KIT,TOLMAR,N,021488,RX,POWDER,SUBCUTANEOUS,2003-02-13,2023-10-15
4182,15MG,9539218,TREATMENT OF DVT AND/OR PE AND REDUCTION IN RISK OF RECURRENT DVT AND/OR PE IN PEDIATRIC PATIENTS (30-49.9 KG) ONCE DAILY WITH RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST 5 CONSECUTIVE DAYS AFTER AT LEAST 5 DAYS PARENTERAL ANTICOAGULANT TREATMENT,XARELTO,JANSSEN PHARMS,N,022406,RX,TABLET,ORAL,2011-11-04,2034-02-17
4182,2.5MG,10828310,"REDUCTION OF RISK OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH CAD BY ADMINISTERING CLINICALLY PROVEN EFFECTIVE AMOUNTS THAT ARE 2.5 MG RIVAROXABAN TWICE DAILY AND 75-100 MG ASPIRIN DAILY",XARELTO,JANSSEN PHARMS,N,022406,RX,TABLET,ORAL,2018-10-11,2039-01-31
5380,EQ 200MG BASE,10369155,METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA,TAZVERIK,EPIZYME INC,N,211723,RX,TABLET,ORAL,2020-01-23,2035-10-16
434,300MG/1.5ML (200MG/ML),9782402,TREATING ADDICTION BY ONCE PER MONTH ADMINISTRATION OF BUPRENORPHINE,SUBLOCADE,INDIVIOR,N,209819,RX,"SOLUTION, EXTENDED RELEASE",SUBCUTANEOUS,2017-11-30,2031-06-06
5276,"75MG;75MG, 50MG",10058546,"TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 12 YEARS AND OLDER, WITH A F508DEL OR G551D CFTR GENE MUTATION AND A A455E, 2789+5G->A, OR 3849+10KBC->T MUTATION, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF U.S PATENT 10058546",SYMDEKO (COPACKAGED),VERTEX PHARMS INC,N,210491,RX,TABLET,ORAL,2019-06-21,2033-07-15
5226,24MG,11648244,TREATMENT OF TARDIVE DYSKINESIA,AUSTEDO XR,TEVA,N,216354,RX,"TABLET, EXTENDED RELEASE",ORAL,2023-02-17,2036-03-07
1709,1GM/VIAL;1GM/VIAL,10183034,"TREATMENT OF COMPLICATED URINARY TRACT INFECTION (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, AND ENTEROBACTER CLOACAE SPECIES COMPLEX",VABOMERE,REMPEX,N,209776,RX,POWDER,INTRAVENOUS,2017-08-29,2031-08-08
1123,2MG/VIAL,8461105,IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE,BYDUREON,ASTRAZENECA AB,N,022200,DISCN,"FOR SUSPENSION, EXTENDED RELEASE",SUBCUTANEOUS,2012-01-27,2025-04-13
4810,140MG,10751342,TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA,IMBRUVICA,PHARMACYCLICS LLC,N,210563,RX,TABLET,ORAL,2018-02-16,2031-06-03
66,500MG,9561204,METHOD OF TREATING ACETAMINOPHEN OVERDOSE WITH ACETYLCYSTEINE SOLUTIONS,CETYLEV,ARBOR PHARMS LLC,N,207916,DISCN,"TABLET, EFFERVESCENT",ORAL,2016-01-29,2032-05-08
52,1GM/100ML (10MG/ML),9399012,MODIFIED DOSING REGIMEN FOR THE REDUCTION OF FEVER,OFIRMEV,MALLINCKRODT HOSP,N,022450,DISCN,SOLUTION,INTRAVENOUS,2010-11-02,2031-09-11
435,90MG;8MG,11278544,FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY,CONTRAVE,NALPROPION,N,200063,RX,"TABLET, EXTENDED RELEASE",ORAL,2014-09-10,2024-04-21
5128,100MG IRON/2ML (50MG IRON/ML),11433091,METHOD TO TREAT IDA IN ADULTS & PEDIATRIC PATIENTS 1 YR & OLDER WITH INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON & WEIGHING AT LEAST 46.7 KG BY ADMINISTERING IV FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST 0.7 G OF ELEMENTAL IRON IN < 15 MINUTES,INJECTAFER,AM REGENT,N,203565,RX,SOLUTION,INTRAVENOUS,2022-02-04,2027-01-08
1878,EQ 0.7MG BASE;EQ 0.18MG BASE,11020388,USE OF ZUBSOLV FOR TREATMENT OF OPIOID DEPENDENCE,ZUBSOLV,OREXO US INC,N,204242,RX,TABLET,SUBLINGUAL,2016-10-04,2032-09-18
2593,100MG;300MG;300MG,8486975,TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS AS A REPLACEMENT THERAPY IN VIROLOGICALLY SUPPRESSED ADULTS WITH NO HISTORY OF TREATMENT FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED WITH RESISTANCE TO THE INDIVIDUAL COMPONENTS OF DELSTRIGO,DELSTRIGO,MSD MERCK CO,N,210807,RX,TABLET,ORAL,2018-08-30,2031-10-07
3972,1%,9782425,TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.,SOOLANTRA,GALDERMA LABS LP,N,206255,RX,CREAM,TOPICAL,2014-12-19,2034-03-13
2029,13.5MG,10004729,"MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE",XTAMPZA ER,COLLEGIUM PHARM INC,N,208090,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2016-04-26,2030-12-10
1679,10MG;7MG,8173708,MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE,NAMZARIC,ABBVIE,N,206439,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2016-07-18,2025-11-22
726,0.6MG,9675613,METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES,MITIGARE,HIKMA INTL PHARMS,N,204820,RX,CAPSULE,ORAL,2014-09-26,2033-08-22
1982,5MG;EQ 10MG BASE,9126977,"METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN",LYBALVI,ALKERMES INC,N,213378,RX,TABLET,ORAL,2021-05-28,2031-08-23
4829,20MG,7208516,USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS,OTEZLA,AMGEN INC,N,205437,RX,TABLET,ORAL,2014-03-21,2023-03-19
4228,50MG/PACKET,8324242,METHOD OF TREATING CYSTIC FIBROSIS,KALYDECO,VERTEX PHARMS INC,N,207925,RX,GRANULE,ORAL,2015-03-17,2027-08-05
4810,560MG,8563563,TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION,IMBRUVICA,PHARMACYCLICS LLC,N,210563,DISCN,TABLET,ORAL,2018-02-16,2027-04-26
4810,560MG,10016435,TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA,IMBRUVICA,PHARMACYCLICS LLC,N,210563,DISCN,TABLET,ORAL,2018-02-16,2031-06-03
5010,125MG/PACKET;100MG/PACKET,9150552,TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR FORM I AND IVACAFTOR,ORKAMBI,VERTEX PHARMS INC,N,211358,RX,GRANULE,ORAL,2018-08-07,2028-12-04
5154,400MG;100MG,8633309,FOR THE TREATMENT OF HEPATITIS C,EPCLUSA,GILEAD SCIENCES INC,N,208341,RX,TABLET,ORAL,2016-06-28,2029-03-26
1386,200MG/5ML;2.5MG/5ML,9549907,"A METHOD OF INCREASING THE BIOAVAILABILITY OF GUAIFENESIN IN A SOLUTION CONTAINING 54% TO 66% BY WEIGHT OF PROPYLENE GLYCOL AND GLYCEROL, WHEREIN THE METHOD INCREASES THE CMAX BY AT LEAST 1.5 AND/OR INCREASES THE AUC (0-INF) BY AT LEAST 1.4",OBREDON,SOVEREIGN PHARMS,N,205474,DISCN,SOLUTION,ORAL,2014-11-14,2035-11-13
4757,120MG,11246850,METHOD OF TREATING MULTIPLE SCLEROSIS,TECFIDERA,BIOGEN INC,N,204063,RX,"CAPSULE, DELAYED RELEASE",ORAL,2013-03-27,2035-11-16
4830,10MG;5MG,8551957,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN,GLYXAMBI,BOEHRINGER INGELHEIM,N,206073,RX,TABLET,ORAL,2015-01-30,2029-10-14
4175,2.5MG;1GM,10022379,"USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS",JENTADUETO XR,BOEHRINGER INGELHEIM,N,208026,RX,"TABLET, EXTENDED RELEASE",ORAL,2016-05-27,2029-04-02
1725,2.5MG;1GM,8501698,TREATMENT OF TYPE 2 DIABETES MELLITUS,XIGDUO XR,ASTRAZENECA AB,N,205649,RX,"TABLET, EXTENDED RELEASE",ORAL,2017-07-28,2027-06-20
4190,EQ 10MG BASE,8822481,FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD),JAKAFI,INCYTE CORP,N,202192,RX,TABLET,ORAL,2011-11-16,2028-06-12
5067,EQ 2.3MG BASE,8871745,USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY,NINLARO,TAKEDA PHARMS USA,N,208462,RX,CAPSULE,ORAL,2015-11-20,2027-08-06
1123,2MG/VIAL,9238076,AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION,BYDUREON,ASTRAZENECA AB,N,022200,DISCN,"FOR SUSPENSION, EXTENDED RELEASE",SUBCUTANEOUS,2012-01-27,2024-04-15
4716,EQ 30MG BASE,9029533,A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA,ICLUSIG,TAKEDA PHARMS USA,N,203469,RX,TABLET,ORAL,2015-04-23,2026-12-22
1413,500MG,8617593,USE OF VASCEPA TO TREAT HYPERTRIGLYCERIDEMIA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (>= 150 MG/DL) AND ON STATIN THERAPY,VASCEPA,AMARIN PHARMS,N,202057,RX,CAPSULE,ORAL,2017-02-16,2030-04-29
4811,200MG;50MG,8575135,FOR THE TREATMENT OF HEPATITIS C,EPCLUSA,GILEAD SCIENCES INC,N,208341,RX,TABLET,ORAL,2020-03-19,2032-11-16
496,36.25MG;145MG,8557283,TREATMENT OF PARKINSONS DISEASE,RYTARY,IMPAX LABS INC,N,203312,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2015-01-07,2028-12-26
5037,EQ 1.5MG BASE,7737142,TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) WITH CARIPRAZINE,VRAYLAR,ABBVIE,N,204370,RX,CAPSULE,ORAL,2015-09-17,2029-09-17
4810,560MG,8999999,TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA,IMBRUVICA,PHARMACYCLICS LLC,N,210563,DISCN,TABLET,ORAL,2018-02-16,2031-06-03
4721,EQ 20MG BASE,9364470,A DOSING REGIMEN FOR THE TREATMENT OF  HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES,JUXTAPID,AMRYT,N,203858,RX,CAPSULE,ORAL,2012-12-21,2025-03-07
1767,70MG,10500162,METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),ADHANSIA XR,PURDUE PHARMA LP,N,212038,DISCN,"CAPSULE, EXTENDED RELEASE",ORAL,2019-02-27,2035-10-30
4893,EQ 6.14MG BASE;15MG,10456399,"TREATMENT OF METASTATIC COLORECTAL CANCER ALONE OR WITH BEVACIZUMAB IN SEVERELY RENALLY IMPAIRED PATIENTS PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN THERAPY, AN ANTI-VEGF BIOLOGIC, AND IF RAS WILD-TYPE, ANTI-EGFR THERAPY",LONSURF,TAIHO ONCOLOGY,N,207981,RX,TABLET,ORAL,2015-09-22,2037-02-03
1003,150MG;150MG;200MG;300MG,9457036,TREATMENT OF HIV INFECTION,STRIBILD,GILEAD SCIENCES INC,N,203100,RX,TABLET,ORAL,2012-08-27,2024-01-13
5280,EQ 100MG BASE,8912170,TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT,TAVALISSE,RIGEL PHARMS INC,N,209299,RX,TABLET,ORAL,2018-04-17,2026-06-17
5077,1.6MG,9173881,METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN,UPTRAVI,ACTELION,N,207947,RX,TABLET,ORAL,2015-12-21,2029-08-12
5288,100MG/ML,9956183,USE IN COMBINATION WITH CLOBAZAM FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME WHO HAVE BEEN PREVIOUSLY TREATED WITH CLOBAZAM,EPIDIOLEX,GW RES LTD,N,210365,RX,SOLUTION,ORAL,2018-09-28,2035-06-17
4810,280MG,10016435,TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA,IMBRUVICA,PHARMACYCLICS LLC,N,210563,RX,TABLET,ORAL,2018-02-16,2031-06-03
4802,EQ 1MG,8703781,"MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS,  AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION",MEKINIST,NOVARTIS,N,204114,DISCN,TABLET,ORAL,2013-05-29,2030-10-15
968,3.5MG,10849857,PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE,DROSPIRENONE,EXELTIS USA INC,N,216285,DISCN,"TABLET, CHEWABLE",ORAL,2022-06-29,2031-06-28
66,6GM/30ML (200MG/ML),8722738,METHOD OF TREATING ACETAMINOPHEN OVERDOSE WITH ACETYLCYSTEINE SOLUTIONS,ACETADOTE,CUMBERLAND PHARMS,N,021539,RX,INJECTABLE,INTRAVENOUS,2004-01-23,2032-04-06
5446,3MG,9062014,"TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS",PONVORY,JANSSEN PHARMS,N,213498,RX,TABLET,ORAL,2021-03-18,2032-05-06
2406,10MG;EQ 40MG BASE,10376470,TREATMENT OF HYPERLIPIDEMIA,ROSZET,ALTHERA PHARMS,N,213072,DISCN,TABLET,ORAL,2021-03-23,2033-05-01
5383,EQ 0.23MG BASE,10239846,INDICATED FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS,ZEPOSIA,CELGENE INTL,N,209899,RX,CAPSULE,ORAL,2020-03-25,2030-11-15
419,0.08MG/INH;0.0045MG/INH,8143239,USE FOR MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE,SYMBICORT,ASTRAZENECA,N,021929,RX,"AEROSOL, METERED",INHALATION,2006-07-21,2023-01-29
5207,EQ 12MG BASE/5ML (EQ 2.4MG BASE/ML),9717750,TREATMENT OF TYPE III SPINAL MUSCULAR ATROPHY,SPINRAZA,BIOGEN IDEC,N,209531,RX,SOLUTION,INTRATHECAL,2016-12-23,2030-06-17
4758,300MG,8513202,TREATMENT OF TYPE 2 DIABETES MELLITUS,INVOKANA,JANSSEN PHARMS,N,204042,RX,TABLET,ORAL,2013-03-29,2027-12-03
1005,1MG/ML,10154987,METHOD OF TREATING HYPERTENSION,EPANED,AZURITY,N,208686,RX,SOLUTION,ORAL,2016-09-20,2036-03-25
4944,200MG;EQ 25MG BASE;EQ 25MG BASE,7125879,TREATMENT OF HIV INFECTION,ODEFSEY,GILEAD SCIENCES INC,N,208351,RX,TABLET,ORAL,2016-03-01,2025-04-21
1386,80MG,9095614,"MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE",HYSINGLA ER,PURDUE PHARMA LP,N,206627,RX,"TABLET, EXTENDED RELEASE",ORAL,2014-11-20,2027-08-24
5133,10MG,9174982,"TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY",VENCLEXTA,ABBVIE,N,208573,RX,TABLET,ORAL,2016-04-11,2030-05-26
4810,70MG,8476284,TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA,IMBRUVICA,PHARMACYCLICS LLC,N,205552,RX,CAPSULE,ORAL,2017-12-20,2026-12-28
961,40MG,8394405,TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA,ORACEA,GALDERMA LABS LP,N,050805,RX,CAPSULE,ORAL,2006-05-26,2024-04-07
4505,35MG,7741374,ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA,FIBRICOR,ATHENA,N,022418,DISCN,TABLET,ORAL,2009-08-14,2027-08-20
5203,EQ 200MG BASE,9861638,"A METHOD FOR TREATING OVARIAN CANCER BY ADMINISTERING RUCAPARIB, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION",RUBRACA,ZR PHARMA,N,209115,RX,TABLET,ORAL,2016-12-19,2031-02-10
3317,2.5MG,7468363,USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT,REVLIMID,CELGENE,N,021880,RX,CAPSULE,ORAL,2011-12-21,2023-10-07
434,128MG/0.36ML (356MG/ML),8545832,A METHOD OF DELIVERY OF A BIOACTIVE AGENT BY SUBCUTANEOUS INJECTION. A METHOD OF TREATMENT OF A HUMAN FOR ADDICTION,BRIXADI,BRAEBURN,N,210136,RX,"SOLUTION, EXTENDED RELEASE",SUBCUTANEOUS,2023-05-23,2025-06-06
5300,EQ 0.1MG BASE,9820985,TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BREAST CANCER SUSCEPTIBILITY GENE (BRCA)-MUTATED (GBRCAM) HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER,TALZENNA,PFIZER,N,211651,RX,CAPSULE,ORAL,2023-06-20,2029-07-27
4498,78MG/0.5ML (78MG/0.5ML),9439906,DOSING REGIMEN FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS BY ADMINISTERING TWO LOADING DOSES OF PALIPERIDONE PALMITATE FOLLOWED BY MAINTENANCE DOSE(S),INVEGA SUSTENNA,JANSSEN PHARMS,N,022264,RX,"SUSPENSION, EXTENDED RELEASE",INTRAMUSCULAR,2009-07-31,2031-01-26
1123,2MG/0.85ML (2MG/0.85ML),9238076,AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AS ADD-ON TO METFORMIN,BYDUREON BCISE,ASTRAZENECA AB,N,209210,RX,"SUSPENSION, EXTENDED RELEASE",SUBCUTANEOUS,2017-10-20,2024-04-15
2032,0.1%,10912765,METHOD OF TREATING BLEPHAROPTOSIS,UPNEEQ,RVL PHARMS,N,212520,RX,SOLUTION/DROPS,OPHTHALMIC,2020-07-08,2031-08-26
4135,60MG,7662788,FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),VYVANSE,TAKEDA PHARMS USA,N,021977,RX,CAPSULE,ORAL,2007-12-10,2023-02-24
4801,EQ 75MG BASE,8835443,"TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION",TAFINLAR,NOVARTIS,N,202806,RX,CAPSULE,ORAL,2013-05-29,2025-06-10
5128,100MG IRON/2ML (50MG IRON/ML),11433091,METHOD OF TREATING IDA IN ADULT PATIENTS WEIGHING AT LEAST 46.7 KG WITH HEART FAILURE & NY HEART ASSOCIATION CLASS II/III TO IMPROVE EXERCISE CAPACITY BY ADMINISTERING IV FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST 0.7 G OF ELEMENTAL IRON IN 15 MINUTES,INJECTAFER,AM REGENT,N,203565,RX,SOLUTION,INTRAVENOUS,2022-02-04,2027-01-08
4811,200MG;50MG,11116783,FOR THE TREATMENT OF HEPATITIS C,EPCLUSA,GILEAD SCIENCES INC,N,208341,RX,TABLET,ORAL,2020-03-19,2034-01-30
4182,15MG,7157456,TREATMENT OF PULMONARY EMBOLISM (PE),XARELTO,JANSSEN PHARMS,N,022406,RX,TABLET,ORAL,2011-11-04,2024-08-28
4135,50MG,7674774,FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),VYVANSE,TAKEDA PHARMS USA,N,208510,RX,"TABLET, CHEWABLE",ORAL,2017-01-28,2023-02-24
242,300MG,11154553,MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER,ABILIFY MAINTENA KIT,OTSUKA PHARM CO LTD,N,202971,RX,"FOR SUSPENSION, EXTENDED RELEASE",INTRAMUSCULAR,2014-09-29,2033-09-24
5153,9-221mCi/ML,10953112,METHOD OF DIAGNOSING TUMORS USING POSITRON EMISSION TOMOGRAPHY,AXUMIN,BLUE EARTH,N,208054,RX,SOLUTION,INTRAVENOUS,2016-05-27,2026-11-28
5010,125MG/PACKET;100MG/PACKET,11564916,TREATMENT OF CF IN A PATIENT AGE 1 TO <6 YEARS AND WEIGHING 7 KG OR MORE WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE COMPOSITION RECITED IN CLAIM 1 OF US 11564916,ORKAMBI,VERTEX PHARMS INC,N,211358,RX,GRANULE,ORAL,2018-08-07,2029-08-13
228,30MG,8846074,TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSONS DISEASE,KYNMOBI,SUMITOMO PHARMA AM,N,210875,DISCN,FILM,SUBLINGUAL,2020-05-21,2031-12-16
1948,100PPM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**,8282966,A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE,INOMAX,MALLINCKRODT HOSP,N,020845,DISCN,GAS,INHALATION,1999-12-23,2029-06-30
842,105MG;45MG,10925842,DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER,AUVELITY,AXSOME,N,215430,RX,"TABLET, EXTENDED RELEASE",ORAL,2022-08-18,2040-01-07
4304,2.5MG;1GM;EQ 2.5MG BASE,8501698,TREATMENT OF TYPE 2 DIABETES MELLITUS,QTERNMET XR,ASTRAZENECA AB,N,210874,DISCN,"TABLET, EXTENDED RELEASE",ORAL,2019-05-02,2027-06-20
2607,30MG/1.5ML ACTUATION **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**,8419307,A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF A PERSON IN NEED THEREOF,AXIRON,ELI LILLY AND CO,N,022504,DISCN,"SOLUTION, METERED",TRANSDERMAL,2010-11-23,2027-02-26
5372,"50MG,37.5MG,25MG; 75MG",8415387,"TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR",TRIKAFTA (COPACKAGED),VERTEX PHARMS INC,N,212273,RX,TABLET,ORAL,2021-06-08,2027-11-12
4303,800MG,11364247,TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT WITH REFRACTORY PARTIAL-ONSET SEIZURES,APTIOM,SUMITOMO PHARMA AM,N,022416,RX,TABLET,ORAL,2013-11-08,2025-05-06
5460,10MG;EQ 10MG BASE,10300054,METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN,LYBALVI,ALKERMES INC,N,213378,RX,TABLET,ORAL,2021-05-28,2031-08-23
1386,200MG/5ML;2.5MG/5ML,9808431,"A METHOD OF INCREASING THE BIOAVAILABILITY OF GUAIFENESIN IN A SOLUTION CONTAINING 54% TO 66% BY WEIGHT OF PROPYLENE GLYCOL AND GLYCEROL, WHEREIN THE METHOD INCREASES THE CMAX BY AT LEAST 1.5 AND/OR INCREASES THE AUC (0-INF) BY AT LEAST 1.4",OBREDON,SOVEREIGN PHARMS,N,205474,DISCN,SOLUTION,ORAL,2014-11-14,2035-11-13
2720,1MG/ML,8653137,ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE DILUENT FOR FLOLAN OR STERILE DILUENT FOR EPOPROSTENOL SODIUM PRIOR TO ADMINISTRATION,REMODULIN,UNITED THERAP,N,021272,RX,INJECTABLE,"IV (INFUSION), SUBCUTANEOUS",2002-05-21,2028-09-05
464,0.03MG,11154509,TREATING SECONDARY HYPERPARATHYROIDISM IN STAGE 3/4 CHRONIC KIDNEY DISEASE WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D TO REDUCE THE PATIENTS SERUM PARATHYROID HORMONE LEVEL WHILE AVOIDING PTH OVERSUPPRESSION,RAYALDEE,EIRGEN,N,208010,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2016-06-17,2028-04-25
5406,2MG/2ML (1MG/ML),9309234,MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION,OLINVYK,TREVENA,N,210730,RX,SOLUTION,INTRAVENOUS,2020-10-30,2032-03-23
1937,6MG/ML,10576070,A METHOD FOR THE IMPROVEMENT OF NEUROLOGICAL OUTCOME BY REDUCING THE INCIDENCE AND SEVERITY OF ISCHEMIC DEFICITS IN ADULT PATIENTS WITH SUBARACHNOID HEMORRHAGE (SAH) FROM RUPTURED INTRACRANIAL BERRY ANEURYSMS,NYMALIZE,AZURITY,N,203340,RX,SOLUTION,ORAL,2020-04-08,2038-04-16
5222,EQ 200MG BASE,8071579,"A METHOD OF TREATMENT OF ADVANCED OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER ASSOCIATED WITH HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) POSITIVE STATUS",ZEJULA,GLAXOSMITHKLINE,N,214876,RX,TABLET,ORAL,2023-04-26,2027-08-12
2720,20MG/ML,10695308,A METHOD OF TREATING A HUMAN PATIENT SUFFERING FROM PULMONARY HYPERTENSION,REMODULIN,UNITED THERAP,N,021272,RX,INJECTABLE,"IV (INFUSION), SUBCUTANEOUS",2021-07-30,2024-12-16
3294,10MG,9074255,DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE,FANAPT,VANDA PHARMS INC,N,022192,RX,TABLET,ORAL,2009-05-06,2030-12-17
4168,120MG,9827242,TREATMENT OF BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN BIPOLAR DISORDER,LATUDA,SUNOVION PHARMS INC,N,200603,RX,TABLET,ORAL,2012-04-26,2031-05-23
4399,EQ 25MG ACID,8071129,TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP),PROMACTA,NOVARTIS,N,022291,RX,TABLET,ORAL,2008-11-20,2027-08-01
4190,EQ 15MG BASE,8829013,FOR THE TREATMENT OF POLYCYTHEMIA VERA,JAKAFI,INCYTE CORP,N,202192,RX,TABLET,ORAL,2011-11-16,2028-06-12
1123,2MG/VIAL,7612176,AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA,BYDUREON,ASTRAZENECA AB,N,022200,DISCN,"FOR SUSPENSION, EXTENDED RELEASE",SUBCUTANEOUS,2012-01-27,2025-04-13
4829,30MG,8455536,TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCETS DISEASE,OTEZLA,AMGEN INC,N,205437,RX,TABLET,ORAL,2014-03-21,2023-03-19
2017,300MG,10220042,TREATMENT OF PARTIAL-ONSET SEIZURES,OXTELLAR XR,SUPERNUS PHARMS,N,202810,RX,"TABLET, EXTENDED RELEASE",ORAL,2012-10-19,2027-04-13
5278,240MG,RE49353,"TREATMENT IN COMBINATION WITH A GNRH AGONIST OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)",ERLEADA,JANSSEN BIOTECH,N,210951,RX,TABLET,ORAL,2023-02-17,2033-09-23
4228,50MG/PACKET,8629162,USE OF IVACAFTOR FOR TREATING CYSTIC FIBROSIS IN A PATIENT WITH A MILD TO MODERATE CF PHENOTYPE WITH AT LEAST ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA,KALYDECO,VERTEX PHARMS INC,N,207925,RX,GRANULE,ORAL,2015-03-17,2025-06-24
4810,560MG,10478439,TREATMENT OF MARGINAL ZONE LYMPHOMA,IMBRUVICA,PHARMACYCLICS LLC,N,210563,DISCN,TABLET,ORAL,2018-02-16,2031-06-03
3909,3.75%;EQ 1.2% BASE,9504704,TOPICAL TREATMENT OF ACNE VULGARIS,ONEXTON,BAUSCH,N,050819,RX,GEL,TOPICAL,2014-11-24,2029-06-03
4228,"100MG,75MG,50MG; 150MG",8598181,"TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR",TRIKAFTA (COPACKAGED),VERTEX PHARMS INC,N,212273,RX,TABLET,ORAL,2019-10-21,2027-05-01
228,15MG,9283219,TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSONS DISEASE,KYNMOBI,SUMITOMO PHARMA AM,N,210875,DISCN,FILM,SUBLINGUAL,2020-05-21,2030-06-11
5394,50MG,11426390,TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS BEING TREATED CONCURRENTLY WITH A CYP3A4 INHIBITOR,QINLOCK,DECIPHERA PHARMS,N,213973,RX,TABLET,ORAL,2020-05-15,2040-08-12
1413,1GM,8691871,USE OF VASCEPA TO TREAT MIXED DYSLIPIDEMIA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (>=150 MG/DL) AND ON STATIN THERAPY,VASCEPA,AMARIN PHARMS,N,202057,RX,CAPSULE,ORAL,2012-07-26,2030-04-29
4123,24MCG,8748481,METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT,AMITIZA,SUCAMPO PHARMA LLC,N,021908,RX,CAPSULE,ORAL,2006-01-31,2025-09-01
1413,500MG,8293728,METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA,VASCEPA,AMARIN PHARMS,N,202057,RX,CAPSULE,ORAL,2017-02-16,2030-02-09
1611,1%,10058511,A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER,INVELTYS,ALCON LABS INC,N,210565,RX,SUSPENSION/DROPS,OPHTHALMIC,2018-08-22,2033-05-03
1057,0.01MG,11351182,TREATMENT OF DYSPAREUNIA,IMVEXXY,MAYNE PHARMA,N,208564,RX,INSERT,VAGINAL,2018-05-29,2032-11-21
5276,"75MG;75MG, 50MG",10058546,"TREATMENT OF CF IN PATIENTS 6 YEARS AND OLDER WHO HAVE A F508DEL OR G551D CFTR MUTATION AND A 2ND MUTATION SELECTED FROM R117H, A455E, 2789+5G->A, AND 3849+10KBC->T, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF US 10058546",SYMDEKO (COPACKAGED),VERTEX PHARMS INC,N,210491,RX,TABLET,ORAL,2019-06-21,2033-07-15
1123,2MG,8329648,AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN,BYDUREON PEN,ASTRAZENECA AB,N,022200,DISCN,"FOR SUSPENSION, EXTENDED RELEASE",SUBCUTANEOUS,2014-02-28,2026-08-18
5260,100MG,9796721,TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA,CALQUENCE,ASTRAZENECA,N,210259,RX,CAPSULE,ORAL,2017-10-31,2036-07-01
4716,EQ 10MG BASE,9493470,A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA,ICLUSIG,TAKEDA PHARMS USA,N,203469,RX,TABLET,ORAL,2020-12-18,2033-12-12
3521,EQ 0.5MG BASE,7815942,TREATMENT OF PARKINSONS DISEASE,AZILECT,TEVA,N,021641,RX,TABLET,ORAL,2006-05-16,2027-08-27
1413,500MG,11154526,"USE OF VASCEPA TO REDUCE TRIGLYCERIDE LEVELS IN AN ADULT PATIENT HAVING TRIGLYCERIDE LEVELS OF AT LEAST ABOUT 500 MG/DL, ON ANTICOAGULANT/ANTIPLATELET/THROMBOLYTIC THERAPY, AND HAVING ATRIAL FIBRILLATION AND/OR ATRIAL FLUTTER",VASCEPA,AMARIN PHARMS,N,202057,RX,CAPSULE,ORAL,2017-02-16,2030-04-29
4175,10MG;5MG;1GM,11564886,TREATMENT OF A TYPE 2 DIABETES PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN,TRIJARDY XR,BOEHRINGER INGELHEIM,N,212614,RX,"TABLET, EXTENDED RELEASE",ORAL,2020-01-27,2032-03-07
4758,100MG,10617668,REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 100 MG CANAGLIFLOZIN PER DAY,INVOKANA,JANSSEN PHARMS,N,204042,RX,TABLET,ORAL,2013-03-29,2031-05-11
2233,1.5MG,8679533,TREATMENT OF PARKINSONS DISEASE,MIRAPEX ER,BOEHRINGER INGELHEIM,N,022421,RX,"TABLET, EXTENDED RELEASE",ORAL,2010-02-19,2029-09-08
5052,441MG/1.6ML (275.63MG/ML),9452131,TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION,ARISTADA,ALKERMES INC,N,207533,RX,"SUSPENSION, EXTENDED RELEASE",INTRAMUSCULAR,2015-10-05,2035-03-19
5075,200MG,8084483,REDUCTION OF SERUM URIC ACID LEVELS,ZURAMPIC,IRONWOOD PHARMS INC,N,207988,DISCN,TABLET,ORAL,2015-12-22,2029-08-17
4907,100MG,8859562,"MAINTENANCE TREATMENT OF BRCA-MUTATED RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY",LYNPARZA,ASTRAZENECA,N,208558,RX,TABLET,ORAL,2017-08-17,2031-08-04
4829,30MG,9018243,USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS,OTEZLA,AMGEN INC,N,205437,RX,TABLET,ORAL,2014-03-21,2023-03-19
5142,EQ 10MG BASE,10953000,TREATMENT OF HALLUCINATIONS AND DELUSIONS ASSOCIATED WITH PARKINSONS DISEASE PSYCHOSIS,NUPLAZID,ACADIA PHARMS INC,N,207318,RX,TABLET,ORAL,2018-06-28,2037-03-23
4115,EQ 10MG BASE,7741358,USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS,SAPHRIS,ALLERGAN,N,022117,RX,TABLET,SUBLINGUAL,2009-08-13,2026-04-06
5305,EQ 25MG BASE,10774085,METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION,VITRAKVI,BAYER HLTHCARE,N,210861,RX,CAPSULE,ORAL,2018-11-26,2029-10-21
5358,EQ 10.5MG BASE,11052084,"TREATMENT OF BIPOLAR DEPRESSION MEDIATED BY THE 5-HT2A RECEPTOR, SEROTONIN TRANSPORTER, AND/OR DOPAMINE D1/D2 SIGNALING PATHWAYS",CAPLYTA,INTRA-CELLULAR,N,209500,RX,CAPSULE,ORAL,2022-04-22,2039-08-30
1567,36.25MG;145MG,9089607,METHOD OF PROVIDING A THERAPEUTICALLY EFFECTIVE AND STABLE MEDIAN BLOOD PLASMA LEVEL OF LEVODOPA,RYTARY,IMPAX LABS INC,N,203312,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2015-01-07,2028-12-26
5052,882MG/3.2ML (275.63MG/ML),8796276,TREATMENT OF SCHIZOPHRENIA,ARISTADA,ALKERMES INC,N,207533,RX,"SUSPENSION, EXTENDED RELEASE",INTRAMUSCULAR,2015-10-05,2030-06-24
5461,320MG,11236091,"TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), AS DETERMINED BY AN FDA-APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR SYSTEMIC THERAPY",LUMAKRAS,AMGEN INC,N,214665,RX,TABLET,ORAL,2023-01-20,2040-05-20
4912,12.5MG;75MG;50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**,9044480,TREATMENT OF HCV INFECTION USING PARITAPREVIR,TECHNIVIE,ABBVIE,N,207931,DISCN,TABLET,ORAL,2015-07-24,2031-04-10
5699,EQ 25MG BASE/0.5ML (EQ 25MG BASE/0.5ML),11286486,AMVUTTRA IS INDICATED FOR THE TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS,AMVUTTRA,ALNYLAM PHARMS INC,N,215515,RX,SOLUTION,SUBCUTANEOUS,2022-06-13,2036-07-28
144,EQ 137MG BASE,8895616,"TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSONS DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS",GOCOVRI,ADAMAS OPERATIONS,N,208944,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2017-08-24,2025-11-23
403,EQ 0.8MG BASE,9895422,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 14 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 14,CYCLOSET,VEROSCIENCE,N,020866,RX,TABLET,ORAL,2009-05-05,2030-06-07
4483,60MG/VIAL,8129346,KYPROLIS IS INDICATED IN COMBINATION WITH DEXAMETHASONE OR WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY,KYPROLIS,ONYX PHARMS AMGEN,N,202714,RX,POWDER,INTRAVENOUS,2012-07-20,2025-04-14
2720,EQ 0.125MG BASE,7544713,USE OF ORENITRAM FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1).,ORENITRAM,UNITED THERAP,N,203496,RX,"TABLET, EXTENDED RELEASE",ORAL,2013-12-20,2024-07-14
4810,70MG,9540382,TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA,IMBRUVICA,PHARMACYCLICS LLC,N,205552,RX,CAPSULE,ORAL,2017-12-20,2033-08-18
4135,40MG,7678771,INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD),VYVANSE,TAKEDA PHARMS USA,N,021977,RX,CAPSULE,ORAL,2007-12-10,2023-02-24
4182,2.5MG,9415053,"REDUCTION OF RISK OF MAJOR CARDIOVASCULAR EVENTS (CV DEATH, MI, AND STROKE) IN CHRONIC CAD OR PAD",XARELTO,JANSSEN PHARMS,N,022406,RX,TABLET,ORAL,2018-10-11,2024-11-13
4855,EQ 20MG BASE;0.45MG,6479535,TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE,DUAVEE,WYETH PHARMS,N,022247,RX,TABLET,ORAL,2013-10-03,2024-05-06
5353,80MG,11142528,TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY,BRUKINSA,BEIGENE,N,213217,RX,CAPSULE,ORAL,2019-11-14,2034-04-22
4802,EQ 0.5MG,8835443,"MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST",MEKINIST,NOVARTIS,N,204114,RX,TABLET,ORAL,2013-05-29,2025-06-10
432,400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML),10632199,"TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION",ZYNRELEF KIT,HERON THERAPS INC,N,211988,RX,"SOLUTION, EXTENDED RELEASE",PERIARTICULAR,2021-05-12,2035-04-20
1407,800MG/8ML (100MG/ML),9138404,"METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER IN A CRITICALLY ILL PATIENT WITH INTRAVENOUS IBUPROFEN IN NEED THEREOF",CALDOLOR,CUMBERLAND PHARMS,N,022348,RX,SOLUTION,INTRAVENOUS,2009-06-11,2029-09-30
2593,150MG;150MG;200MG;300MG,9457036,TREATMENT OF HIV INFECTION,STRIBILD,GILEAD SCIENCES INC,N,203100,RX,TABLET,ORAL,2012-08-27,2024-01-13
4811,200MG;50MG,8735372,FOR THE TREATMENT OF HEPATITIS C,EPCLUSA,GILEAD SCIENCES INC,N,208341,RX,TABLET,ORAL,2020-03-19,2028-03-21
5233,180MG,9611283,TREATMENT OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC),ALUNBRIG,TAKEDA PHARMS USA,N,208772,RX,TABLET,ORAL,2017-10-02,2034-04-10
5154,150MG;37.5MG/PACKET,8735372,FOR THE TREATMENT OF HEPATITIS C,EPCLUSA,GILEAD SCIENCES INC,N,214187,RX,PELLETS,ORAL,2021-06-10,2028-03-21
1948,800PPM,9770570,A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY MEASURING AND DISPLAYING AN INDICATION OF THE CALCULATED DELIVERY CONCENTRATION OF NITRIC OXIDE AS COMPARED TO THE DESIRED DELIVERY CONCENTRATION OF NITRIC OXIDE,INOMAX,MALLINCKRODT HOSP,N,020845,RX,GAS,INHALATION,1999-12-23,2036-05-03
242,720MG/2.4ML (300MG/ML),8338427,USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION,ABILIFY ASIMTUFII,OTSUKA,N,217006,RX,"SUSPENSION, EXTENDED RELEASE",INTRAMUSCULAR,2023-04-27,2025-03-15
4830,5MG;2.5MG;1GM,11090323,"METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2",TRIJARDY XR,BOEHRINGER INGELHEIM,N,212614,RX,"TABLET, EXTENDED RELEASE",ORAL,2020-01-27,2034-04-03
5154,150MG;37.5MG/PACKET,8921341,FOR THE TREATMENT OF HEPATITIS C,EPCLUSA,GILEAD SCIENCES INC,N,214187,RX,PELLETS,ORAL,2021-06-10,2032-11-16
4298,2.5MG,6967208,PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT),ELIQUIS,BRISTOL MYERS SQUIBB,N,202155,RX,TABLET,ORAL,2012-12-28,2026-11-21
5299,EQ 150MG BASE,10124014,TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTION,NUZYRA,PARATEK PHARMS INC,N,209816,RX,TABLET,ORAL,2018-10-02,2029-03-05
4716,EQ 30MG BASE,11192897,A METHOD FOR TREATING CHRONIC MYELOID LEUKEMIA,ICLUSIG,TAKEDA PHARMS USA,N,203469,RX,TABLET,ORAL,2015-04-23,2033-12-12
4283,EQ 200MG BASE,8536130,MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY,NUCYNTA ER,COLLEGIUM PHARM INC,N,200533,RX,"TABLET, EXTENDED RELEASE",ORAL,2011-08-25,2028-09-22
1225,0.137MG/SPRAY;0.05MG/SPRAY,8163723,"TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL ALLERGIC RHINITIS",DYMISTA,MYLAN SPECIALITY LP,N,202236,RX,"SPRAY, METERED",NASAL,2012-05-01,2023-08-29
1057,1MG;0.5MG;40MG,11033551,MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE LEIOMYOMAS (FIBROIDS) IN PREMENOPAUSAL WOMEN,MYFEMBREE,MYOVANT SCIENCES,N,214846,RX,TABLET,ORAL,2021-05-26,2037-09-29
1123,2MG/VIAL,8431685,IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE,BYDUREON,ASTRAZENECA AB,N,022200,DISCN,"FOR SUSPENSION, EXTENDED RELEASE",SUBCUTANEOUS,2012-01-27,2025-04-13
5203,EQ 300MG BASE,7351701,"A METHOD FOR TREATING OVARIAN CANCER BY ADMINISTERING RUCAPARIB, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION",RUBRACA,ZR PHARMA,N,209115,RX,TABLET,ORAL,2016-12-19,2024-07-23
4810,420MG,8952015,TREATMENT OF MANTLE CELL LYMPHOMA,IMBRUVICA,PHARMACYCLICS LLC,N,210563,RX,TABLET,ORAL,2018-02-16,2026-12-28
2720,20MG/20ML (1MG/ML),9713599,A METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING PARENTERALLY ADMINISTERING A FORMULATION COMPRISING A) 0.1 TO 5% W/V OF TREPROSTINIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND B) A CITRATE BUFFER,REMODULIN,UNITED THERAP,N,208276,DISCN,SOLUTION,"INTRAVENOUS, SUBCUTANEOUS",2018-07-30,2024-12-16
24,5GM/PACKET,11202767,"TREATMENT OF A UREA CYCLE DISORDER INVOLVING DEFICIENCIES OF CARBAMYLPHOSPHATE SYNTHETASE, ORNITHINE TRANSCARBAMYLASE, OR ARGININOSUCCINIC ACID SYNTHETASE",OLPRUVA,ACER,N,214860,RX,FOR SUSPENSION,ORAL,2022-12-22,2036-10-17
2352,EQ 100MG BASE,7754731,TREATMENT OF HIV INFECTION,ISENTRESS,MSD SUB MERCK,N,203045,RX,"TABLET, CHEWABLE",ORAL,2011-12-21,2029-03-11
1239,0.0048MG/INH;0.0090MG/INH,8703806,USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD),BEVESPI AEROSPHERE,ASTRAZENECA,N,208294,RX,"AEROSOL, METERED",INHALATION,2016-04-25,2030-05-28
4811,400MG;100MG;100MG,8580765,TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR,VOSEVI,GILEAD SCIENCES INC,N,209195,RX,TABLET,ORAL,2017-07-18,2028-03-21
4566,0.234GM/ML;0.096GM/ML;0.13GM/ML;0.04GM/ML,8772306,METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS AND/OR CATAPLEXY IN NARCOLEPSY PATIENTS WITH SODIUM OXYBATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED.,XYWAV,JAZZ,N,212690,RX,SOLUTION,ORAL,2020-07-21,2033-03-15
4399,EQ 25MG ACID,7547719,PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY,PROMACTA,NOVARTIS,N,022291,RX,TABLET,ORAL,2008-11-20,2025-07-13
242,400MG,11344547,"TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA",ABILIFY MAINTENA KIT,OTSUKA PHARM CO LTD,N,202971,RX,"FOR SUSPENSION, EXTENDED RELEASE",INTRAMUSCULAR,2014-09-29,2033-09-24
4616,8MG/0.4ML (8MG/0.4ML),8247425,TREATMENT OF OPIOID-INDUCED CONSTIPATION,RELISTOR,SALIX PHARMS,N,021964,RX,SOLUTION,SUBCUTANEOUS,2010-09-27,2030-12-31
5468,1.2MG,10981952,METHOD OF TREATING CHOLESTATIC PRURITUS IN PATIENTS 12 MONTHS OR OLDER SUFFERING FROM ALAGILLE SYNDROME (ALGS),BYLVAY,ALBIREO,N,215498,RX,CAPSULE,ORAL,2021-07-20,2031-11-08
2029,9MG,9682075,"MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE",XTAMPZA ER,COLLEGIUM PHARM INC,N,208090,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2016-04-26,2030-12-10
5495,EQ 40MG BASE,8829195,TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML),SCEMBLIX,NOVARTIS,N,215358,RX,TABLET,ORAL,2021-10-29,2033-05-13
5446,7MG,9062014,"TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS",PONVORY,JANSSEN PHARMS,N,213498,RX,TABLET,ORAL,2021-03-18,2032-05-06
1567,23.75MG;95MG,8377474,"TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION",RYTARY,IMPAX LABS INC,N,203312,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2015-01-07,2028-12-26
5260,100MG,10239883,TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA,CALQUENCE,ASTRAZENECA,N,210259,RX,CAPSULE,ORAL,2017-10-31,2032-07-11
4399,EQ 12.5MG ACID/PACKET,7547719,PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY,PROMACTA KIT,NOVARTIS,N,207027,RX,FOR SUSPENSION,ORAL,2018-09-27,2025-07-13
2706,100MG,10314790,USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE,TROKENDI XR,SUPERNUS PHARMS,N,201635,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2013-08-16,2027-11-16
3317,20MG,7468363,"USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB",REVLIMID,CELGENE,N,021880,RX,CAPSULE,ORAL,2013-06-05,2023-10-07
2389,50MG,9532991,TREATMENT OF SCHIZOPHRENIA IN ADULTS,RYKINDO,SHANDONG LUYE,N,212849,RX,"FOR SUSPENSION, EXTENDED RELEASE",INTRAMUSCULAR,2023-01-13,2032-04-10
5252,EQ 40MG BASE,8518446,"EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY STAGE HER2-OVEREXPRESSED/AMPLIFIED BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASE THERAPY",NERLYNX,PUMA BIOTECH,N,208051,RX,TABLET,ORAL,2017-07-17,2030-11-20
496,48.75MG;195MG,9901640,TREATMENT OF PARKINSONS DISEASE,RYTARY,IMPAX LABS INC,N,203312,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2015-01-07,2028-12-26
3317,10MG,9155730,USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED FOLLICULAR LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT,REVLIMID,CELGENE,N,021880,RX,CAPSULE,ORAL,2005-12-27,2023-05-15
4498,1.092GM/3.5ML (312MG/ML),11324751,TREATMENT OF SCHIZOPHRENIA BY ADMINISTERING A DOSE UP TO TWO WEEKS BEFORE OR THREE WEEKS AFTER THE SCHEDULED SIX-MONTH DOSE,INVEGA HAFYERA,JANSSEN PHARMS,N,207946,RX,"SUSPENSION, EXTENDED RELEASE",INTRAMUSCULAR,2021-08-30,2041-05-07
5493,EQ 50MG BASE,10023560,TREATMENT OF INSOMNIA,QUVIVIQ,IDORSIA,N,214985,RX,TABLET,ORAL,2022-04-07,2034-12-02
4721,EQ 10MG BASE,10555938,A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES,JUXTAPID,AMRYT,N,203858,RX,CAPSULE,ORAL,2012-12-21,2025-03-07
4749,60MG,8236861,TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE,OSPHENA,DUCHESNAY,N,203505,RX,TABLET,ORAL,2013-02-26,2026-08-11
5468,1.2MG,10011633,METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 12 MONTHS OR OLDER SUFFERING FROM ALAGILLE SYNDROME (ALGS),BYLVAY,ALBIREO,N,215498,RX,CAPSULE,ORAL,2021-07-20,2031-11-08
4830,5MG;2.5MG;1GM,8178541,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN,TRIJARDY XR,BOEHRINGER INGELHEIM,N,212614,RX,"TABLET, EXTENDED RELEASE",ORAL,2020-01-27,2023-08-12
5468,0.4MG,11583539,METHOD OF TREATING PRURITUS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC),BYLVAY,ALBIREO,N,215498,RX,CAPSULE,ORAL,2021-07-20,2041-11-12
2391,"EQ 250MG BASE;12.5MG, 75MG, 50MG",8642538,TREATMENT OF HCV INFECTION USING PARITAPREVIR,VIEKIRA PAK (COPACKAGED),ABBVIE,N,206619,DISCN,TABLET,ORAL,2014-12-19,2029-09-10
271,0.2055MG/SPRAY,8518919,"TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL AND PERENNIAL ALLERGIC RHINITIS",ASTEPRO,MYLAN SPECIALITY LP,N,022203,DISCN,"SPRAY, METERED",NASAL,2009-08-31,2025-11-22
4228,"150MG;150MG, 100MG",10081621,"TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 6 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR WHO HAVE AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,081,621",SYMDEKO (COPACKAGED),VERTEX PHARMS INC,N,210491,RX,TABLET,ORAL,2018-02-12,2031-03-25
391,3.5MG/1.4ML (2.5MG/ML),11679119,TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA,BORTEZOMIB,MAIA PHARMS INC,N,215331,RX,SOLUTION,INTRAVENOUS,2022-07-27,2042-09-23
2572,EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**,8133883,METHOD OF TREATING BACTERIAL INFECTIONS,ZOSYN,WYETH PHARMS,N,050684,DISCN,INJECTABLE,INJECTION,1993-10-22,2023-04-14
434,100MG/0.5ML (100MG/0.5ML),9827241,TREATING OPIOID ADDICTION BY ADMINISTRATION OF BUPRENORPHINE,SUBLOCADE,INDIVIOR,N,209819,RX,"SOLUTION, EXTENDED RELEASE",SUBCUTANEOUS,2017-11-30,2031-06-06
1123,2MG/VIAL,9884092,AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA,BYDUREON,ASTRAZENECA AB,N,022200,DISCN,"FOR SUSPENSION, EXTENDED RELEASE",SUBCUTANEOUS,2012-01-27,2026-08-18
5203,EQ 200MG BASE,8859562,"A METHOD FOR TREATING OVARIAN CANCER BY ADMINISTERING RUCAPARIB, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION",RUBRACA,ZR PHARMA,N,209115,RX,TABLET,ORAL,2016-12-19,2031-08-04
4721,EQ 5MG BASE,10555938,A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES,JUXTAPID,AMRYT,N,203858,RX,CAPSULE,ORAL,2012-12-21,2025-03-07
2868,EQ 5MG BASE/100ML,8052987,TREATMENT AND PREVENTION OF POSTMENOPAUSAL OR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS,RECLAST,SANDOZ,N,021817,RX,INJECTABLE,INTRAVENOUS,2007-04-16,2023-10-27
4627,0.005MG/VIAL,11318100,"ACCELERATE THE TRANSIT OF A BARIUM MEAL THROUGH THE SMALL BOWEL, THEREBY DECREASING THE TIME AND EXTENT OF RADIATION ASSOCIATED WITH FLUOROSCOPY AND X-RAY EXAMINATION OF THE INTESTINAL TRACT",SINCALIDE,MAIA PHARMS INC,N,210850,RX,POWDER,INTRAVENOUS,2022-11-22,2038-04-20
5122,272MG IRON/PACKET,7816404,METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT,TRIFERIC,ROCKWELL MEDICAL INC,N,208551,DISCN,FOR SOLUTION,INTRAVENOUS,2016-04-25,2029-04-17
4190,EQ 20MG BASE,8822481,USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.,JAKAFI,INCYTE CORP,N,202192,RX,TABLET,ORAL,2011-11-16,2028-06-12
144,EQ 129MG BASE,10500171,TREATMENT OF DRUG-INDUCED EXTRAPYRAMIDAL REACTION IN ADULT PATIENTS,OSMOLEX ER,ADAMAS OPERATIONS,N,209410,RX,"TABLET, EXTENDED RELEASE",ORAL,2018-02-16,2038-02-15
5389,150MG,9693989,TREATMENT OF BREAST CANCER INCLUDING HER2 (ERBB2)-POSITIVE OR -OVEREXPRESSING BREAST CANCER,TUKYSA,SEAGEN,N,213411,RX,TABLET,ORAL,2020-04-17,2027-05-09
432,133MG/10ML (13.3MG/ML),11452691,"METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA NERVE BLOCK, FOR EXAMPLE, NTERSCALENE BRACHIAL PLEXUS FOR REGIONAL ANALGESIA",EXPAREL,PACIRA PHARMS INC,N,022496,RX,"INJECTABLE, LIPOSOMAL",INJECTION,2011-10-28,2041-01-22
2044,100MG/VIAL,7820788,TREATMENT OF PANCREATIC CANCER,ABRAXANE,BRISTOL-MYERS,N,021660,RX,POWDER,INTRAVENOUS,2005-01-07,2024-10-27
682,20MG,11541002,METHOD OF TREATING SEIZURES,SYMPAZAN,OTTER PHARMS,N,210833,RX,FILM,ORAL,2018-11-01,2040-01-31
5468,0.4MG,11365182,METHOD OF TREATING PRURITUS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC),BYLVAY,ALBIREO,N,215498,RX,CAPSULE,ORAL,2021-07-20,2039-06-20
4212,7.54GM;140GM;2.2GM;48.11GM;5.2GM;9GM,10792306,FOR CLEANSING OF THE COLON IN PREPARATION FOR COLONOSCOPY IN ADULTS,PLENVU,SALIX,N,209381,RX,FOR SOLUTION,ORAL,2018-05-04,2032-03-09
4874,10%,11213519,"ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS; TOPICAL TREATMENT OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES",JUBLIA,BAUSCH,N,203567,RX,SOLUTION,TOPICAL,2014-06-06,2028-01-03
5293,EQ 200MG BASE,7176211,MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS,ORILISSA,ABBVIE,N,210450,RX,TABLET,ORAL,2018-07-23,2024-07-06
4810,280MG,8563563,TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION,IMBRUVICA,PHARMACYCLICS LLC,N,210563,RX,TABLET,ORAL,2018-02-16,2027-04-26
4228,125MG;200MG,10597384,"TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING A PHARMACEUTICAL COMPOSITION ACCORDING TO CLAIM 2 OF U.S. PATENT NO. 10,597,384, FURTHER COMPRISING IVACAFTOR",ORKAMBI,VERTEX PHARMS INC,N,206038,RX,TABLET,ORAL,2015-07-02,2028-12-04
4716,EQ 30MG BASE,9029533,A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA,ICLUSIG,TAKEDA PHARMS USA,N,203469,RX,TABLET,ORAL,2015-04-23,2026-12-22
4988,20MG/2ML (10MG/ML),7754230,METHOD FOR REDUCTION OF SUBMENTAL FAT,KYBELLA,KYTHERA BIOPHARMS,N,206333,RX,SOLUTION,SUBCUTANEOUS,2015-04-29,2027-12-10
3317,2.5MG,8648095,"USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE",REVLIMID,CELGENE,N,021880,RX,CAPSULE,ORAL,2011-12-21,2023-05-15
5046,EQ 20MG BASE,11254649,METHOD OF USING COBIMETINIB FOR THE TREATMENT OF MELANOMA,COTELLIC,GENENTECH INC,N,206192,RX,TABLET,ORAL,2015-11-10,2036-06-30
4746,2MG,8735428,USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA,POMALYST,BRISTOL,N,204026,RX,CAPSULE,ORAL,2013-02-08,2023-05-15
3972,1%,9233118,TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.,SOOLANTRA,GALDERMA LABS LP,N,206255,RX,CREAM,TOPICAL,2014-12-19,2034-03-13
4190,EQ 25MG BASE,9079912,"FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF",JAKAFI,INCYTE CORP,N,202192,RX,TABLET,ORAL,2011-11-16,2026-12-12
435,105MG;45MG,9168234,DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER,AUVELITY,AXSOME,N,215430,RX,"TABLET, EXTENDED RELEASE",ORAL,2022-08-18,2034-11-05
1123,2MG,7612176,AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN,BYDUREON PEN,ASTRAZENECA AB,N,022200,DISCN,"FOR SUSPENSION, EXTENDED RELEASE",SUBCUTANEOUS,2014-02-28,2025-04-13
282,5MG/PACKET,10792262,METHOD FOR TREATING SPASTICITY,LYVISPAH,AMNEAL,N,215422,RX,GRANULES,ORAL,2021-11-22,2039-07-29
403,EQ 0.8MG BASE,9993474,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 12 AND 19,CYCLOSET,VEROSCIENCE,N,020866,RX,TABLET,ORAL,2009-05-05,2032-04-30
4483,60MG/VIAL,7491704,TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY,KYPROLIS,ONYX PHARMS AMGEN,N,202714,RX,POWDER,INTRAVENOUS,2012-07-20,2025-04-14
1800,0.25%;81.35%;15%,8147852,USE FOR TREATMENT OF DIAPER DERMATITIS COMPLICATED BY CANDIDIASIS,VUSION,MYLAN,N,021026,RX,OINTMENT,TOPICAL,2006-02-16,2028-03-30
2608,150MG,10576089,METHOD OF TREATING TESTOSTERONE DEFICIENCY,KYZATREX,MARIUS PHARMS LLC,N,213953,RX,CAPSULE,ORAL,2022-07-27,2030-12-31
2608,237MG,11426416,A METHOD OF TREATING TESTOSTERONE DEFICIENCY IN MEN,JATENZO,TOLMAR,N,206089,RX,CAPSULE,ORAL,2019-03-27,2030-04-12
1765,90MG;8MG,8815889,FOR EFFECT ON BLOOD GLUCOSE PARAMETERS IN PATIENTS WITH INSULIN RESISTANCE,CONTRAVE,NALPROPION,N,200063,RX,"TABLET, EXTENDED RELEASE",ORAL,2014-09-10,2024-07-20
5415,EQ 94.5MG/0.5ML BASE (EQ 94.5MG/0.5ML BASE),10465195,TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1),OXLUMO,ALNYLAM PHARMS INC,N,214103,RX,SOLUTION,SUBCUTANEOUS,2020-11-23,2034-12-26
5393,80MG,10786489,THE TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC),RETEVMO,LOXO ONCOL ELI LILLY,N,213246,RX,CAPSULE,ORAL,2020-05-08,2038-10-10
4224,801MG,7635707,FULL DAILY DOSING FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF,ESBRIET,GENENTECH INC,N,208780,RX,TABLET,ORAL,2017-01-11,2029-04-22
5203,EQ 250MG BASE,10130636,"MAINTENANCE TREATMENT OF RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY",RUBRACA,ZR PHARMA,N,209115,RX,TABLET,ORAL,2017-05-01,2035-08-17
2720,20MG/ML,8653137,ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE DILUENT FOR FLOLAN OR STERILE DILUENT FOR EPOPROSTENOL SODIUM PRIOR TO ADMINISTRATION,REMODULIN,UNITED THERAP,N,021272,RX,INJECTABLE,"IV (INFUSION), SUBCUTANEOUS",2021-07-30,2028-09-05
1164,0.6MG,9642797,TREATMENT OF PAIN,SUBSYS,BTCP PHARMA,N,202788,DISCN,SPRAY,SUBLINGUAL,2012-01-04,2027-01-25
4944,150MG;150MG;200MG;EQ 10MG BASE,8754065,TREATMENT OF HIV INFECTION,GENVOYA,GILEAD SCIENCES INC,N,207561,RX,TABLET,ORAL,2015-11-05,2032-08-15
179,10MG/4ML (2.5MG/ML),9545426,PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING,BARHEMSYS,ACACIA,N,209510,RX,SOLUTION,INTRAVENOUS,2020-09-01,2031-03-10
4135,40MG,7659253,FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),VYVANSE,TAKEDA PHARMS USA,N,021977,RX,CAPSULE,ORAL,2007-12-10,2023-02-24
1413,500MG,10881632,USE OF VASCEPA TO REDUCE TRIGLYCERIDE LEVELS IN AN ADULT PATIENT ON STATIN THERAPY AND HAVING ATRIAL FIBRILLATION AND TRIGLYCERIDE LEVELS OF GREATER THAN 500 MG/DL,VASCEPA,AMARIN PHARMS,N,202057,RX,CAPSULE,ORAL,2017-02-16,2030-04-29
5448,EQ 7.8MG BASE;EQ 39.2MG BASE,10858341,TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) WITH SERDEXMETHYLPHENIDATE AND DEXMETHYLPHENIDATE,AZSTARYS,COMMAVE THERAP,N,212994,RX,CAPSULE,ORAL,2021-05-07,2037-12-09
230,125MG/KIT,8258132,PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY (CINV),EMEND,MSD MERCK CO,N,207865,RX,FOR SUSPENSION,ORAL,2015-12-17,2027-09-26
2034,7.5MG,8808737,METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE,OPANA ER,ENDO PHARMS,N,201655,DISCN,"TABLET, EXTENDED RELEASE",ORAL,2011-12-09,2027-06-21
5285,EQ 20MG BASE,8765764,TREATMENT OF THROMBOCYTOPENIA IN AN ADULT PATIENT WITH CHRONIC LIVER DISEASE WHO IS SCHEDULED TO UNDERGO A PROCEDURE,DOPTELET,AKARX INC,N,210238,RX,TABLET,ORAL,2018-05-21,2023-01-15
4554,0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH,RE44874,"INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA; AND ASTHMA",TRELEGY ELLIPTA,GLAXOSMITHKLINE,N,209482,RX,POWDER,INHALATION,2017-09-18,2023-03-23
4810,140MG,9540382,TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA,IMBRUVICA,PHARMACYCLICS LLC,N,205552,RX,CAPSULE,ORAL,2013-11-13,2033-08-18
852,7.5MG/SPRAY,8927497,"NASAL ADMINISTRATION OF DIAZEPAM FOR TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY IN PATIENTS 6 YEARS OF AGE AND OLDER",VALTOCO,NEURELIS INC,N,211635,RX,SPRAY,NASAL,2020-01-10,2025-07-21
4187,200MG,7825137,"METHOD OF REVERSING OR INHIBITING THE PROGRESS OF UNRESECTABLE, RECURRENT, OR REFRACTORY INFLAMMATORY MYOFIBROBLASTIC TUMOR (IMT) THAT IS ALK-POSITIVE IN ADULT AND PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER",XALKORI,PF PRISM CV,N,202570,RX,CAPSULE,ORAL,2011-08-26,2027-05-12
2571,0.01%;0.045%,10478502,TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS,DUOBRII,BAUSCH,N,209354,RX,LOTION,TOPICAL,2019-04-25,2031-11-02
1725,12.5MG;500MG,10258637,METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN,SYNJARDY,BOEHRINGER INGELHEIM,N,206111,RX,TABLET,ORAL,2015-08-26,2034-04-03
2029,4.8MG;40MG,8685443,"MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING A PLURALITY OF COMPOSITE SUBUNITS AS CLAIMED",TROXYCA ER,PFIZER,N,207621,DISCN,"CAPSULE, EXTENDED RELEASE",ORAL,2016-08-19,2025-07-03
5227,EQ 40MG BASE,10844058,TREATMENT OF TARDIVE DYSKINESIA,INGREZZA,NEUROCRINE,N,209241,RX,CAPSULE,ORAL,2017-04-11,2036-10-28
144,EQ 193MG BASE,8895616,TREATMENT OF PARKINSONS DISEASE,OSMOLEX ER,ADAMAS OPERATIONS,N,209410,RX,"TABLET, EXTENDED RELEASE",ORAL,2018-02-16,2025-11-23
5372,"50MG,37.5MG,25MG; 75MG",10081621,TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH A COMPOSITION ACCORDING TO CLAIM 1 OF US 10081621,TRIKAFTA (COPACKAGED),VERTEX PHARMS INC,N,212273,RX,TABLET,ORAL,2021-06-08,2031-03-25
5203,EQ 200MG BASE,7531530,"A METHOD FOR TREATING METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA-MUTATION",RUBRACA,ZR PHARMA,N,209115,RX,TABLET,ORAL,2016-12-19,2024-07-23
4829,10MG,6962940,USE OF OTEZLA (APREMILAST) FOR INHIBITING PDE4,OTEZLA,AMGEN INC,N,205437,RX,TABLET,ORAL,2014-03-21,2023-03-19
5379,200MG,9200002,"TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS, INCLUDING PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), AND MAST CELL LEUKEMIA (MCL)",AYVAKIT,BLUEPRINT MEDICINES,N,212608,RX,TABLET,ORAL,2020-01-09,2034-10-15
4816,EQ 62.5MCG BASE/INH,8183257,"INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA.",INCRUSE ELLIPTA,GLAXO GRP ENGLAND,N,205382,RX,POWDER,INHALATION,2014-04-30,2025-07-27
2807,EQ 2GM BASE/400ML (EQ 5MG BASE/ML),10188697,METHOD OF TREATING BACTERIAL INFECTIONS,VANCOMYCIN HYDROCHLORIDE,XELLIA PHARMS APS,N,211962,RX,SOLUTION,INTRAVENOUS,2019-02-15,2035-11-06
4340,EQ 25MG BASE;EQ 30MG BASE,7807689,METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN,OSENI,TAKEDA PHARMS USA,N,022426,RX,TABLET,ORAL,2013-01-25,2028-06-27
4749,60MG,8470890,TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE,OSPHENA,DUCHESNAY,N,203505,RX,TABLET,ORAL,2013-02-26,2024-02-13
2389,25MG,9446135,TREATMENT OF SCHIZOPHRENIA IN ADULTS,RYKINDO,SHANDONG LUYE,N,212849,RX,"FOR SUSPENSION, EXTENDED RELEASE",INTRAMUSCULAR,2023-01-13,2032-04-10
5010,188MG/PACKET;150MG/PACKET,11564916,TREATMENT OF CF IN A PATIENT AGE 1 TO <6 YEARS AND WEIGHING 7 KG OR MORE WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE COMPOSITION RECITED IN CLAIM 1 OF US 11564916,ORKAMBI,VERTEX PHARMS INC,N,211358,RX,GRANULE,ORAL,2018-08-07,2029-08-13
4758,50MG;500MG,8222219,"REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS",INVOKAMET,JANSSEN PHARMS,N,204353,RX,TABLET,ORAL,2014-08-08,2025-04-11
2607,1.62% (20.25MG/1.25GM ACTUATION),8741881,TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE,ANDROGEL,BESINS HLTHCARE,N,022309,RX,"GEL, METERED",TRANSDERMAL,2011-04-29,2026-10-12
5711,400MG,9993461,TREATMENT OF PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) IN ADULTS AT RISK OF RAPID DISEASE PROGRESSION,FILSPARI,TRAVERE,N,216403,RX,TABLET,ORAL,2023-02-17,2030-03-29
1386,30MG,9492391,"MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE",HYSINGLA ER,PURDUE PHARMA LP,N,206627,RX,"TABLET, EXTENDED RELEASE",ORAL,2014-11-20,2027-08-24
302,100MG/4ML (25MG/ML),9034908,FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR NON-HODGKINS LYMPHOMA,BENDEKA,EAGLE PHARMS,N,208194,RX,SOLUTION,IV (INFUSION),2015-12-07,2033-03-15
1239,0.16MG/INH;0.0045MG/INH,7759328,USE FOR REDUCING EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE,SYMBICORT,ASTRAZENECA,N,021929,RX,"AEROSOL, METERED",INHALATION,2006-07-21,2023-01-29
1725,50MG;500MG,7943582,REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS,INVOKAMET,JANSSEN PHARMS,N,204353,RX,TABLET,ORAL,2014-08-08,2029-02-26
4174,600MG/3ML (200MG/ML);900MG/3ML (300MG/ML),11389447,TREATMENT OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG BY MONTHLY ADMINISTRATION OF RILPIVIRINE SUSPENSION AS PART OF COMBINATION THERAPY,CABENUVA KIT,VIIV HLTHCARE,N,212888,RX,"SUSPENSION, EXTENDED RELEASE",INTRAMUSCULAR,2021-01-21,2027-06-30
4913,EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**,8642538,TREATMENT OF HCV INFECTION USING PARITAPREVIR,VIEKIRA XR,ABBVIE,N,208624,DISCN,"TABLET, EXTENDED RELEASE",ORAL,2016-07-22,2029-09-10
1725,50MG;500MG,8513202,TREATMENT OF TYPE 2 DIABETES MELLITUS,INVOKAMET,JANSSEN PHARMS,N,204353,RX,TABLET,ORAL,2014-08-08,2027-12-03
4758,300MG,8222219,REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS,INVOKANA,JANSSEN PHARMS,N,204042,RX,TABLET,ORAL,2013-03-29,2025-04-11
1751,27.5MG/0.55ML (27.5MG/0.55ML),8664231,SUBCUTANEOUS INJECTION OF METHOTREXATE,RASUVO,MEDEXUS,N,205776,DISCN,SOLUTION,SUBCUTANEOUS,2014-07-10,2029-06-01
4301,121.5mCi/30ML (4.05mCi/ML),7351401,DIAGNOSTIC RADIOIMAGING,VIZAMYL,GE HEALTHCARE,N,203137,RX,INJECTABLE,INTRAVENOUS,2013-10-25,2023-01-24
4340,EQ 12.5MG BASE;500MG,7807689,METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN,KAZANO,TAKEDA PHARMS USA,N,203414,RX,TABLET,ORAL,2013-01-25,2028-06-27
5441,EQ 200MG BASE,10072013,RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN,UKONIQ,TG THERAPS,N,213176,DISCN,TABLET,ORAL,2021-02-05,2033-07-02
4283,EQ 150MG BASE,11344512,"A METHOD OF TITRATING AN OPIOID TO MANAGE NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE",NUCYNTA ER,COLLEGIUM PHARM INC,N,200533,RX,"TABLET, EXTENDED RELEASE",ORAL,2011-08-25,2028-04-21
435,90MG;8MG,10403170,FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY,CONTRAVE,NALPROPION,N,200063,RX,"TABLET, EXTENDED RELEASE",ORAL,2014-09-10,2033-06-05
1725,5MG;2.5MG;1GM,10406172,"METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN",TRIJARDY XR,BOEHRINGER INGELHEIM,N,212614,RX,"TABLET, EXTENDED RELEASE",ORAL,2020-01-27,2030-06-15
1982,5MG;EQ 10MG BASE,9517235,"METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCTION OF THE ADVERSE METABOLIC PROFILE",LYBALVI,ALKERMES INC,N,213378,RX,TABLET,ORAL,2021-05-28,2031-08-23
2646,"0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium",7101569,METHOD OF USE OF ADMINISTERING LEVOTHYROXINE,LEVOXYL,KING PHARMS,N,021301,RX,TABLET,ORAL,2001-05-25,2023-10-02
1813,EQ 100MG BASE/VIAL,9278105,METHOD OF TREATING BACTERIAL INFECTIONS,MINOCIN,REMPEX,N,050444,RX,INJECTABLE,INJECTION,,2031-05-12
4907,100MG,8859562,MAINTENANCE TREATMENT WITH BEVACIZUMAB OF ADV. EPITHELIAL OVARIAN CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION,LYNPARZA,ASTRAZENECA,N,208558,RX,TABLET,ORAL,2017-08-17,2031-08-04
1164,0.2MG,9289387,TREATMENT OF PAIN,SUBSYS,BTCP PHARMA,N,202788,DISCN,SPRAY,SUBLINGUAL,2012-01-04,2027-01-25
5128,100MG IRON/2ML (50MG IRON/ML),11291645,METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WITH NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE,INJECTAFER,AM REGENT,N,203565,RX,SOLUTION,INTRAVENOUS,2022-02-04,2023-10-20
403,EQ 0.8MG BASE,10688155,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 19 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1,CYCLOSET,VEROSCIENCE,N,020866,RX,TABLET,ORAL,2009-05-05,2030-06-07
4303,400MG,9763954,TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY WHO HAVE BEEN PREVIOUSLY TREATED WITH OXCARBAZEPINE,APTIOM,SUMITOMO PHARMA AM,N,022416,RX,TABLET,ORAL,2013-11-08,2028-09-13
4810,420MG,8703780,TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA,IMBRUVICA,PHARMACYCLICS LLC,N,210563,RX,TABLET,ORAL,2018-02-16,2026-12-28
4811,400MG,9549941,"FOR THE TREATMENT OF GENOTYPE 1, 2, 3 OR 4 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION AS A COMPONENT OF A COMBINATION ANTIVIRAL TREATMENT REGIMEN WITH RIBAVIRIN",SOVALDI,GILEAD SCIENCES INC,N,204671,RX,TABLET,ORAL,2013-12-06,2029-03-26
5372,"100MG,75MG,50MG; 150MG",9974781,"TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR",TRIKAFTA (COPACKAGED),VERTEX PHARMS INC,N,212273,RX,TABLET,ORAL,2019-10-21,2027-04-09
1057,0.004MG,10398708,TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY,IMVEXXY,MAYNE PHARMA,N,208564,RX,INSERT,VAGINAL,2018-05-29,2033-12-20
1878,EQ 2MG BASE;EQ 0.5MG BASE,11135216,TREATING OPIOID USE DISORDER,SUBOXONE,INDIVIOR,N,022410,RX,FILM,"BUCCAL, SUBLINGUAL",2010-08-30,2029-08-07
726,0.5MG,11026899,A METHOD FOR TREATING AND/OR REDUCING THE RISK OF A CARDIOVASCULAR EVENT,LODOCO,AGEPHA PHARMA FZ,N,215727,RX,TABLET,ORAL,2023-06-16,2035-01-22
5313,EQ 10MG BASE/5ML (EQ 2MG BASE/ML),11079379,TREATMENT OF POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS,ONPATTRO,ALNYLAM PHARMS INC,N,210922,RX,SOLUTION,INTRAVENOUS,2018-08-10,2035-08-27
4224,801MG,8609701,"DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE, FOLLOWED BY ADMINISTERING AT LEAST 1602 MG/DAY",ESBRIET,GENENTECH INC,N,208780,RX,TABLET,ORAL,2017-01-11,2029-04-22
1813,EQ 90MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**,7790705,TREATMENT OF ACNE,SOLODYN,BAUSCH,N,050808,DISCN,"TABLET, EXTENDED RELEASE",ORAL,2006-05-08,2025-06-24
5468,1.2MG,9694018,METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC),BYLVAY,ALBIREO,N,215498,RX,CAPSULE,ORAL,2021-07-20,2031-11-08
4399,EQ 50MG ACID,7795293,TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP),PROMACTA,NOVARTIS,N,022291,RX,TABLET,ORAL,2008-11-20,2023-05-21
1239,0.0048MG/INH;0.0090MG/INH,10716753,USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD),BEVESPI AEROSPHERE,ASTRAZENECA,N,208294,RX,"AEROSOL, METERED",INHALATION,2016-04-25,2030-05-28
4758,50MG;1GM,8513202,"REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS",INVOKAMET,JANSSEN PHARMS,N,204353,RX,TABLET,ORAL,2014-08-08,2027-12-03
5067,EQ 4MG BASE,9233115,USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY,NINLARO,TAKEDA PHARMS USA,N,208462,RX,CAPSULE,ORAL,2015-11-20,2024-08-12
4820,20MG,11633377,TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON,HETLIOZ,VANDA PHARMS INC,N,205677,RX,CAPSULE,ORAL,2014-01-31,2033-01-25
489,200MG,6977253,"THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.",EQUETRO,VALIDUS PHARMS,N,021710,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2004-12-10,2024-05-19
2806,24MG;26MG,9517226,TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION,ENTRESTO,NOVARTIS PHARMS CORP,N,207620,RX,TABLET,ORAL,2015-07-07,2033-08-22
24,3GM/PACKET; 1GM/PACKET,9872865,TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS,RELYVRIO,AMYLYX,N,216660,RX,FOR SUSPENSION,ORAL,2022-09-29,2033-12-24
1551,0.005%,9539262,REDUCING ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION,XELPROS,SUN PHARM,N,206185,RX,EMULSION,OPHTHALMIC,2018-09-12,2028-10-15
5372,"100MG,75MG,50MG; 150MG",8629162,"TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELX, TEZ, AND IVA",TRIKAFTA (COPACKAGED),VERTEX PHARMS INC,N,212273,RX,TABLET,ORAL,2019-10-21,2025-06-24
4810,140MG,10478439,TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA,IMBRUVICA,PHARMACYCLICS LLC,N,205552,RX,CAPSULE,ORAL,2013-11-13,2031-06-03
5259,50MG,7855211,"IN COMBINATION WITH ENDOCRINE THERAPY (TAMOXIFEN OR AN AROMATASE INHIBITOR) FOR THE ADJUVANT TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE, NODE-POSITIVE, EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE AND A KI-67 SCORE >=20%",VERZENIO,ELI LILLY AND CO,N,208716,RX,TABLET,ORAL,2017-09-28,2029-12-15
5182,500MG/10ML (50MG/ML),RE47751,TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING BY RESTORING OR INCREASING FUNCTIONAL DYSTROPHIN PROTEIN PRODUCTION,EXONDYS 51,SAREPTA THERAPS INC,N,206488,RX,SOLUTION,INTRAVENOUS,2016-09-19,2025-06-28
1003,EQ 30MG BASE;120MG;EQ 15MG BASE,10385067,TREATMENT OF HIV INFECTION,BIKTARVY,GILEAD SCIENCES INC,N,210251,RX,TABLET,ORAL,2021-10-07,2035-06-19
4899,45MG;200MG/PACKET,8273341,FOR THE TREATMENT OF HEPATITIS C,HARVONI,GILEAD SCIENCES INC,N,212477,RX,PELLETS,ORAL,2019-08-28,2030-05-12
2054,EQ 40MG BASE,7550153,"EROSIVE ESOPHAGITIS, HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND REDUCTION OF SYMPTOMS IN PATIENTS WITH GERD",PROTONIX,WYETH PHARMS,N,022020,RX,"FOR SUSPENSION, DELAYED RELEASE",ORAL,2007-11-14,2024-09-30
4135,40MG,7718619,FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),VYVANSE,TAKEDA PHARMS USA,N,208510,RX,"TABLET, CHEWABLE",ORAL,2017-01-28,2023-02-24
4810,420MG,11672803,TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA,IMBRUVICA,PHARMACYCLICS LLC,N,210563,RX,TABLET,ORAL,2018-02-16,2031-06-03
1118,2.5MG,8410131,"TREATMENT OF SOLID EXCRETORY SYSTEM TUMORS; ADVANCED RENAL CELL CARCINOMA (RCC), AFTER FAILURE OF TREATMENT WITH SUNITINIB OR SORAFENIB",AFINITOR,NOVARTIS,N,022334,RX,TABLET,ORAL,2010-07-09,2025-11-01
865,35MG,9180095,TREATMENT OF PAIN,ZORVOLEX,ZYLA,N,204592,DISCN,CAPSULE,ORAL,2013-10-18,2030-04-23
4944,150MG;800MG;200MG;EQ 10MG BASE,8148374,TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE IN ADULTS WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS,SYMTUZA,JANSSEN PRODS,N,210455,RX,TABLET,ORAL,2018-07-17,2029-09-03
4920,0.3%,9504691,TREATMENT OF ACUTE OTITIS EXTERNA,XTORO,FONSECA BIOSCIENCES,N,206307,DISCN,SUSPENSION/DROPS,OTIC,2014-12-17,2033-11-21
4340,EQ 12.5MG BASE,8173663,METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN,NESINA,TAKEDA PHARMS USA,N,022271,RX,TABLET,ORAL,2013-01-25,2025-12-02
4810,280MG,8754090,TREATMENT OF MANTLE CELL LYMPHOMA,IMBRUVICA,PHARMACYCLICS LLC,N,210563,RX,TABLET,ORAL,2018-02-16,2031-06-03
4829,30MG,9018243,TREATMENT OF ADULT PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS,OTEZLA,AMGEN INC,N,205437,RX,TABLET,ORAL,2014-03-21,2023-03-19
4718,5MG/VIAL,7847061,TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT,GATTEX KIT,TAKEDA PHARMS USA,N,203441,RX,POWDER,SUBCUTANEOUS,2012-12-21,2025-11-01
4483,10MG/VIAL,9511109,KYPROLIS IS INDICATED IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY,KYPROLIS,ONYX PHARMS AMGEN,N,202714,RX,POWDER,INTRAVENOUS,2018-06-07,2029-10-21
4303,800MG,11364247,TREATMENT OF PARTIAL-ONSET SEIZURES,APTIOM,SUMITOMO PHARMA AM,N,022416,RX,TABLET,ORAL,2013-11-08,2025-05-06
5296,15MG,9216982,FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR SMALL LYMPHOCYTIC LEUKEMIA (SLL),COPIKTRA,SECURA,N,211155,RX,CAPSULE,ORAL,2018-09-24,2029-01-05
4228,125MG;200MG,8716338,"METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING THE DOSAGE UNIT OF CLAIM 1 OF U.S. PATENT NO. 8,716,338",ORKAMBI,VERTEX PHARMS INC,N,206038,RX,TABLET,ORAL,2015-07-02,2030-09-20
144,EQ 137MG BASE,11077073,"TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSONS DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS",GOCOVRI,ADAMAS OPERATIONS,N,208944,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2017-08-24,2038-08-23
5128,500MG IRON/10ML (50MG IRON/ML),11123321,METHOD OF TREATING IDA IN ADULT PATIENTS WITH NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE & WEIGHING AT LEAST 40 KG BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 GRAMS OF ELEMENTAL IRON,INJECTAFER,AM REGENT,N,203565,RX,SOLUTION,INTRAVENOUS,2020-10-08,2023-10-20
1123,2MG,8431685,AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA,BYDUREON PEN,ASTRAZENECA AB,N,022200,DISCN,"FOR SUSPENSION, EXTENDED RELEASE",SUBCUTANEOUS,2014-02-28,2025-04-13
4907,150MG,8859562,"MAINTENANCE TREATMENT OF GBRCA- OR SBRCA-MUTATED ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY",LYNPARZA,ASTRAZENECA,N,208558,RX,TABLET,ORAL,2017-08-17,2031-08-04
5037,EQ 3MG BASE,7737142,TREATMENT OF SCHIZOPHRENIA AND/OR ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE,VRAYLAR,ABBVIE,N,204370,RX,CAPSULE,ORAL,2015-09-17,2029-09-17
865,25MG,7884095,NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN,ZIPSOR,ASSERTIO,N,022202,RX,CAPSULE,ORAL,2009-06-16,2029-02-24
4907,150MG,9169235,"TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE OR SOMATIC HOMOLOGOUS RECOMBINATION REPAIR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, WHICH HAS PROGRESSED FOLLOWING PRIOR TREATMENT WITH ENZALUTAMIDE OR ABIRATERONE",LYNPARZA,ASTRAZENECA,N,208558,RX,TABLET,ORAL,2017-08-17,2024-03-12
1028,EQ 1MG BASE/ML (EQ 1MG BASE/ML),9295657,"EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE I), INCLUDING ANAPHYLAXIS",ADRENALIN,PAR STERILE PRODUCTS,N,204200,RX,SOLUTION,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",2012-12-07,2035-03-13
3294,2MG,9074255,DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE,FANAPT,VANDA PHARMS INC,N,022192,RX,TABLET,ORAL,2009-05-06,2030-12-17
5276,"150MG;150MG, 100MG",10022352,"TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HETEROZYGOUS FOR F508DEL AND A SECOND CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR",SYMDEKO (COPACKAGED),VERTEX PHARMS INC,N,210491,RX,TABLET,ORAL,2018-02-12,2027-04-09
4912,EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**,8188104,USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.,VIEKIRA XR,ABBVIE,N,208624,DISCN,"TABLET, EXTENDED RELEASE",ORAL,2016-07-22,2029-05-17
5380,EQ 200MG BASE,8691507,METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION,TAZVERIK,EPIZYME INC,N,211723,RX,TABLET,ORAL,2020-01-23,2031-09-12
2255,330MG,10022447,TREATMENT OF POSTHERPETIC NEURALGIA,LYRICA CR,UPJOHN,N,209501,RX,"TABLET, EXTENDED RELEASE",ORAL,2017-10-11,2026-11-02
4554,0.2MG/INH;EQ 0.025MG BASE/INH,8511304,"MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS AGED 5 YEARS AND OLDER. RECOMMENDED DOSAGES: BREO 100/25 OR 200/25 AGES 18 YEARS AND OLDER; BREO 100/25 AGES 12-17 YEARS, AND BREO 50/25, AGES 5-11 YEARS",BREO ELLIPTA,GLAXO GRP LTD,N,204275,RX,POWDER,INHALATION,2015-04-30,2027-06-14
5415,EQ 94.5MG/0.5ML BASE (EQ 94.5MG/0.5ML BASE),11401517,TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1),OXLUMO,ALNYLAM PHARMS INC,N,214103,RX,SOLUTION,SUBCUTANEOUS,2020-11-23,2035-08-14
4812,EQ 150MG BASE,8754106,METHOD OF TREATING HEPATITIS C,OLYSIO,JANSSEN PRODS,N,205123,DISCN,CAPSULE,ORAL,2013-11-22,2026-07-28
1813,EQ 135MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**,7790705,TREATMENT OF ACNE,SOLODYN,BAUSCH,N,050808,DISCN,"TABLET, EXTENDED RELEASE",ORAL,2006-05-08,2025-06-24
1676,300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML),11413350,"TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER FOOT AND ANKLE, SMALL-TO-MEDIUM OPEN ABDOMINAL, AND LOWER EXTREMITY TOTAL JOINT ARTHROPLASTY SURGICAL PROCEDURES VIA INSTILLATION",ZYNRELEF KIT,HERON THERAPS INC,N,211988,DISCN,"SOLUTION, EXTENDED RELEASE",PERIARTICULAR,2021-05-12,2035-04-20
403,EQ 0.8MG BASE,9993474,"ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 30, 41, AND 42",CYCLOSET,VEROSCIENCE,N,020866,RX,TABLET,ORAL,2009-05-05,2032-04-30
4758,150MG;500MG,8222219,TREATMENT OF TYPE 2 DIABETES MELLITUS,INVOKAMET XR,JANSSEN PHARMS,N,205879,RX,"TABLET, EXTENDED RELEASE",ORAL,2016-09-20,2025-04-11
2407,1MG/24HR,8617591,"A METHOD FOR THE TREATMENT OF A PATIENT SUFFERING FROM A DISEASE TREATABLE WITH ROTIGOTINE, COMPRISING APPLYING THE CLAIMED TRANSDERMAL DELIVERY SYSTEM (TDS) TO THE SKIN OF THE PATIENT",NEUPRO,UCB INC,N,021829,RX,"FILM, EXTENDED RELEASE",TRANSDERMAL,2012-04-02,2023-07-22
5006,50MG/VIAL,9427448,"METHOD OF TREATING, REDUCING THE INCIDENCE OF, OR PREVENTING AN ISCHEMIC EVENT IN A PATIENT UNDERGOING PCI BY ADMINISTERING INTRAVENOUSLY 30 UG/KG BOLUS BEFORE PCI AND CONTINUOUS INFUSION OF 4 UG/KG/MIN FOR AT LEAST 2 HOURS OR THE DURATION OF THE PCI",KENGREAL,CHIESI,N,204958,RX,POWDER,INTRAVENOUS,2015-06-22,2030-11-10
5305,EQ 100MG BASE,10047097,METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION AFTER SURGICAL RESECTION,VITRAKVI,BAYER HLTHCARE,N,210861,RX,CAPSULE,ORAL,2018-11-26,2029-10-21
5312,0.002%,10179127,METHOD OF TREATING OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION IN PATIENTS,OMLONTI,SANTEN,N,215092,DISCN,SOLUTION,OPHTHALMIC,2022-09-22,2035-01-08
5274,EQ 50MG BASE;200MG;EQ 25MG BASE,9296769,TREATMENT OF HIV INFECTION,BIKTARVY,GILEAD SCIENCES INC,N,210251,RX,TABLET,ORAL,2018-02-07,2032-08-15
5408,250MG/5ML (50MG/ML),10870676,TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 53 SKIPPING,VILTEPSO,NIPPON SHINYAKU,N,212154,RX,SOLUTION,INTRAVENOUS,2020-08-12,2031-08-31
1563,750MG,9669009,METHOD OF ADMINISTERING LEVETIRACETAM,SPRITAM,APRECIA PHARMS,N,207958,RX,"TABLET, FOR SUSPENSION",ORAL,2015-07-31,2034-03-14
2389,100MG/0.28ML (100MG/0.28ML),8221778,TREATMENT OF SCHIZOPHRENIA,UZEDY,TEVA,N,213586,RX,"SUSPENSION, EXTENDED RELEASE",SUBCUTANEOUS,2023-04-28,2027-11-12
270,15%,8435498,TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA,FINACEA,LEO PHARMA AS,N,207071,RX,"AEROSOL, FOAM",TOPICAL,2015-07-29,2024-03-01
5154,400MG;100MG,9284342,FOR THE TREATMENT OF HEPATITIS C,EPCLUSA,GILEAD SCIENCES INC,N,208341,RX,TABLET,ORAL,2016-06-28,2030-09-13
5390,9MG,10131667,"FOR THE TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) FUSION OR OTHER REARRANGEMENT",PEMAZYRE,INCYTE CORP,N,213736,RX,TABLET,ORAL,2020-04-17,2033-06-12
5075,200MG,9956205,TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A XANTHINE OXIDASE INHIBITOR ALONE,ZURAMPIC,IRONWOOD PHARMS INC,N,207988,DISCN,TABLET,ORAL,2015-12-22,2031-12-28
4135,20MG,7718619,FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),VYVANSE,TAKEDA PHARMS USA,N,208510,RX,"TABLET, CHEWABLE",ORAL,2017-01-28,2023-02-24
1667,125MG/ML,7101576,"TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)",MEGACE ES,ENDO PHARMS INC,N,021778,RX,SUSPENSION,ORAL,2005-07-05,2024-04-22
157,EQ 590MG BASE/8.4ML,9827317,TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN ADULTS AS PART OF A COMBINATION ANTIBACTERIAL DRUG REGIMEN,ARIKAYCE KIT,INSMED INC,N,207356,RX,"SUSPENSION, LIPOSOMAL",INHALATION,2018-09-28,2024-04-08
1606,2MG,8999393,ONCE DAILY TREATMENT OF ANXIETY DISORDER IN ADULTS,LOREEV XR,ALMATICA,N,214826,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2021-08-27,2034-01-08
4758,150MG;500MG,8222219,"REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS",INVOKAMET XR,JANSSEN PHARMS,N,205879,RX,"TABLET, EXTENDED RELEASE",ORAL,2016-09-20,2025-04-11
4452,0.05%,8460641,TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES,OLUX E,MYLAN,N,022013,RX,"AEROSOL, FOAM",TOPICAL,2007-01-12,2028-11-05
1407,800MG/8ML (100MG/ML),9114068,"METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER WITH INTRAVENOUS IBUPROFEN SUCH THAT MEAN ARTERIAL BLOOD PRESSURE DOES NOT INCREASE THE DOSAGE INTERVAL",CALDOLOR,CUMBERLAND PHARMS,N,022348,RX,SOLUTION,INTRAVENOUS,2009-06-11,2029-09-30
5128,750MG IRON/15ML (50MG IRON/ML),11123321,A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 GRAMS OF ELEMENTAL IRON,INJECTAFER,AM REGENT,N,203565,RX,SOLUTION,INTRAVENOUS,2013-07-25,2023-10-20
1386,40MG,9095614,"MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE",HYSINGLA ER,PURDUE PHARMA LP,N,206627,RX,"TABLET, EXTENDED RELEASE",ORAL,2014-11-20,2027-08-24
2187,EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**,8133883,METHOD OF TREATING BACTERIAL INFECTIONS,ZOSYN,WYETH PHARMS,N,050684,DISCN,INJECTABLE,INJECTION,1993-10-22,2023-04-14
5075,300MG;200MG,8546437,TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE,DUZALLO,IRONWOOD PHARMS INC,N,209203,DISCN,TABLET,ORAL,2017-08-18,2029-04-29
1767,60MG,9603809,METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),JORNAY PM,IRONSHORE PHARMS,N,209311,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2018-08-08,2032-03-23
4799,0.1MG/INH;EQ 0.025MG BASE/INH,7439393,INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER,BREO ELLIPTA,GLAXO GRP LTD,N,204275,RX,POWDER,INHALATION,2013-05-10,2025-05-21
4224,534MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**,8754109,"ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT ADMINISTRATION OF A STRONG INDUCER OF CYP1A2, INCLUDING CIGARETTE SMOKE, TO AVOID REDUCED PIRFENIDONE EFFICACY",ESBRIET,GENENTECH INC,N,208780,DISCN,TABLET,ORAL,2017-01-11,2030-01-08
842,105MG;45MG,10966942,DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER,AUVELITY,AXSOME,N,215430,RX,"TABLET, EXTENDED RELEASE",ORAL,2022-08-18,2040-01-07
5313,EQ 10MG BASE/5ML (EQ 2MG BASE/ML),8822668,TREATMENT OF POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS,ONPATTRO,ALNYLAM PHARMS INC,N,210922,RX,SOLUTION,INTRAVENOUS,2018-08-10,2029-04-15
4228,"50MG,37.5MG,25MG; 75MG",8354427,"TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE A R117H MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR",TRIKAFTA (COPACKAGED),VERTEX PHARMS INC,N,212273,RX,TABLET,ORAL,2021-06-08,2026-07-06
4810,140MG,8476284,TREATMENT OF MANTLE CELL LYMPHOMA,IMBRUVICA,PHARMACYCLICS LLC,N,205552,RX,CAPSULE,ORAL,2013-11-13,2026-12-28
242,5MG,9444503,METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT,ABILIFY MYCITE KIT,OTSUKA,N,207202,RX,TABLET,ORAL,2017-11-13,2027-11-19
3317,20MG,7468363,USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED FOLLICULAR LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT,REVLIMID,CELGENE,N,021880,RX,CAPSULE,ORAL,2013-06-05,2023-10-07
2994,1MG/0.2ML (1MG/0.2ML),9649364,TREATMENT OF SEVERE HYPOGLYCEMIA,GVOKE HYPOPEN,XERIS,N,212097,RX,SOLUTION,SUBCUTANEOUS,2019-09-10,2036-04-22
4300,150MG;150MG;200MG;EQ 10MG BASE,8754065,TREATMENT OF HIV INFECTION,GENVOYA,GILEAD SCIENCES INC,N,207561,RX,TABLET,ORAL,2015-11-05,2032-08-15
242,20MG,8547248,METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER,ABILIFY MYCITE KIT,OTSUKA,N,207202,RX,TABLET,ORAL,2017-11-13,2030-12-18
1725,1GM;EQ 5MG BASE,RE44186,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT  WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE,KOMBIGLYZE XR,ASTRAZENECA AB,N,200678,RX,"TABLET, EXTENDED RELEASE",ORAL,2010-11-05,2023-07-31
2255,165MG,10022447,TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY,LYRICA CR,UPJOHN,N,209501,RX,"TABLET, EXTENDED RELEASE",ORAL,2017-10-11,2026-11-02
4234,EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML),7414105,TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE,OMONTYS PRESERVATIVE FREE,TAKEDA PHARMS USA,N,202799,DISCN,SOLUTION,"INTRAVENOUS, SUBCUTANEOUS",2012-03-27,2024-05-12
5267,2.4MG/0.75ML (2.4MG/0.75ML),9764003,METHOD FOR WEIGHT MANAGEMENT ACCORDING TO A DOSE ESCALATION SCHEDULE,WEGOVY,NOVO,N,215256,RX,SOLUTION,SUBCUTANEOUS,2021-06-04,2033-06-21
403,EQ 0.8MG BASE,9352025,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 19 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 19,CYCLOSET,VEROSCIENCE,N,020866,RX,TABLET,ORAL,2009-05-05,2030-06-07
435,105MG;45MG,10864209,DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER,AUVELITY,AXSOME,N,215430,RX,"TABLET, EXTENDED RELEASE",ORAL,2022-08-18,2034-11-05
4721,EQ 10MG BASE,9861622,A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES,JUXTAPID,AMRYT,N,203858,RX,CAPSULE,ORAL,2012-12-21,2025-03-07
1767,35MG,10292939,METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),ADHANSIA XR,PURDUE PHARMA LP,N,212038,DISCN,"CAPSULE, EXTENDED RELEASE",ORAL,2019-02-27,2035-10-30
625,EQ 40MG MEDOXOMIL;12.5MG,9387249,TREATMENT OF HYPERTENSION,EDARBYCLOR,AZURITY,N,202331,RX,TABLET,ORAL,2011-12-20,2031-07-01
4832,EQ 12.5MG BASE,8067431,TREATMENT OF OPIOID-INDUCED CONSTIPATION,MOVANTIK,VALINOR,N,204760,RX,TABLET,ORAL,2014-09-16,2024-12-16
2029,13.5MG,9248195,"MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE",XTAMPZA ER,COLLEGIUM PHARM INC,N,208090,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2016-04-26,2023-07-07
5457,1080MG/20ML (54MG/ML),11292815,TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF PEGCETACOPLAN SO AS TO REDUCE THE SENSITIVITY OF CELLS TO COMPLEMENT-DEPENDENT DAMAGE,EMPAVELI,APELLIS PHARMS,N,215014,RX,SOLUTION,SUBCUTANEOUS,2021-05-14,2033-11-15
5252,EQ 40MG BASE,9211291,"EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY-STAGE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-POSITIVE BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASED THERAPY",NERLYNX,PUMA BIOTECH,N,208051,RX,TABLET,ORAL,2017-07-17,2030-03-24
4228,188MG/PACKET;150MG/PACKET,8846718,TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR FORM I AND IVACAFTOR,ORKAMBI,VERTEX PHARMS INC,N,211358,RX,GRANULE,ORAL,2018-08-07,2029-07-02
2720,EQ 0.25MG BASE,8747897,A METHOD OF ORAL DELIVERY OF TREPROSTINIL COMPRISING ADMINISTERING AN ORAL OSMOTIC PHARMACEUTICAL DOSAGE FORM,ORENITRAM,UNITED THERAP,N,203496,RX,"TABLET, EXTENDED RELEASE",ORAL,2013-12-20,2031-08-11
5260,100MG,9796721,TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED SMALL LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB,CALQUENCE,ASTRAZENECA,N,210259,RX,CAPSULE,ORAL,2017-10-31,2036-07-01
1413,1GM,9918954,"USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CARDIOVASCULAR EVENT (CORONARY REVASCULARIZATION, UNSTABLE ANGINA, STROKE AND/OR MYOCARDIAL INFARCTION) IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS",VASCEPA,AMARIN PHARMS,N,202057,RX,CAPSULE,ORAL,2012-07-26,2033-06-28
4340,EQ 12.5MG BASE;EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**,7807689,METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN,OSENI,TAKEDA PHARMS USA,N,022426,DISCN,TABLET,ORAL,2013-01-25,2028-06-27
4810,560MG,8952015,TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA,IMBRUVICA,PHARMACYCLICS LLC,N,210563,DISCN,TABLET,ORAL,2018-02-16,2026-12-28
2870,3.5MG,8242131,METHOD OF TREATING MIDDLE-OF-THE-NIGHT INSOMNIA,INTERMEZZO,PURDUE PHARMA,N,022328,DISCN,TABLET,SUBLINGUAL,2011-11-23,2029-08-20
228,15MG,8414922,TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSONS DISEASE,KYNMOBI,SUMITOMO PHARMA AM,N,210875,DISCN,FILM,SUBLINGUAL,2020-05-21,2031-12-16
4811,400MG;100MG,8618076,FOR THE TREATMENT OF HEPATITIS C,EPCLUSA,GILEAD SCIENCES INC,N,208341,RX,TABLET,ORAL,2016-06-28,2030-12-11
5393,40MG,10137124,TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE),RETEVMO,LOXO ONCOL ELI LILLY,N,213246,RX,CAPSULE,ORAL,2020-05-08,2037-10-10
2379,550MG,10456384,TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS 65 YEARS OF AGE OR OLDER,XIFAXAN,SALIX PHARMS,N,021361,RX,TABLET,ORAL,2010-03-24,2029-02-26
434,EQ 2.9MG BASE;EQ 0.71MG BASE,8658198,SUBLINGUAL OR BUCCAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE,ZUBSOLV,OREXO US INC,N,204242,RX,TABLET,SUBLINGUAL,2015-06-04,2027-12-03
4174,600MG/3ML (200MG/ML);900MG/3ML (300MG/ML),8410103,TREATMENT OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG,CABENUVA KIT,VIIV HLTHCARE,N,212888,RX,"SUSPENSION, EXTENDED RELEASE",INTRAMUSCULAR,2021-01-21,2026-04-28
5376,100MG/VIAL,11491169,"TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG) REQUIRING HOSPITALIZATION AND FOR WHOM CONCOMITANT USE OF CHLOROQUINE, OR AN ANALOG OR SALE THEREOF, IS NOT RECOMMENDED",VEKLURY,GILEAD SCIENCES INC,N,214787,RX,POWDER,INTRAVENOUS,2020-10-22,2041-05-28
2612,100MG/PACKET,RE43797,KUVAN IS INDICATED TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA,KUVAN,BIOMARIN PHARM,N,205065,RX,POWDER,ORAL,2013-12-19,2024-11-17
3909,3.75%;EQ 1.2% BASE,9504704,TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER,ONEXTON,BAUSCH,N,050819,RX,GEL,TOPICAL,2014-11-24,2029-06-03
144,EQ 258MG BASE,8389578,TREATMENT OF PARKINSONS DISEASE,OSMOLEX ER,ADAMAS OPERATIONS,N,209410,DISCN,"TABLET, EXTENDED RELEASE",ORAL,2018-02-16,2028-01-22
2464,150MG/10ML (15MG/ML),10799138,USE FOR LOADING DOSE IN PATIENTS WITH SYMPTOMATIC AFIB/AFL WHO ARE CURRENTLY IN SINUS RHYTHM OR FOR THE TREATMENT OF LIFE-THREATENING VENTRICULAR TACHYCARDIA,SOTALOL HYDROCHLORIDE,ALTATHERA PHARMS LLC,N,022306,RX,SOLUTION,INTRAVENOUS,2009-07-02,2039-04-05
1123,2MG/VIAL,8906851,AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA,BYDUREON,ASTRAZENECA AB,N,022200,DISCN,"FOR SUSPENSION, EXTENDED RELEASE",SUBCUTANEOUS,2012-01-27,2026-08-18
1802,5MG/SPRAY,8217033,"ACUTE TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E., SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENTS USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER",NAYZILAM,UCB INC,N,211321,RX,SPRAY,NASAL,2019-05-17,2028-01-18
5421,6MG,8815884,TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE,JESDUVROQ,GLAXOSMITHKLINE,N,216951,RX,TABLET,ORAL,2023-02-01,2027-06-22
434,32MG/0.64ML (50MG/ML),8236292,A METHOD OF DELIVERY OF A BIOACTIVE AGENT BY SUBCUTANEOUS INJECTION. A METHOD OF TREATMENT OF A HUMAN FOR ADDICTION,BRIXADI,BRAEBURN,N,210136,RX,"SOLUTION, EXTENDED RELEASE",SUBCUTANEOUS,2023-05-23,2027-01-10
4228,150MG,8324242,METHOD OF TREATING CYSTIC FIBROSIS,KALYDECO,VERTEX PHARMS,N,203188,RX,TABLET,ORAL,2012-01-31,2027-08-05
4169,600MG/VIAL,8247400,METHOD OF TREATING BACTERIAL INFECTIONS,TEFLARO,ABBVIE,N,200327,RX,POWDER,INTRAVENOUS,2010-10-29,2031-02-10
2448,10MG;EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**,7326708,METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE,JUVISYNC,MERCK SHARP DOHME,N,202343,DISCN,TABLET,ORAL,2012-09-18,2026-04-11
1057,0.01MG,11266661,TREATMENT OF DYSPAREUNIA,IMVEXXY,MAYNE PHARMA,N,208564,RX,INSERT,VAGINAL,2018-05-29,2034-02-02
4135,50MG,7718619,FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),VYVANSE,TAKEDA PHARMS USA,N,208510,RX,"TABLET, CHEWABLE",ORAL,2017-01-28,2023-02-24
4566,0.5GM/ML,10213400,METHOD OF REDUCING ADVERSE EFFECTS IN PATIENTS SUFFERING FROM EXCESSIVE DAYTIME SLEEPINESS AND/OR CATAPLEXY IN NARCOLEPSY WHO ARE CONCOMITANTLY ADMINISTERED SODIUM OXYBATE AND DIVALPROEX SODIUM,XYREM,JAZZ PHARMS,N,021196,RX,SOLUTION,ORAL,2002-07-17,2033-03-15
5414,50MG,8828356,REDUCING THE RISK OF MORTALITY IN HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS),ZOKINVY,EIGER BIOPHARMS,N,213969,RX,CAPSULE,ORAL,2020-11-20,2023-10-17
1123,2MG/0.85ML (2MG/0.85ML),7456254,AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA,BYDUREON BCISE,ASTRAZENECA AB,N,209210,RX,"SUSPENSION, EXTENDED RELEASE",SUBCUTANEOUS,2017-10-20,2025-06-30
5218,EQ 200MG BASE,9416136,"IN COMBINATION WITH AN AROMATASE INHIBITOR FOR THE TREATMENT OF PRE/PERIMENOPAUSAL OR POSTMENOPAUSAL WOMEN WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE-BASED THERAPY",KISQALI,NOVARTIS,N,209092,RX,TABLET,ORAL,2017-03-13,2029-08-20
5460,20MG;EQ 10MG BASE,10300054,METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN,LYBALVI,ALKERMES INC,N,213378,RX,TABLET,ORAL,2021-05-28,2031-08-23
328,0.3%;2.5%,9381179,TREATMENT OF ACNE,EPIDUO FORTE,GALDERMA LABS,N,207917,RX,GEL,TOPICAL,2015-07-15,2023-03-12
4498,78MG/0.5ML (78MG/0.5ML),9439906,TREATMENT OF SCHIZOAFFECTIVE DISORDER AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS,INVEGA SUSTENNA,JANSSEN PHARMS,N,022264,RX,"SUSPENSION, EXTENDED RELEASE",INTRAMUSCULAR,2009-07-31,2031-01-26
4810,560MG,8952015,TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION,IMBRUVICA,PHARMACYCLICS LLC,N,210563,DISCN,TABLET,ORAL,2018-02-16,2026-12-28
4801,EQ 75MG BASE,9233956,TAFINLAR IS INDICATED AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST,TAFINLAR,NOVARTIS,N,202806,RX,CAPSULE,ORAL,2013-05-29,2029-05-04
1005,1MG/ML,9808442,TREATMENT OF HEART FAILURE,EPANED,AZURITY,N,208686,RX,SOLUTION,ORAL,2016-09-20,2036-03-25
2593,100MG;300MG;300MG,8486975,FOR THE TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS WITH NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY,DELSTRIGO,MSD MERCK CO,N,210807,RX,TABLET,ORAL,2018-08-30,2031-10-07
432,300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML),11083797,"TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION",ZYNRELEF KIT,HERON THERAPS INC,N,211988,DISCN,"SOLUTION, EXTENDED RELEASE",PERIARTICULAR,2021-05-12,2035-04-20
3317,10MG,7189740,USE OF REVLIMID (LENALIDOMIDE) FOR TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA DUE TO LOW-OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A DELETION 5Q ABNORMALITY WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES,REVLIMID,CELGENE,N,021880,RX,CAPSULE,ORAL,2005-12-27,2023-04-11
5037,EQ 1.5MG BASE,RE49110,TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) WITH CARIPRAZINE,VRAYLAR,ABBVIE,N,204370,RX,CAPSULE,ORAL,2015-09-17,2029-07-16
2391,"EQ 250MG BASE;12.5MG, 75MG, 50MG",8188104,USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.,VIEKIRA PAK (COPACKAGED),ABBVIE,N,206619,DISCN,TABLET,ORAL,2014-12-19,2029-05-17
5001,75MG,8344011,TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).,VIBERZI,ABBVIE,N,206940,RX,TABLET,ORAL,2015-05-27,2025-03-14
432,133MG/10ML (13.3MG/ML),11304904,METHOD OF PROVIDING LOCAL OR REGIONAL ANALGESIA VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK OR FEMORAL NERVE BLOCK FOR REGIONAL ANALGESIA,EXPAREL,PACIRA PHARMS INC,N,022496,RX,"INJECTABLE, LIPOSOMAL",INJECTION,2011-10-28,2041-01-22
5446,7MG,8273779,"TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS",PONVORY,JANSSEN PHARMS,N,213498,RX,TABLET,ORAL,2021-03-18,2025-12-17
5253,1GM/VIAL;1GM/VIAL,10183034,"TREATMENT OF COMPLICATED URINARY TRACT INFECTION (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, AND ENTEROBACTER CLOACAE SPECIES COMPLEX",VABOMERE,REMPEX,N,209776,RX,POWDER,INTRAVENOUS,2017-08-29,2031-08-08
4622,145MCG,7304036,METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULTS,LINZESS,ABBVIE,N,202811,RX,CAPSULE,ORAL,2012-08-30,2026-08-30
4941,125MG,7456168,PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR IN PTS AS INITIAL ENDOCRINE-BASED THERAPY OR WITH FULVESTRANT WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY,IBRANCE,PFIZER,N,212436,RX,TABLET,ORAL,2019-11-01,2023-01-16
5203,EQ 300MG BASE,9861638,"A METHOD FOR TREATING OVARIAN CANCER BY ADMINISTERING RUCAPARIB, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION",RUBRACA,ZR PHARMA,N,209115,RX,TABLET,ORAL,2016-12-19,2031-02-10
403,EQ 0.8MG BASE,9895422,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 9 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 9,CYCLOSET,VEROSCIENCE,N,020866,RX,TABLET,ORAL,2009-05-05,2030-06-07
144,EQ 129MG BASE,8389578,TREATMENT OF DRUG-INDUCED EXTRAPYRAMIDAL REACTIONS IN ADULT PATIENTS WITH PARKINSONS DISEASE,OSMOLEX ER,ADAMAS OPERATIONS,N,209410,RX,"TABLET, EXTENDED RELEASE",ORAL,2018-02-16,2028-01-22
4190,EQ 10MG BASE,10016429,FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD),JAKAFI,INCYTE CORP,N,202192,RX,TABLET,ORAL,2011-11-16,2028-06-12
496,61.25MG;245MG,8454998,TREATMENT OF PARKINSONS DISEASE,RYTARY,IMPAX LABS INC,N,203312,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2015-01-07,2028-12-26
4198,7.54GM;140GM;2.2GM;48.11GM;5.2GM;9GM,11529368,FOR CLEANSING OF THE COLON IN PREPARATION FOR COLONOSCOPY IN ADULTS,PLENVU,SALIX,N,209381,RX,FOR SOLUTION,ORAL,2018-05-04,2032-03-09
2810,40UNITS/100ML (0.4UNITS/ML),9981006,"TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES",VASOSTRICT,PAR STERILE PRODUCTS,N,204485,RX,SOLUTION,INTRAVENOUS,2020-04-15,2035-01-30
939,160MG/8ML (20MG/ML),8940786,METHOD OF ADMINISTERING AN ETHANOL-FREE TAXANE LIQUID NANODISPERSION FORMULATION TO A SUBJECT COMBINING THE FORMULATION WITH AN AQUEOUS MEDIUM TO PROVIDE AN ETHANOL-FREE TAXANE DILUTED SOLUTION,DOCETAXEL,SHILPA,N,205934,RX,INJECTABLE,INJECTION,2015-12-22,2033-09-30
1413,1GM,10842768,USE OF VASCEPA TO LOWER TRIGLYCERIDES AND LDL-C IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON STATIN THERAPY,VASCEPA,AMARIN PHARMS,N,202057,RX,CAPSULE,ORAL,2012-07-26,2030-06-15
4758,100MG,8222219,"REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS",INVOKANA,JANSSEN PHARMS,N,204042,RX,TABLET,ORAL,2013-03-29,2025-04-11
4810,420MG,8952015,TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION,IMBRUVICA,PHARMACYCLICS LLC,N,210563,RX,TABLET,ORAL,2018-02-16,2026-12-28
888,0.725MG/SPRAY,9919117,NASAL ADMINISTRATION OF DIHYDROERGOTAMINE MESYLATE BY METERED SPRAY FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA,TRUDHESA,IMPEL PHARMS,N,213436,RX,"SPRAY, METERED",NASAL,2021-09-02,2033-03-17
4721,EQ 5MG BASE,9364470,A DOSING REGIMEN FOR THE TREATMENT OF  HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES,JUXTAPID,AMRYT,N,203858,RX,CAPSULE,ORAL,2012-12-21,2025-03-07
4874,10%,11654139,TOPICAL TREATMENT OF ONYCHOMYCOSIS OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES,JUBLIA,BAUSCH,N,203567,RX,SOLUTION,TOPICAL,2014-06-06,2034-10-02
5154,400MG;100MG;100MG,8735372,TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR,VOSEVI,GILEAD SCIENCES INC,N,209195,RX,TABLET,ORAL,2017-07-18,2028-03-21
5128,500MG IRON/10ML (50MG IRON/ML),7754702,METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULTS WHO HAVE INTOLERANCE TO OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON ASSOCIATED WITH HEAVY UTERINE BLEEDING OR A GASTROINTESTINAL DISORDER BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE,INJECTAFER,AM REGENT,N,203565,RX,SOLUTION,INTRAVENOUS,2020-10-08,2028-02-15
242,5MG,8674825,METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT,ABILIFY MYCITE KIT,OTSUKA,N,207202,RX,TABLET,ORAL,2017-11-13,2029-04-09
4746,3MG,8735428,USE OF POMALIDOMIDE WITH DEXAMETHASONE FOR PATIENTS WITH MULTIPLE MYELOMA AFTER AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR AND DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETING THE LAST THERAPY,POMALYST,BRISTOL,N,204026,RX,CAPSULE,ORAL,2013-02-08,2023-05-15
795,6.5MG,8957054,"INTRAVAGINAL PRASTERONE (DEHYDROEPIANDROSTERONE) AT A DAILY DOSE OF 6.5MG FOR THE TREATMENT OF DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE",INTRAROSA,MILLICENT,N,208470,RX,INSERT,VAGINAL,2016-11-16,2030-01-08
4366,7.9MG,11622991,TREATMENT OF PATIENTS WITH ACTIVE LUPUS NEPHRITIS,LUPKYNIS,AURINIA,N,213716,RX,CAPSULE,ORAL,2021-01-22,2037-12-07
419,0.16MG/INH;0.0048MG/INH;0.009MG/INH,8815258,USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD),BREZTRI AEROSPHERE,ASTRAZENECA AB,N,212122,RX,"AEROSOL, METERED",INHALATION,2020-07-23,2031-03-17
1767,20MG,8916588,METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),JORNAY PM,IRONSHORE PHARMS,N,209311,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2018-08-08,2032-03-23
5259,100MG,7855211,"AS MONOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY AND PRIOR CHEMOTHERAPY IN THE METASTATIC SETTING",VERZENIO,ELI LILLY AND CO,N,208716,RX,TABLET,ORAL,2017-09-28,2029-12-15
4622,72MCG,8933030,TREATMENT OF FUNCTIONAL CONSTIPATION IN PEDIATRIC PATIENTS 6 TO 17 YEARS OF AGE,LINZESS,ABBVIE,N,202811,RX,CAPSULE,ORAL,2017-01-25,2031-02-17
1057,0.5MG;100MG,9114145,"TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS",BIJUVA,MAYNE PHARMA,N,210132,DISCN,CAPSULE,ORAL,2021-12-28,2032-11-21
4304,10MG,8329648,REDUCING HBA1C IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4,FARXIGA,ASTRAZENECA AB,N,202293,RX,TABLET,ORAL,2014-01-08,2026-08-18
4135,30MG,7105486,FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),VYVANSE,TAKEDA PHARMS USA,N,021977,RX,CAPSULE,ORAL,2007-02-23,2023-02-24
1587,1MG/ML,9616096,REDUCTION OF MORTALITY IN ACUTE MYOCARDIAL INFARCTION,QBRELIS,AZURITY,N,208401,RX,SOLUTION,ORAL,2016-07-29,2035-11-06
4212,1.6GM/BOT;3.13GM/BOT;17.5GM/BOT,6946149,GASTROINTESTINAL LAVAGE INDICATED FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN ADULTS,SUPREP BOWEL PREP KIT,BRAINTREE LABS,N,022372,RX,SOLUTION,ORAL,2010-08-05,2023-03-07
5143,50MG,8524746,METHOD OF TREATING PARKINSONS DISEASE,ONGENTYS,NEUROCRINE,N,212489,RX,CAPSULE,ORAL,2020-04-24,2029-07-14
5460,20MG;EQ 10MG BASE,11351166,METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN,LYBALVI,ALKERMES INC,N,213378,RX,TABLET,ORAL,2021-05-28,2031-08-23
5077,1.4MG,10828298,METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A TABLET CONTAINING SELEXIPAG,UPTRAVI,ACTELION,N,207947,RX,TABLET,ORAL,2015-12-21,2036-12-01
1164,EQ 40MCG BASE/ACTIVATION,8428709,METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE,IONSYS,THE MEDICINES CO,N,021338,DISCN,SYSTEM,"IONTOPHORESIS, TRANSDERMAL",2006-05-22,2032-06-11
403,EQ 0.8MG BASE,10688155,ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 56 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44,CYCLOSET,VEROSCIENCE,N,020866,RX,TABLET,ORAL,2009-05-05,2030-06-07
1123,2MG/VIAL,8431685,AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION,BYDUREON,ASTRAZENECA AB,N,022200,DISCN,"FOR SUSPENSION, EXTENDED RELEASE",SUBCUTANEOUS,2012-01-27,2025-04-13
5288,100MG/ML,10137095,USE IN COMBINATION WITH CLOBAZAM FOR TREATMENT OF DROP SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME,EPIDIOLEX,GW RES LTD,N,210365,RX,SOLUTION,ORAL,2018-09-28,2035-06-17
4190,EQ 15MG BASE,8829013,FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS,JAKAFI,INCYTE CORP,N,202192,RX,TABLET,ORAL,2011-11-16,2028-06-12
5384,EQ 1MG BASE,8609862,CUSHINGS DISEASE,ISTURISA,RECORDATI RARE,N,212801,RX,TABLET,ORAL,2020-03-06,2031-01-13
4810,280MG,8952015,TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION,IMBRUVICA,PHARMACYCLICS LLC,N,210563,RX,TABLET,ORAL,2018-02-16,2026-12-28
4135,20MG,7674774,FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),VYVANSE,TAKEDA PHARMS USA,N,208510,RX,"TABLET, CHEWABLE",ORAL,2017-01-28,2023-02-24
5461,120MG,11426404,"TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), AS DETERMINED BY AN FDA-APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR SYSTEMIC THERAPY",LUMAKRAS,AMGEN INC,N,214665,RX,TABLET,ORAL,2021-05-28,2040-09-15
4299,150MG;150MG;200MG;300MG,7635704,TREATMENT OF HIV INFECTION,STRIBILD,GILEAD SCIENCES INC,N,203100,RX,TABLET,ORAL,2012-08-27,2026-10-26
4810,420MG,10016435,TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA,IMBRUVICA,PHARMACYCLICS LLC,N,210563,RX,TABLET,ORAL,2018-02-16,2031-06-03
5508,50MG/ML,8618087,TREATMENT OF SEIZURES ASSOCIATED WITH CYCLIN-DEPENDENT KINASE-LIKE 5 (CDKL5) DEFICIENCY DISORDER (CDD) IN PATIENTS 2 YEARS OF AGE AND OLDER,ZTALMY,MARINUS,N,215904,RX,SUSPENSION,ORAL,2022-06-01,2026-11-28
723,4%,10987347,METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES IN PATIENTS WITH HEPATIC IMPAIRMENT,GOPRELTO,GENUS LIFESCIENCES,N,209963,RX,SOLUTION,NASAL,2017-12-14,2037-02-07
403,EQ 0.8MG BASE,8877708,TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE WHEREIN THE COMBINED THERAPEUTIC EFFECT IS GREATER THAN THE ADDITIVE EFFECT OF ADMINISTERING EACH AGENT ALONE,CYCLOSET,VEROSCIENCE,N,020866,RX,TABLET,ORAL,2009-05-05,2030-06-07
5298,EQ 100MG BASE,9255068,A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE CRYSTALLINE SALT,SEYSARA,ALMIRALL,N,209521,RX,TABLET,ORAL,2018-10-01,2033-02-09
4498,819MG/2.625ML (312MG/ML),10143693,REINITIATION OF SCHIZOPHRENIA TREATMENT FOLLOWING A MISSED DOSE MORE THAN 9 MONTHS AGO,INVEGA TRINZA,JANSSEN PHARMS,N,207946,RX,"SUSPENSION, EXTENDED RELEASE",INTRAMUSCULAR,2015-05-18,2036-04-05
4483,30MG/VIAL,8207127,KYPROLIS IS INDICATED AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE OR MORE LINES OF THERAPY,KYPROLIS,ONYX PHARMS AMGEN,N,202714,RX,POWDER,INTRAVENOUS,2016-06-03,2025-04-14
4168,120MG,9827242,TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA,LATUDA,SUNOVION PHARMS INC,N,200603,RX,TABLET,ORAL,2012-04-26,2031-05-23
5154,200MG;50MG/PACKET,8575135,FOR THE TREATMENT OF HEPATITIS C,EPCLUSA,GILEAD SCIENCES INC,N,214187,RX,PELLETS,ORAL,2021-06-10,2032-11-16
4721,EQ 30MG BASE,7932268,A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES,JUXTAPID,AMRYT,N,203858,RX,CAPSULE,ORAL,2015-04-23,2027-08-19
4745,1.1GM/ML,10045959,TREATMENT OF A UREA CYCLE DISORDER,RAVICTI,HORIZON THERAP US,N,203284,RX,LIQUID,ORAL,2013-02-01,2030-09-22
87,0.3%,7868044,TREATMENT OF ACNE,DIFFERIN,GALDERMA LABS LP,N,021753,RX,GEL,TOPICAL,2007-06-19,2023-03-12
1611,0.25%,10058511,A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER,EYSUVIS,ALCON LABS INC,N,210933,RX,SUSPENSION/DROPS,OPHTHALMIC,2020-10-26,2033-05-03
4224,267MG,8383150,"METHOD OF ADMINISTERING A GRANULATE FORMULATION OF 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE AS RECITED IN CLAIM 1, TO TREAT IDIOPATHIC PULMONARY FIBROSIS",ESBRIET,GENENTECH INC,N,208780,RX,TABLET,ORAL,2017-01-11,2028-05-10
5259,150MG,7855211,"IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY",VERZENIO,ELI LILLY AND CO,N,208716,RX,TABLET,ORAL,2017-09-28,2029-12-15
4299,150MG;150MG;200MG;300MG,8592397,TREATMENT OF HIV INFECTION,STRIBILD,GILEAD SCIENCES INC,N,203100,RX,TABLET,ORAL,2012-08-27,2024-01-13
4224,267MG,8592462,CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS,ESBRIET,GENENTECH INC,N,022535,RX,CAPSULE,ORAL,2014-10-15,2029-04-22
4944,EQ 30MG BASE;120MG;EQ 15MG BASE,9296769,TREATMENT OF HIV INFECTION,BIKTARVY,GILEAD SCIENCES INC,N,210251,RX,TABLET,ORAL,2021-10-07,2032-08-15
2427,2GM/PACKET,10682338,TREATMENT OF BACTERIAL VAGINOSIS IN ADULT WOMEN,SOLOSEC,LUPIN,N,209363,RX,GRANULE,ORAL,2017-09-15,2035-09-04
3312,5MG/5ML (1MG/ML),7867996,A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE,CORLANOR,AMGEN INC,N,209964,RX,SOLUTION,ORAL,2019-04-22,2026-12-12
4135,50MG,7671030,FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),VYVANSE,TAKEDA PHARMS USA,N,021977,RX,CAPSULE,ORAL,2007-02-23,2023-02-24
242,10MG,8674825,METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT,ABILIFY MYCITE KIT,OTSUKA,N,207202,RX,TABLET,ORAL,2017-11-13,2029-04-09
434,EQ 0.3MG BASE,9655843,"MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE",BELBUCA,BDSI,N,207932,RX,FILM,BUCCAL,2015-10-23,2027-07-23
4907,150MG,8071579,"TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE OR SOMATIC BRCA-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, WHICH HAS PROGRESSED FOLLOWING PRIOR TREATMENT WITH ENZALUTAMIDE OR ABIRATERONE",LYNPARZA,ASTRAZENECA,N,208558,RX,TABLET,ORAL,2017-08-17,2027-08-12
5292,250MG,10717764,"A METHOD OF TREATING PREVIOUSLY TREATED, LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA CHARACTERIZED BY AN IDH1 MUTATION",TIBSOVO,SERVIER,N,211192,RX,TABLET,ORAL,2018-07-20,2033-01-18
4811,150MG;37.5MG/PACKET,8580765,FOR THE TREATMENT OF HEPATITIS C,EPCLUSA,GILEAD SCIENCES INC,N,214187,RX,PELLETS,ORAL,2021-06-10,2028-03-21
5154,400MG;100MG;100MG,9085573,TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR,VOSEVI,GILEAD SCIENCES INC,N,209195,RX,TABLET,ORAL,2017-07-18,2028-03-21
4914,EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**,8492386,"TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN",VIEKIRA XR,ABBVIE,N,208624,DISCN,"TABLET, EXTENDED RELEASE",ORAL,2016-07-22,2032-09-04
4810,420MG,9814721,TREATMENT OF MARGINAL ZONE LYMPHOMA,IMBRUVICA,PHARMACYCLICS LLC,N,210563,RX,TABLET,ORAL,2018-02-16,2031-06-03
4829,30MG,9018243,USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIASIS,OTEZLA,AMGEN INC,N,205437,RX,TABLET,ORAL,2014-03-21,2023-03-19
4810,420MG,8476284,TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA,IMBRUVICA,PHARMACYCLICS LLC,N,210563,RX,TABLET,ORAL,2018-02-16,2026-12-28
5203,EQ 200MG BASE,8143241,"A METHOD FOR TREATING METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA-MUTATION",RUBRACA,ZR PHARMA,N,209115,RX,TABLET,ORAL,2016-12-19,2027-08-12
4830,10MG;5MG;1GM,11564886,TREATMENT OF A TYPE 2 DIABETES PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN,TRIJARDY XR,BOEHRINGER INGELHEIM,N,212614,RX,"TABLET, EXTENDED RELEASE",ORAL,2020-01-27,2032-03-07
4164,18MG/3ML (6MG/ML),9968659,CARDIOVASCULAR OUTCOMES TRIAL OF LIRAGLUTIDE 1.8 MG IN PATIENTS WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE,SAXENDA,NOVO,N,206321,RX,SOLUTION,SUBCUTANEOUS,2014-12-23,2037-01-09
751,15MG,7544372,RELIEF OF MUSCLE SPASM,AMRIX,TEVA PHARMS INTL,N,021777,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2007-02-01,2023-11-14
4228,"100MG,75MG,50MG; 150MG",10758534,"TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR",TRIKAFTA (COPACKAGED),VERTEX PHARMS INC,N,212273,RX,TABLET,ORAL,2019-10-21,2035-10-06
4810,420MG,8476284,TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA,IMBRUVICA,PHARMACYCLICS LLC,N,210563,RX,TABLET,ORAL,2018-02-16,2026-12-28
4228,"80MG, 60MG, 40MG;59.5MG",9670163,"TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE AT LEAST ONE F508DEL MUTATION OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA USING A SOLID COMPOSITION COMPRISING ELX, TEZ, AMORPHOUS IVA, AND < ~30% CRYSTALLINE IVA",TRIKAFTA (COPACKAGED),VERTEX PHARMS INC,N,217660,RX,GRANULES,ORAL,2023-04-26,2026-12-28
5472,60MG,9499545,PREVENTIVE TREATMENT OF MIGRAINE IN ADULTS,QULIPTA,ABBVIE,N,215206,RX,TABLET,ORAL,2021-09-28,2031-11-10
2044,100MG/VIAL,7758891,TREATMENT OF PANCREATIC CANCER,ABRAXANE,BRISTOL-MYERS,N,021660,RX,POWDER,INTRAVENOUS,2005-01-07,2026-02-21
4820,20MG,9060995,TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH FLUVOXAMINE,HETLIOZ,VANDA PHARMS INC,N,205677,RX,CAPSULE,ORAL,2014-01-31,2033-01-25
1152,30MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**,8026281,TREATING SEVERE HYPERTRIGLYCERIDEMIA,ANTARA (MICRONIZED),LUPIN,N,021695,DISCN,CAPSULE,ORAL,2013-10-18,2025-04-22
4913,EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**,9006387,TREATMENT OF HCV INFECTION USING OMBITASVIR,VIEKIRA XR,ABBVIE,N,208624,DISCN,"TABLET, EXTENDED RELEASE",ORAL,2016-07-22,2030-06-10
5128,500MG IRON/10ML (50MG IRON/ML),8895612,METHOD OF TREATING IDA IN ADULT PATIENTS WITH NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE & WEIGHING AT LEAST 40 KG BY INTRAVENOUSLY ADMINISTERING AT LEAST ABOUT 0.6 GRAMS OF IRON AS FERRIC CARBOXYMALTOSE IN ABOUT 15 MINUTES OR LESS,INJECTAFER,AM REGENT,N,203565,RX,SOLUTION,INTRAVENOUS,2020-10-08,2027-01-08
5440,600MG/3ML (200MG/ML);900MG/3ML (300MG/ML),8410103,TREATMENT OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG,CABENUVA KIT,VIIV HLTHCARE,N,212888,RX,"SUSPENSION, EXTENDED RELEASE",INTRAMUSCULAR,2021-01-21,2026-04-28
4811,400MG;100MG,9284342,FOR THE TREATMENT OF HEPATITIS C,EPCLUSA,GILEAD SCIENCES INC,N,208341,RX,TABLET,ORAL,2016-06-28,2030-09-13
1883,60MG;EQ 10MG BASE,7332183,ACUTE TREATMENT OF MIGRAINE,TREXIMET,CURRAX,N,021926,DISCN,TABLET,ORAL,2015-05-14,2025-10-02
4616,8MG/0.4ML (8MG/0.4ML),9180125,TREATMENT OF OPIOID-INDUCED CONSTIPATION,RELISTOR,SALIX PHARMS,N,021964,RX,SOLUTION,SUBCUTANEOUS,2010-09-27,2029-09-30
4135,60MG,7659254,TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS,VYVANSE,TAKEDA PHARMS USA,N,021977,RX,CAPSULE,ORAL,2007-12-10,2023-02-24
5379,50MG,9944651,"TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS, INCLUDING PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), AND MAST CELL LEUKEMIA (MCL)",AYVAKIT,BLUEPRINT MEDICINES,N,212608,RX,TABLET,ORAL,2021-06-16,2034-10-15
4399,EQ 25MG ACID,8052993,TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP),PROMACTA,NOVARTIS,N,022291,RX,TABLET,ORAL,2008-11-20,2027-08-01
1207,0.4%;0.3%,10293047,"OCULAR EXAMINATION, INTRAOCULAR PRESSURE MEASUREMENT, OR REMOVAL OF FOREIGN BODIES OR SUTURES, IN ADULT AND PEDIATRIC PATIENTS REQUIRING A DISCLOSING AGENT IN COMBINATION WITH A TOPICAL OPHTHALMIC ANESTHETIC",FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE,BAUSCH LOMB IRELAND,N,211039,RX,SOLUTION/DROPS,OPHTHALMIC,2020-03-09,2037-11-15
5133,100MG,11110087,TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) BY ORALLY ADMINISTERING VENETOCLAX WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE IN ADULTS 75 YEARS OR OLDER OR HAVING CERTAIN COMORBIDITIES ACCORDING TO A DOSE RAMP-UP INCLUDING A 100 MG PER DAY DOSE,VENCLEXTA,ABBVIE,N,208573,RX,TABLET,ORAL,2016-04-11,2033-09-06
1386,30MG,8808740,"MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE",HYSINGLA ER,PURDUE PHARMA LP,N,206627,RX,"TABLET, EXTENDED RELEASE",ORAL,2014-11-20,2031-12-21
5276,"150MG;150MG, 100MG",10206877,"TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 6 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,206,877",SYMDEKO (COPACKAGED),VERTEX PHARMS INC,N,210491,RX,TABLET,ORAL,2018-02-12,2035-04-14
5468,0.4MG,10487111,METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC),BYLVAY,ALBIREO,N,215498,RX,CAPSULE,ORAL,2021-07-20,2031-11-08
4684,2MG,6949571,TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY 4 YEARS OF AGE AND OLDER,FYCOMPA,CATALYST PHARMS,N,202834,RX,TABLET,ORAL,2012-10-22,2024-06-08
5393,80MG,10172851,TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY,RETEVMO,LOXO ONCOL ELI LILLY,N,213246,RX,CAPSULE,ORAL,2020-05-08,2037-10-10
1164,0.6MG,8835460,TREATMENT OF PAIN,SUBSYS,BTCP PHARMA,N,202788,DISCN,SPRAY,SUBLINGUAL,2012-01-04,2027-01-25
242,400MG/VIAL,11344547,TREATMENT OF SCHIZOPHRENIA,ABILIFY MAINTENA KIT,OTSUKA PHARM CO LTD,N,202971,RX,"FOR SUSPENSION, EXTENDED RELEASE",INTRAMUSCULAR,2013-02-28,2033-09-24
4190,EQ 5MG BASE,9079912,FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD),JAKAFI,INCYTE CORP,N,202192,RX,TABLET,ORAL,2011-11-16,2026-12-12
4190,EQ 5MG BASE,10016429,FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD),JAKAFI,INCYTE CORP,N,202192,RX,TABLET,ORAL,2011-11-16,2028-06-12
465,0.064%;0.005%,10660908,TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 12 YEARS AND OLDER,ENSTILAR,LEO PHARMA AS,N,207589,RX,"AEROSOL, FOAM",TOPICAL,2015-10-16,2031-06-10
1123,2MG,9884092,REDUCING FASTING PLASMA GLUCOSE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML,BYDUREON PEN,ASTRAZENECA AB,N,022200,DISCN,"FOR SUSPENSION, EXTENDED RELEASE",SUBCUTANEOUS,2014-02-28,2026-08-18
5272,EQ 0.5MG BASE/ML (EQ 0.5MG BASE/ML),10500247,"TREATING LOW BLOOD PRESSURE WITH ANGIOTENSIN II WITH AN INITIAL RATE OF ABOUT 5 NG/KG/MIN TO ABOUT 20 NG/KG/MIN IN A SUBJECT HAVING REFRACTORY HYPOTENSION OR SEVERE HYPOTENSION, AND TITRATING THE RATE UP",GIAPREZA,LA JOLLA PHARMA,N,209360,RX,SOLUTION,INTRAVENOUS,2021-12-23,2029-12-16
242,10MG,8847766,METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER,ABILIFY MYCITE KIT,OTSUKA,N,207202,RX,TABLET,ORAL,2017-11-13,2030-03-29
824,0.7MG,8506987,TREATMENT OF MACULAR EDEMA,OZURDEX,ABBVIE,N,022315,RX,IMPLANT,INTRAVITREAL,2009-06-17,2023-01-09
4907,100MG,8143241,"MAINTENANCE TREATMENT OF GBRCA- OR SBRCA-MUTATED ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY",LYNPARZA,ASTRAZENECA,N,208558,RX,TABLET,ORAL,2017-08-17,2027-08-12
2552,EQ 4MG BASE,10864199,PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS CONVERTED FROM TACROLIMUS IMMEDIATE-RELEASE FORMULATIONS,ENVARSUS XR,VELOXIS PHARMS INC,N,206406,RX,"TABLET, EXTENDED RELEASE",ORAL,2015-07-10,2028-05-30
4175,2.5MG;1GM,8178541,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA,JENTADUETO,BOEHRINGER INGELHEIM,N,201281,RX,TABLET,ORAL,2012-01-30,2023-08-12
4922,EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL,10420841,"COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), USED IN COMBINATION WITH METRONIDAZOLE, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE)",ZERBAXA,CUBIST PHARMS LLC,N,206829,RX,POWDER,INTRAVENOUS,2014-12-19,2034-03-14
2029,27MG,10188644,"MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE",XTAMPZA ER,COLLEGIUM PHARM INC,N,208090,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2016-04-26,2036-09-02
5233,90MG,9273077,TREATMENT OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC),ALUNBRIG,TAKEDA PHARMS USA,N,208772,RX,TABLET,ORAL,2017-04-28,2029-05-21
4810,280MG,11672803,TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION,IMBRUVICA,PHARMACYCLICS LLC,N,210563,RX,TABLET,ORAL,2018-02-16,2031-06-03
1813,EQ 4% BASE,10137200,TREATMENT OF NON-NODULAR ACNE VULGARIS,AMZEEQ,JOURNEY,N,212379,RX,"AEROSOL, FOAM",TOPICAL,2019-10-18,2030-10-01
432,400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML),10898575,"TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION",ZYNRELEF KIT,HERON THERAPS INC,N,211988,RX,"SOLUTION, EXTENDED RELEASE",PERIARTICULAR,2021-05-12,2035-04-20
5346,15MG,8962629,TREATMENT OF ADULTS WITH ACTIVE ANKYLOSING SPONDYLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS,RINVOQ,ABBVIE,N,211675,RX,"TABLET, EXTENDED RELEASE",ORAL,2019-08-16,2031-01-15
3294,8MG,8999638,DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE,FANAPT,VANDA PHARMS INC,N,022192,RX,TABLET,ORAL,2009-05-06,2030-10-28
2543,EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML),10537554,TREATMENT OF MIGRAINE,ZEMBRACE SYMTOUCH,TONIX MEDS,N,208223,RX,SOLUTION,SUBCUTANEOUS,2016-01-28,2036-01-29
5345,200MG,11091469,TREATMENT OF ROS1-POSITIVE NON-SMALL CELL LUNG CANCER,ROZLYTREK,GENENTECH INC,N,212725,RX,CAPSULE,ORAL,2019-08-15,2037-05-18
1725,150MG;1GM,7943582,TREATMENT OF TYPE 2 DIABETES MELLITUS,INVOKAMET,JANSSEN PHARMS,N,204353,RX,TABLET,ORAL,2014-08-08,2029-02-26
5291,200MG/20ML (10MG/ML),9907859,TPOXX IS INDICATED FOR THE TREATMENT OF HUMAN SMALLPOX DISEASE IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 3 KG,TPOXX,SIGA TECHNOLOGIES,N,214518,RX,SOLUTION,INTRAVENOUS,2022-05-18,2031-08-02
2029,10MG,9492391,"MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE",OXYCONTIN,PURDUE PHARMA LP,N,022272,RX,"TABLET, EXTENDED RELEASE",ORAL,2010-04-05,2027-08-24
2810,40UNITS/100ML (0.4UNITS/ML),9962422,"TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES",VASOSTRICT,PAR STERILE PRODUCTS,N,204485,RX,SOLUTION,INTRAVENOUS,2020-04-15,2035-01-30
5288,100MG/ML,10709671,USE FOR THE TREATMENT OF FOCAL SEIZURES IN PATIENTS WITH DRAVET SYNDROME,EPIDIOLEX,GW RES LTD,N,210365,RX,SOLUTION,ORAL,2018-09-28,2035-06-17
4829,10MG,9724330,TREATMENT OF PATIENTS WITH PLAQUE PSORIASIS WHO ARE CANDIDATES FOR PHOTOTHERAPY OR SYSTEMIC THERAPY,OTEZLA,AMGEN INC,N,205437,RX,TABLET,ORAL,2014-03-21,2023-03-19
865,1.5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**,8546450,COMBINATION USE OF TOPICAL DICLOFENAC ON THE KNEE AND ADMINISTRATION OF AN ORAL NSAID.,PENNSAID,NUVO PHARMS INC,N,020947,DISCN,SOLUTION,TOPICAL,2009-11-04,2030-08-09
5292,250MG,10980788,TREATING NEWLY DIAGNOSED ACUTE MYELOGENOUS LEUKEMIA (AML) CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 BY ADMINISTERING A ONCE DAILY 500 MG ORAL DOSE TO A SUBJECT THAT HAS NOT INGESTED A HIGH-FAT MEAL,TIBSOVO,SERVIER,N,211192,RX,TABLET,ORAL,2018-07-20,2039-06-07
4226,0.015%,8735375,USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS,PICATO,LEO LABS,N,202833,DISCN,GEL,TOPICAL,2012-01-23,2026-12-18
4166,30MG,8426392,ELLA IS A PROGESTERONE AGONIST/ANTAGONIST EMERGENCY CONTRACEPTION INDICATED FOR THE PREVENTION OF PREGNANCY FOLLOWING UNPROTECTED INTERCOURSE OR A KNOWN OR SUSPECTED CONTRACEPTIVE FAILURE. ELLA CAN BE TAKEN WITH OR WITHOUT FOOD,ELLA,LAB HRA PHARMA,N,022474,RX,TABLET,ORAL,2010-08-13,2030-06-12
5128,100MG IRON/2ML (50MG IRON/ML),11590097,METHOD TO TREAT IDA IN ADULTS & PEDIATRIC PATIENTS 1 YR & OLDER WITH INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON & WEIGHING AT LEAST 40 KG BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 G OF ELEMENTAL IRON,INJECTAFER,AM REGENT,N,203565,RX,SOLUTION,INTRAVENOUS,2022-02-04,2023-10-20
5128,750MG IRON/15ML (50MG IRON/ML),11433091,METHOD OF TREATING IDA IN ADULT PATIENTS WITH NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE & WEIGHING AT LEAST 46.7 KG BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST 0.7 G OF ELEMENTAL IRON IN LESS THAN 15 MINUTES,INJECTAFER,AM REGENT,N,203565,RX,SOLUTION,INTRAVENOUS,2013-07-25,2027-01-08
4135,50MG,7662788,FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),VYVANSE,TAKEDA PHARMS USA,N,021977,RX,CAPSULE,ORAL,2007-02-23,2023-02-24
5128,1GM IRON/20ML (50MG IRON/ML),11478502,METHOD TO TREAT IRON DEFICIENCY ANEMIA IN ADULTS WITH INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON & WEIGHING AT LEAST 40 KG BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST 0.6 G OF ELEMENTAL IRON IN 15 MINUTES OR LESS,INJECTAFER,AM REGENT,N,203565,RX,SOLUTION,INTRAVENOUS,2021-04-28,2027-01-08
4907,100MG,9566276,MAINTENANCE TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GBRCA-MUTATED METASTATIC PANCREATIC ADENOCARCINOMA WHOSE DISEASE HAS NOT PROGRESSED ON AT LEAST 16 WEEKS OF A FIRST-LINE PLATINUM-BASED CHEMOTHERAPY REGIMEN,LYNPARZA,ASTRAZENECA,N,208558,RX,TABLET,ORAL,2017-08-17,2024-03-12
403,EQ 0.8MG BASE,10688094,"ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 4, 5, AND 6",CYCLOSET,VEROSCIENCE,N,020866,RX,TABLET,ORAL,2009-05-05,2032-04-30
4829,10MG,10092541,TREATMENT OF PSORIASIS USING A DOSAGE TITRATION SCHEDULE,OTEZLA,AMGEN INC,N,205437,RX,TABLET,ORAL,2014-03-21,2034-05-29
4228,"75MG;75MG, 50MG",8415387,TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVING AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE,SYMDEKO (COPACKAGED),VERTEX PHARMS INC,N,210491,RX,TABLET,ORAL,2019-06-21,2027-11-12
769,500MG/10ML (50MG/ML),11510942,METHOD OF USING L-CYSTEINE IN AN ADMIXTURE FOR TREATING PATIENTS NEEDING PARENTERAL NUTRITION,ELCYS,EXELA PHARMA,N,210660,RX,SOLUTION,INTRAVENOUS,2019-04-16,2039-01-15
989,600MG;200MG;300MG,9018192,TREATMENT OF HIV-1 INFECTION IN ADULTS,ATRIPLA,GILEAD SCIENCES,N,021937,RX,TABLET,ORAL,2006-07-12,2026-06-13
1407,26.6MG;800MG,8067451,RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS,DUEXIS,HORIZON,N,022519,RX,TABLET,ORAL,2011-04-23,2026-07-18
4538,EQ 210MG IRON,9757416,CONTROL OF SERUM PHOSPHOROUS LEVELS,AURYXIA,KERYX BIOPHARMS,N,205874,RX,TABLET,ORAL,2014-09-05,2024-02-18
5006,50MG/VIAL,6130208,P2Y12 PLATELET INHIBITOR FOR USE AS ADJUNCT TO PERCUTANEOUS CORONARY INTERVENTION TO REDUCE RISK OF VARIOUS DISEASES/CONDITIONS IN PATIENTS NOT TREATED WITH A P2Y12 PLATELET INHIBITOR AND NOT GIVEN A GLYCOPROTEIN IIB/IIIA INHIBITOR,KENGREAL,CHIESI,N,204958,RX,POWDER,INTRAVENOUS,2015-06-22,2023-06-29
2706,50MG,9622983,USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY,TROKENDI XR,SUPERNUS PHARMS,N,201635,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2013-08-16,2027-11-16
5393,80MG,10584124,"TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC THYROID CANCER WITH A RET GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY",RETEVMO,LOXO ONCOL ELI LILLY,N,213246,RX,CAPSULE,ORAL,2020-05-08,2038-10-10
1725,1GM;EQ 100MG BASE,7326708,METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE,JANUMET XR,MERCK SHARP DOHME,N,202270,RX,"TABLET, EXTENDED RELEASE",ORAL,2012-02-02,2026-11-24
5460,10MG;EQ 10MG BASE,11351166,METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN,LYBALVI,ALKERMES INC,N,213378,RX,TABLET,ORAL,2021-05-28,2031-08-23
4190,EQ 20MG BASE,7598257,"FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF",JAKAFI,INCYTE CORP,N,202192,RX,TABLET,ORAL,2011-11-16,2027-12-24
2706,100MG,10314790,USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY,TROKENDI XR,SUPERNUS PHARMS,N,201635,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2013-08-16,2027-11-16
230,40MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**,8258132,PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING,EMEND,MERCK,N,021549,DISCN,CAPSULE,ORAL,2006-06-30,2027-09-26
4801,EQ 75MG BASE,9233956,"TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION",TAFINLAR,NOVARTIS,N,202806,RX,CAPSULE,ORAL,2013-05-29,2029-05-04
1948,800PPM,8291904,A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT,INOMAX,MALLINCKRODT HOSP,N,020845,RX,GAS,INHALATION,1999-12-23,2031-01-06
5227,EQ 60MG BASE,10952997,TREATMENT OF TARDIVE DYSKINESIA,INGREZZA,NEUROCRINE,N,209241,RX,CAPSULE,ORAL,2021-04-23,2037-10-10
419,0.16MG/INH;0.0048MG/INH,10716753,MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD),SYMBICORT AEROSPHERE,ASTRAZENECA,N,216579,RX,"AEROSOL, METERED",INHALATION,2023-04-28,2030-05-28
1944,10MG,10328029,TREATMENT OF HEREDITARY TYROSINEMIA TYPE 1 (HT-1) IN COMBINATION WITH DIETARY RESTRICTION OF TYROSINE AND PHENYLALANINE,NITYR,CYCLE,N,209449,RX,TABLET,ORAL,2017-07-26,2035-01-05
4829,10MG,9018243,TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCETS DISEASE,OTEZLA,AMGEN INC,N,205437,RX,TABLET,ORAL,2014-03-21,2023-03-19
435,105MG;45MG,10894047,DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER,AUVELITY,AXSOME,N,215430,RX,"TABLET, EXTENDED RELEASE",ORAL,2022-08-18,2034-11-05
4907,150MG,9566276,MAINTENANCE TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GBRCA-MUTATED METASTATIC PANCREATIC ADENOCARCINOMA WHOSE DISEASE HAS NOT PROGRESSED ON AT LEAST 16 WEEKS OF A FIRST-LINE PLATINUM-BASED CHEMOTHERAPY REGIMEN,LYNPARZA,ASTRAZENECA,N,208558,RX,TABLET,ORAL,2017-08-17,2024-03-12
4135,10MG,7671030,FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),VYVANSE,TAKEDA PHARMS USA,N,208510,RX,"TABLET, CHEWABLE",ORAL,2017-01-28,2023-02-24
1123,2MG/VIAL,7612176,"AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES",BYDUREON,ASTRAZENECA AB,N,022200,DISCN,"FOR SUSPENSION, EXTENDED RELEASE",SUBCUTANEOUS,2012-01-27,2025-04-13
4175,2.5MG;500MG,8119648,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR,JENTADUETO,BOEHRINGER INGELHEIM,N,201281,RX,TABLET,ORAL,2012-01-30,2023-08-12
1413,500MG,10792270,USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CORONARY REVASCULARIZATION IN AN ADULT PATIENT WITH ESTABLISHED CARDIOVASCULAR DISEASE,VASCEPA,AMARIN PHARMS,N,202057,RX,CAPSULE,ORAL,2017-02-16,2033-06-28
5012,49MG;51MG,8796331,TREATMENT OF HEART FAILURE,ENTRESTO,NOVARTIS PHARMS CORP,N,207620,RX,TABLET,ORAL,2015-07-07,2023-01-14
2706,100MG,8992989,USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY,TROKENDI XR,SUPERNUS PHARMS,N,201635,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2013-08-16,2027-11-16
3317,10MG,9101622,"USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE, WHEREIN THOSE PATIENTS HAVE NOT RECEIVED PREVIOUS TREATMENT FOR MULTIPLE MYELOMA",REVLIMID,CELGENE,N,021880,RX,CAPSULE,ORAL,2005-12-27,2023-05-15
5372,"100MG,75MG,50MG; 150MG",9931334,"TREATMENT OF CF IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE USING A SOLID COMPOSITION COMPRISING ELEXACAFTOR, TEZACAFTOR, AMORPHOUS IVACAFTOR, AND LESS THAN ABOUT 30% CRYSTALLINE IVACAFTOR",TRIKAFTA (COPACKAGED),VERTEX PHARMS INC,N,212273,RX,TABLET,ORAL,2019-10-21,2026-12-28
4810,140MG,10751342,TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA,IMBRUVICA,PHARMACYCLICS LLC,N,210563,RX,TABLET,ORAL,2018-02-16,2031-06-03
242,9.75MG/1.3ML (7.5MG/ML),7115587,TREATMENT OF SCHIZOPHRENIA,ABILIFY,OTSUKA,N,021866,DISCN,INJECTABLE,INTRAMUSCULAR,2006-09-20,2024-07-21
2607,1.62% (40.5MG/2.5GM PACKET) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**,8741881,TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE,ANDROGEL,BESINS HLTHCARE,N,022309,DISCN,GEL,TRANSDERMAL,2012-09-07,2026-10-12
4907,150MG,8071579,MAINTENANCE TREATMENT WITH BEVACIZUMAB OF ADV. EPITHELIAL OVARIAN CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION,LYNPARZA,ASTRAZENECA,N,208558,RX,TABLET,ORAL,2017-08-17,2027-08-12
1386,100MG,8309060,"MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE",HYSINGLA ER,PURDUE PHARMA LP,N,206627,RX,"TABLET, EXTENDED RELEASE",ORAL,2014-11-20,2023-11-20
726,0.6MG,8440722,METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES,COLCRYS,TAKEDA PHARMS USA,N,022352,RX,TABLET,ORAL,2009-07-29,2029-02-17
4758,150MG;500MG,7943582,"REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS",INVOKAMET XR,JANSSEN PHARMS,N,205879,RX,"TABLET, EXTENDED RELEASE",ORAL,2016-09-20,2029-02-26
4190,EQ 25MG BASE,8822481,FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY,JAKAFI,INCYTE CORP,N,202192,RX,TABLET,ORAL,2011-11-16,2028-06-12
1123,2MG/0.85ML (2MG/0.85ML),8329648,AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN,BYDUREON BCISE,ASTRAZENECA AB,N,209210,RX,"SUSPENSION, EXTENDED RELEASE",SUBCUTANEOUS,2017-10-20,2026-08-18
4806,EQ 20MG BASE,9125910,"USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION",TRINTELLIX,TAKEDA PHARMS USA,N,204447,RX,TABLET,ORAL,2013-09-30,2027-06-15
5227,EQ 60MG BASE,10851103,TREATMENT OF TARDIVE DYSKINESIA,INGREZZA,NEUROCRINE,N,209241,RX,CAPSULE,ORAL,2021-04-23,2036-10-28
4135,40MG,7678771,FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD),VYVANSE,TAKEDA PHARMS USA,N,208510,RX,"TABLET, CHEWABLE",ORAL,2017-01-28,2023-02-24
4810,420MG,10695350,TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE REFRACTORY TO SYSTEMIC THERAPY,IMBRUVICA,PHARMACYCLICS LLC,N,210563,RX,TABLET,ORAL,2018-02-16,2034-10-24
5276,"75MG;75MG, 50MG",8415387,TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVING AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE,SYMDEKO (COPACKAGED),VERTEX PHARMS INC,N,210491,RX,TABLET,ORAL,2019-06-21,2027-11-12
2179,EQ 25MG BASE;EQ 45MG BASE,7807689,METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN,OSENI,TAKEDA PHARMS USA,N,022426,RX,TABLET,ORAL,2013-01-25,2028-06-27
1225,0.137MG/SPRAY;0.05MG/SPRAY,9259428,TREATMENT OF SEASONAL ALLERGIC RHINITIS,DYMISTA,MYLAN SPECIALITY LP,N,202236,RX,"SPRAY, METERED",NASAL,2012-05-01,2023-06-13
1057,0.01MG,10835487,TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY,IMVEXXY,MAYNE PHARMA,N,208564,RX,INSERT,VAGINAL,2018-05-29,2032-11-21
1152,90MG,8026281,TREATING SEVERE HYPERTRIGLYCERIDEMIA,ANTARA (MICRONIZED),LUPIN,N,021695,DISCN,CAPSULE,ORAL,2013-10-18,2025-04-22
1567,25MG;100MG,11033521,TREATMENT OF PARKINSONS DISEASE,DHIVY,AVION PHARMS,N,214869,RX,TABLET,ORAL,2021-11-12,2039-03-28
2572,EQ 60MG BASE/ML;EQ 7.5MG BASE/ML,8133883,METHOD OF TREATING BACTERIAL INFECTIONS,ZOSYN IN PLASTIC CONTAINER,BAXTER HLTHCARE CORP,N,050750,RX,INJECTABLE,INJECTION,1998-02-24,2023-04-14
5358,EQ 42MG BASE,11026951,"TREATMENT OF BIPOLAR I DISORDER, BIPOLAR II DISORDER, OR BIPOLAR DEPRESSION",CAPLYTA,INTRA-CELLULAR,N,209500,RX,CAPSULE,ORAL,2019-12-20,2034-12-03
2608,198MG,11564933,TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE,JATENZO,TOLMAR,N,206089,RX,CAPSULE,ORAL,2019-03-27,2039-04-12
1725,150MG;500MG,8222219,"REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS",INVOKAMET XR,JANSSEN PHARMS,N,205879,RX,"TABLET, EXTENDED RELEASE",ORAL,2016-09-20,2025-04-11
5280,EQ 100MG BASE,9266912,TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT,TAVALISSE,RIGEL PHARMS INC,N,209299,RX,TABLET,ORAL,2018-04-17,2026-01-19
5276,"75MG;75MG, 50MG",9012496,TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HETEROZYGOUS FOR THE F508DEL MUTATION AND A SECOND MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR,SYMDEKO (COPACKAGED),VERTEX PHARMS INC,N,210491,RX,TABLET,ORAL,2019-06-21,2033-07-15
2379,550MG,11564912,TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULT FEMALE SUBJECTS,XIFAXAN,SALIX PHARMS,N,021361,RX,TABLET,ORAL,2010-03-24,2029-02-26
2448,EQ 100MG BASE,7326708,METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR,JANUVIA,MERCK SHARP DOHME,N,021995,RX,TABLET,ORAL,2006-10-16,2026-11-24
2029,13.5MG,10646485,"MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE",XTAMPZA ER,COLLEGIUM PHARM INC,N,208090,RX,"CAPSULE, EXTENDED RELEASE",ORAL,2016-04-26,2036-09-02
1386,10MG,10092559,TREATMENT OF PAIN,ZOHYDRO ER,RECRO GAINESVILLE,N,202880,DISCN,"CAPSULE, EXTENDED RELEASE",ORAL,2013-10-25,2034-09-12
4228,125MG/PACKET;100MG/PACKET,9670163,TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS AND LESS THAN ABOUT 30% CRYSTALLINE IVACAFTOR,ORKAMBI,VERTEX PHARMS INC,N,211358,RX,GRANULE,ORAL,2018-08-07,2026-12-28
4907,150MG,8859562,MAINTENANCE TREATMENT WITH BEVACIZUMAB OF ADV. EPITHELIAL OVARIAN CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH GENOMIC INSTABILITY,LYNPARZA,ASTRAZENECA,N,208558,RX,TABLET,ORAL,2017-08-17,2031-08-04
1164,EQ 0.1MG BASE,8889176,MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER,LAZANDA,BTCP PHARMA,N,022569,DISCN,"SPRAY, METERED",NASAL,2011-06-30,2024-01-16
4166,30MG,8962603,"METHOD FOR PROVIDING POST COITAL CONTRACEPTION TO A WOMAN BY ADMINISTERING ABOUT 30 MG OF ULIPRISTAL ACETATE WITHIN ABOUT 120 HOURS AFTER INTERCOURSE, WHEREIN THE WOMAN IS OVERWEIGHT  HAVING A BMI OF 25 TO 29.99",ELLA,LAB HRA PHARMA,N,022474,RX,TABLET,ORAL,2010-08-13,2030-06-12
1386,20MG,9713611,TREATMENT OF PAIN,ZOHYDRO ER,RECRO GAINESVILLE,N,202880,DISCN,"CAPSULE, EXTENDED RELEASE",ORAL,2013-10-25,2034-09-12
4684,4MG,6949571,TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY 4 YEARS OF AGE AND OLDER,FYCOMPA,CATALYST PHARMS,N,202834,RX,TABLET,ORAL,2012-10-22,2024-06-08
1386,20MG,8309060,"MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE",HYSINGLA ER,PURDUE PHARMA LP,N,206627,RX,"TABLET, EXTENDED RELEASE",ORAL,2014-11-20,2023-11-20
4228,"75MG;75MG, 50MG",10058546,"TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER, WITH A F508DEL OR G551D CFTR GENE MUTATION AND A A455E, 2789+5G->, OR 3849+10KBC->T MUTATION, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF U.S. PATENT 10058546",SYMDEKO (COPACKAGED),VERTEX PHARMS INC,N,210491,RX,TABLET,ORAL,2019-06-21,2033-07-15
4721,EQ 40MG BASE,10555938,A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES,JUXTAPID,AMRYT,N,203858,DISCN,CAPSULE,ORAL,2015-04-23,2025-03-07
5182,100MG/2ML (50MG/ML),9506058,RESTORING AN MRNA READING FRAME TO INDUCE DYSTROPHIN PROTEIN PRODUCTION IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING,EXONDYS 51,SAREPTA THERAPS INC,N,206488,RX,SOLUTION,INTRAVENOUS,2016-09-19,2034-03-14
1725,12.5MG;500MG,9949997,METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN,SYNJARDY,BOEHRINGER INGELHEIM,N,206111,RX,TABLET,ORAL,2015-08-26,2034-05-17
4228,"75MG;75MG, 50MG",11578062,TREATMENT OF CF IN A PATIENT AGE 6 YEARS AND OLDER WHO IS HOMOZYGOUS FOR F508DEL OR HAS AT LEAST ONE CFTR GENE MUTATION RESPONSIVE TO TEZ/IVA BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE USING THE COMPOSITION RECITED IN US 11578062 CLAIM 6 OR 13,SYMDEKO (COPACKAGED),VERTEX PHARMS INC,N,210491,RX,TABLET,ORAL,2019-06-21,2031-03-25
5052,882MG/3.2ML (275.63MG/ML),10112903,TREATMENT OF SCHIZOPHRENIA,ARISTADA,ALKERMES INC,N,207533,RX,"SUSPENSION, EXTENDED RELEASE",INTRAMUSCULAR,2015-10-05,2030-06-24
4811,200MG;50MG/PACKET,8618076,FOR THE TREATMENT OF HEPATITIS C,EPCLUSA,GILEAD SCIENCES INC,N,214187,RX,PELLETS,ORAL,2021-06-10,2030-12-11
5442,EQ 300MG BASE/VIAL,11529352,A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A PLATINUM/ETOPOSIDE-CONTAINING REGIMEN THAT INCLUDES AN IMMUNE CHECKPOINT INHIBITOR FOR EXTENSIVE-STAGE SMALL CELL CANCER,COSELA,G1 THERAP,N,214200,RX,POWDER,INTRAVENOUS,2021-02-12,2039-07-23
4810,280MG,8952015,TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA,IMBRUVICA,PHARMACYCLICS LLC,N,210563,RX,TABLET,ORAL,2018-02-16,2026-12-28
4303,200MG,10695354,TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT WITH REFRACTORY PARTIAL-ONSET SEIZURES,APTIOM,SUMITOMO PHARMA AM,N,022416,RX,TABLET,ORAL,2013-11-08,2025-05-06
124,300MG;200MG,9216179,TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE,DUZALLO,IRONWOOD PHARMS INC,N,209203,DISCN,TABLET,ORAL,2017-08-18,2031-08-01
4234,EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML),7550433,TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE,OMONTYS PRESERVATIVE FREE,TAKEDA PHARMS USA,N,202799,DISCN,SOLUTION,"INTRAVENOUS, SUBCUTANEOUS",2012-03-27,2026-06-02
